raeport on innovativeness of health sector in poland in 2012

REPORTon Innovativeness of the Health

Sector in Poland in 2012

scientific editor Tadeusz Baczko

Institute of EconomicsPolish Academy of SciencesWarsaw 2012

RAPORT o innowacyjności

w Polsce w 2012 roku

sektoramedycznego

redakcja naukowa Tadeusz Baczko

Instytut Nauk EkonomicznychPolskiej Akademii Nauk Warszawa 2012

Rapo

rt o

inno

wacy

jnoś

cise

ktor

a m

edyc

zneg

o w

Polsc

e w

2012

roku

Report on Innovativenessof the Health Sector in Poland in 2012

Prepared by

Coordinated by

Under honorary patronage of

MSN Scientific Network Assessment of the Impact of Research and Development (R&D) Activity and Innovation on the Social and Economic Development

Institute of Economics of the Polish Academy of Sciences

Professor Michał Kleiber President of the Polish Academy of Sciences

Scientific EditorTadeusz Baczko

Editor of “Sector Analyses”Małgorzata Pieńkowska

Editor of “Microeconomic Analyses”Ewa Puchała-Krzywina

Polish Language EditorWładysława Czech-Matuszewska

Copy editorJoanna Pęczkowska

English Language EditorsLesław Pietrewicz, Dorota Winter, Tadeusz Żydkiewicz

Digital Copy EditorMichał Baranowski

Cover design byGrażyna Klechniowska

Typeset and layout design byJacek Tarasiewicz, Anna Wojda

The Report will be available on-line at: www.innovation-in-healthcare.pl

Publication co-financed by the European Union under the European Social Fund

© Copyright 2012 INE PANISBN 978-83-61597-30-8

Institute of Economics, Polish Academy of Sciences00–330 Warsaw, Nowy Świat 72www.inepan.waw.pl, [email protected]

Implementation PublishingWydawnictwo Key Text sp. z o.o.01–134 Warszawa, ul. Wolska 64Awww.keytext.com.pl, [email protected]

5

Foreword

The European Union and its Member States have nowadays reached a crucial turning point. The debt crisis and the resulting budget constraints, the acceleration of globalisation and the emergence of new global actors, the ageing of population and the rapid progress of science and technology, all represent unprecedented economic and societal challenges for our European model and the future standard of living in the EU.

In its EU2020 strategy, the Commission has highlighted innovation as our best means of successfully tackling the major societal challenges. We need to harness all opportunities to develop new product and processes, increase the efficiency of our systems and models, and seize the new perspectives of competitiveness, growth, employment and increased welfare open by scientific and technological progress.

The efficiency and sustainability of health systems and their ability to respond to the challenges of demographic change and scientific and technological development are among the most pressing issues needing adaptation and innovation. Innovation in medical technology and healthcare and the resulting improvement in public health may be part of the solution, decreasing the burden of diseases and creating opportunities for growth and employment.

Life expectancy is growing fast for both men and women in the EU, but the unhealthy life years still represent on average 20% of people’s life. As a consequence of the life expectancy extension, we expect by 2060 an increase of 90% in the number of over 65 years and 80% of over 80, and, if nothing is done, a substantial increase of chronic diseases with their associated human and economic burden. The number of EU citizens in the working age for each retired person will decrease from 4 to 2. The spending on healthcare represents nowadays more than 9% of the EU GDP and has been rapidly growing. Finally, medical science and technology as well as the organisation of healthcare are on the brink of a revolution with the development of personalised medicine, the progress of imaging techniques, the appearance of nano-medicine and the application of ICT in healthcare.

Clearly these trends would not be sustainable with the current approaches and the forthcoming developments demand substantial change and adaptation. The solution can only come from innovation in the technologies, processes, structures and practices.

The EU has devoted significant resources to promote research and innovation in the health sector within its research programmes. Around 6 billion EUR were allocated to health in the 7th Framework Programme. Health is again a top priority in the forthcoming new programme Horizon 2020 that will start in 2014 and the European Commission has accordingly proposed an increase to more than 9 billion EUR in the resources specifically devoted to health research in such programme. The new programme will reinforce even more the accent on innovation, translation of research results into practical applications and marketable products and processes. It will cover the entire range of medical technologies as well as health systems issues.

6

In light of these considerations, I very much welcome the publication of this report on the Innovativeness of the Health Sector in Poland. The report is a very valuable contribution to document and analyse the situation and performance of the medical and public health sectors in Poland, putting the findings in the broader European and international perspective. I find particularly interesting that a relevant input into this report comes from a project co-financed by the European Regional Fund, showing how different EU instruments can converge in assessing and supporting innovation in the health sector. It is also encouraging to see from the list of innovative companies in the medical sector in Poland that medical innovation opens concrete opportunities for both healthcare improvement and competitive business development.

I am sure that this report will contribute to stimulate reflection and action on innovation in the health sector in Poland and beyond.

John DalliEuropean Commissioner

for Health and Consumer Policy

Contens

IntroductIon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9Tadeusz Baczko, Foundations of Innovation in Healthcare . . . . . . . . . . . . . . . . . . . . . 9

SectorAL AnALySeS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Urszula Skorupska, Development of the healthcare sector in Poland in international

perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Barbara Liberska, Offshoring of medical services . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17Iwona Nowicka, Medical issues in the Polish foresight projects . . . . . . . . . . . . . . . . . 20Grażyna K. Niedbalska, Health-related R&D primary indicators and measurement

problems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23Beata Kwiecińska, Innovativeness and financing of the health care sector from

the EU funds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26Joanna Pęczkowska, Medical sector universities and institutes which received EU

funds for innovation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29Urszula Skorupska, The private health insurance market in Poland . . . . . . . . . . . . . . 32Elżbieta Szymańska, Innovative character of health tourism . . . . . . . . . . . . . . . . . . . 35Nela Grądzka, Kamil Kasner, Aesthetic medicine in Poland . . . . . . . . . . . . . . . . . . . . 38Paweł Krzywina, Reimbursement law vs. R&D financing . . . . . . . . . . . . . . . . . . . . . . 43

MIcroeconoMIc AnALySeS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47Marek Niechciał, Development of pharmaceutical industry in Poland. . . . . . . . . . . . . 47Ewa Puchała-Krzywina, Barriers impeding innovative actions in the medical sector

enterprises. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51Jan Maria Wójcicki, Nałęcz Institute of Biocybernetics and Biomedical Engeneering

of the Polish Academy of Sciences. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55Artur Chaberski, Innovative family companies of the medical sector . . . . . . . . . . . . . 59

LISt oF LArGeSt InVeStorS In r&d In MedIcAL Sector In PoLAnd In 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

LISt oF the MoSt InnoVAtIVe coMPAnIeS oF the MedIcAL Sector In PoLAnd In 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66

Alphabetical List of Companies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72Explanation of codes for the surveyed group of subclasses of NACE based Polish

Classification of Activities 2007. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75Glossary to the List of most innovative companies of the medical sector in 2010 . . . 76

InForMAtIon on SeLected InnoVAtIVe coMPAnIeS oF the MedIcAL Sector In PoLAnd. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

Explanation to description of innovative companies in the medical sector . . . . . . . . . 129

InnoVAtIVeS reSeArch ProGrAM At Ine PAn . . . . . . . . . . . . . . . . . . . . . . . . . 131MSN Scientific Network. Assessment of the Impact of Research and Development

(R&D) Activity and Innovation on the Social and Economic Development . . . . . . . 134

Foudations of Innovation in Healthcare 9

Tadeusz BaczkoInstitute of Economics, Polish Academy of Sciences

Foudations oF innovation in HealtHCare

Discontented patients are a powerful source of healthcare development. Health is a good for which we are willing to pay any price. At the same time, health systems, even those of the most affluent countries, have been wavering one by one: they all go bankrupt, just at various levels of prosperity. What are the odds of escaping from this greatest trap of modernity?

Works conducted as part of the Economic Panel project, The condition and prospects of medical technologies development in Poland, realised by the ROTMED Consortium and coordinated by the Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences (PAN)1, indicated that a breakthrough in the organisation of health services is possible. Paradoxically, it is the medical technologies, the development of which not only prolongs lives but also brings about growing costs, that make possible a breakthrough in the financing of the healthcare system even today.

Success depends on the healthcare system’s bloodstream reversal and leaving the narrow-minded approach to the sector. The patient and his/her needs should be in the centre of interest of the healthcare system. Services of the type must be treated as an important element of the value chain; however, they may not be unrelated to the remaining linkages, where tangible and intangible values are formed, without which it is impossible to provide healthcare in a proper manner.

Today, owing to medical technologies development, it can be assured that the needs of the patient are linked with diagnostic centres, and that information concerning real health needs are transferred to relevant components of the chain value of health services, including diagnostic services networks and research centres of applied and basic sciences. Modification of the healthcare system in above direction makes it possible to activize its great latent potential. In principle, all elements of said value chain exist today, and diagnostic systems allow us to reduce the huge social energy and money waste caused by the contemporary healthcare systems.

A significant share of drugs is not well suited to patients’ needs. Doctors, being a professional group which comprises the intellectual elite of successive generations, are brought down to the role of cogs in the bureaucratic systems. Returning the doctor to his active role, giving him the scope for professional diagnosis, and initiating innovative processes constitute the source of healthcare system development, and subsequently – in the face of the rapid increase of its role in the services sector – a central source of potential economic growth.

1 The project was commissioned by the Polish Ministry of Science and Higher Education and co-financed by the European Regional Development Fund, see www.nauka.gov.pl/fileadmin/user_upload/Finansowanie/fundusze_europejskie/SPO-WKP/20100825_SYSTEM_MONITOROWANIA_I_SCENARIUSZE_ROZWOJU_TECHNOLOGII_MEDYCZNYCH_W_POLSCE.pdf

introduCtion

Tadeusz Baczko10

The present Report and the conference during which it is going to be announced undertake the issue of creating an Innovative Health Care System (IHCS). It is an economic, social and scientific challenge. The challenge concerns a majority of the world’s countries. These include very rich countries and countries contending with the most dramatic hunger threats, epidemics, or lack of access to hygiene.

The Report carries out an informative and integrative function. It serves a goal of notifying the public opinion, government and self-government administration in Poland, and decision-making centres both at home and abroad, about the indications and opportunities of innovation development in the medical sector. It is crucial to make conditions for the highest possible engagement of the circles of doctors, industry, science and administration representatives in the initiation of the healthcare system of the future.

We would like to point at Poland as a country still without a complete system of institutional and organisational solutions for healthcare, and as a place where such international programme could be implemented. Developed solutions could subsequently be applied to other countries.

Healthcare is one of the sectors of the unfinished systemic transformation to which multiple modifications are introduced. Nonetheless, the private medical sector in Poland is developing dynamically. There are still many inconsistencies between the public healthcare and market solutions. Formation of a system of healthcare funding worthy of the 21st century requires innovative solutions to numerous problems.

A good, historically consolidated tradition of medical sciences in Poland constitute a valuable foundation. Many individuals graduating from Polish medical academies are the authors of spectacular achievements on a global scale. An unprecedented influx of European funds contributed to significant improvement of the technological basis and the healthcare system infrastructure.

The Report presents statistics on the Polish healthcare expenditure in relation to GDP in an international context. the statictics cover the funding of healthcare with both public and private funds. Poland is a country of growing spending on healthcare. Some nonstandard forms of healthcare funding by employers are being developed, too. The pharmaceutical sector is developing rapidly. Currently, the world’s largest medical corporations are present on the Polish market.

Some of them conduct clinical trials, which are an important input into research and development expenditure in Poland, and also involve in the production and distribution of medicines. These companies made Poland a base for their expansion into other countries. Frequently, it is a continuation of Polish pharmaceutical industry expansion into the former USSR.

The pharmaceutical, generic medicines-oriented industry is also flourishing in Poland. In addition to expanding abroad, it conducts own research in innovative medicines, improvement of their characteristics, or reduction of side effects evoked by medicines. These companies are associated with the Polish Innovative Medicine Technological Platform (Polska Platforma Technologiczna Innowacyjnej Medycyny) or professional economic chambers.

Also worth noting are companies’ activities directed at innovative medicines development within specially created platforms related to such major global challenges as neoplastic, cardiologic, and psychiatric diseases. These platforms combine businesses with the leading Polish medical and biotechnological sciences centres.

Poland boasts entrepreneurship boom, also in the medical sector. The dynamic growth of pharmaceutical companies after transformation, where enterprises based on private capital and pre-established institutional framework expand into domestic and international markets creating new job posts, is well worth attention.

There are also numerous examples of impressive dynamics of innovative companies in the medical technologies and dressing materials sector. They include research

Foudations of Innovation in Healthcare 11

institutes, which on their own initiative manufacture and export medical equipment2. There are multiple innovative companies in the medical technologies and materials sector. Additionally, in Poland some of the largest IT companies in the Visegrád Group (V4) devoted to software production for companies and other organisation, including but not limited to medical facilities, are developing. And here we could not disregard the dynamic growth of the telecommunication market, in particular, mobile communications without which it is difficult to imagine e-Health or m-Health.

Medical services networks, which also begin to erect their own hospitals and diagnostic stations, are developing dynamically. These companies have extensive networks of units providing medical services across the country but they also expand abroad. The quality of their services meets the high standards of the Polish National Health Fund (Narodowy Fundusz Zdrowia, NFZ).

These facilities are situated in cities, however, more and more often they tend to be located in spas. The high quality, modern character and competitive prices of their medical and rehabilitation services, or aesthetic medicine services, lead to the growth of health tourism. Innovative materials and implants are produced in Poland and exported to such medically advanced countries as Sweden and the USA.

Infrastructural, rescue and medicinal activities have received significant support from European funds3. There is still a great potential in this area, especially in the sphere of public-private partnership. It is the centre of interest of many European and world financial institutions.

A very important part of the Polish healthcare system is an extended circle of non-profit organisations. They have become serious players in the process of investing in healthcare in Poland. Their experience deserves to be disseminated around the world. The sector undertakes activities not only on a domestic but also international scale. It creates model solutions that may be regarded as social innovations on a global scale. One example could be activities of the Great Orchestra of Christmas Charity (Wielka Orkiestra Świątecznej Pomocy, WOŚP) initiated by Jerzy Owsiak, but there are many other initiatives.

The Report indicates the growth of companies in the innovative medical sector in Poland. Various aspects of its dynamism presented in the Report should not conceal the fact that the health sector faces huge financial and institutional barriers. The Poles continue to assess its quality as low. Numerous controversies arouse over medicine and medical procedures funding.

The scale of dynamic changes, multiple challenges related to the integration of the public and private sectors, and unmet needs of patients constitute a central motivation to create the Innovative Health Care System in Poland. Taking up these efforts may become a valuable contribution of the Polish Presidency 2012–2013 of the Visegrád Group countries aiming at V4+ cooperation development and elevation of their international position.

2 See. T. Baczko, G. Gierszewska, E. Puchała-Krzywina, The functions of scientific research units in the transfer of knowledge to enterprises [in Polish], in: The influence of structural funds on the transfer of knowledge to enterprises [in Polish], J. Kotowicz-Jawor (ed.), INE PAN, Key Text, Warsaw 2012, pp. 63–64.

3 A good example is an endowment of helicopters for emergency medical service.

Development of the healthcare sector in Poland in international perspective 13

Urszula SkorupskaInstitute of Economics, Polish Academy of Sciences

development oF tHe HealtHCare seCtor in poland in international perspeCtive

Over the last decades, we have been observing a rapid growth of the healthcare sector in developed countries − its dynamics is constantly exceeding that of GDP. Between 2000 and 2010, the real yearly healthcare expenditure in Poland grew at an average rate of 6.4%, which compares very favourably with other OECD states’ seems an outstanding results (compare Fig. 1).

Figure 1

dynamics of healthcare expenditure in comparison with Gdp growth (per capita) between 2000 and 2010

0,0

2,0

4,0

6,0

8,0

10,0

12,0

real yearly healthcare expenditure increase per capita, 2000–2010 (%)

real yearly GDP increase per capita, 2000–2010 (%)

Slov

akia

Sout

h Ko

rea

Chile

Turk

ey*

Irela

ndPo

land

Holla

ndSp

ain*

Esto

nia

New

Zea

land

Czec

h Re

publ

icUn

ited

King

dom

Gree

ceAu

stra

lia*

Cana

daBe

lgiu

m U

SAFi

nlan

dM

exic

oSw

eden

Slov

enia

Luxe

mbo

urg*

Nor

way

Denm

ark

Hung

ary

Switz

erla

ndIs

rael

*Ja

pan*

Fran

ceAu

stria

Portu

gal

Germ

any

Icel

and

Ital

y

* Dynamics of health expenditure for the years 2000–2009.

Source: Own research based on: www.oecd.org/health/, http://databank.worldbank.org (accessed on 31Aug2012).

In all countries presented in Figure 1, healthcare expenditure grew faster than GDP (per capita), which redirects the fact that healthcare has features characteristic of luxury goods (flexibility >1), i.e. expenditures on health services increase more

seCtoral analyses

Urszula Skorupska14

rapidly than income. This result was also affected by the fact that around the world, including Europe, medical highly specialised procedures segment intensive development can now be observed in the medical. Moreover, there is an imitation effect (which is observed also outside the health services market), which involves societies aiming at the achievement of a degree of needs’ fulfilment similar to that of other countries. Progress in the highly specialised treatment is closely related to the dynamic development of medical technologies preconditioned by innovativeness in education, scientific and developmental research, and in the implementation of innovative solutions in medical production and practice4. Furthermore, a major role in the development of the sector is played by demographic factors, in particular, the demographic structure of a population. Population aging, understood both as an increase in the proportion of people in a post-productive age in the social structures, and as a rise in life expectancy, results in an escalation of the needs for health-related services – healthcare, social care, and public health; thus, it generates more spending on health5. Moreover, it should be highlighted that demand for health services arises not only from various bodily dysfunctions of various individuals, but it may also be created by marketing activities, e.g. of pharmaceutical companies. An increase in health conscious lifestyle also translates into a rise in the tendency to bear additional health-related expenses.

Amongst the OECD member countries, Poland is one of the leaders in terms of the dynamics of healthcare expenditure and it has perspectives for its further growth. Said projection is supported by the fact that Poland ranks among the last in national health expenditures’ share in GDP in 2010. Lower share was recorded only by Estonia, Mexico and Turkey (compare Tab. 1). The United States of America rank first in the table, with healthcare expenditure in 2010 at 17.6% of GDP. It is worth mentioning that apart from their high level, high growth dynamics of said expenditure has also been observed. In the first decade of the 21st century, real expenditure grew on average by app. 4% per year; whereas present projections6 assume that 19% of GDP will be attained as early as in 2017.

table 1

share of healthcare expenditure in Gdp in 2010a (in %)

Countries total expenditure

public expenditure

private expenditure

USA 17.6 8.5 9.1

Holland 12.0 10.3 1.7

France 11.6 8.9 2.7

Germany 11.6 8.9 2.7

Switzerland 11.5 7.4 4.1

4 Compare Monitoring system and Medical technologies advancement scenarios in Poland, J.M. Wójcicki i P. Ładyżyński (ed.), konsorcjum ROTMED, Warsaw 2008, p. 19.

5 A strong concentration of health expenditure addressed at a relatively small part of the population can now be observed across healthcare systems. In 2009 in Poland, more than 72% of NFZ (National Health Service) spending was indicated for the treatment of barely 10% of the insured. The proportion in the USA is quite similar: 70% of health expenditure concerned 10% of the Population (compare The analysis of health service rendition in 2009 and distribution of National Health Fund expenditures, NFZ, Warszawa 2010, pp. 4−5).

6 Centers for Medicare & Medicaid Services, Office of the Actuary (2010), National Health Expenditure Projections 2009–2019 (September 2010) (https://www.cms.gov/NationalHealth Expend Data/downloads/NHEProjections2009to2019.pdf)

Development of the healthcare sector in Poland in international perspective 15

Canada 11.4 8.1 3.3

Denmark 11.1 9.4 1.7

Austria 11.0 8.4 2.6

Portugal 10.7 7.0 3.7

Belgium 10.5 7.9 2.6

Greece 10.2 6.1 4.1

New Zealand 10.1 8.4 1.7

Spain 9.6 7.1 2.5

Sweden 9.6 7.8 1.8

United Kingdom 9.6 8.0 1.6

Japan 9.5 7.6 1.9

Norway 9.4 8.0 1.4

Iceland 9.3 7.5 1.8

Italy 9.3 7.4 1.9

Ireland 9.2 6.4 2.8

Australia 9.1 6.2 2.9

Slovakia 9.0 5.8 3.2

Slovenia 9.0 6.6 2.4

Finland 8.9 6.6 2.3

Chile 8.0 3.9 4.1

Israel 7.9 4.8 3.1

Luxembourg 7.9 6.6 1.3

Hungary 7.8 5.1 2.7

Czech 7.5 6.3 1.2

South Korea 7.1 4.1 3.0

Poland 7.0 5.0 2.0

Estonia 6.3 5.0 1.3

Mexico 6.2 2.9 3.3

Turkey 6.1 4.5 1.6

a Or the last year for which data was available.

Source: Own research based on: www.oecd.org/health/ (accessed on 31 Aug 2012).

The level of development, as measured by GDP, has major influence on the value of healthcare expenditures in a given country; whereas its social policy determines the proportion of funding from public and private sources. Figure 2 illustrates the level of public and private healthcare expenditure (in USD acc. to ppp) in 2010.

Urszula Skorupska16

Figure 2

Health service public and private expenditure per capita in selected countries in 2010a in usd by purchasing power parity (ppp)

0

1 000

2 000

3 000

4 000

5 000

6 000

7 000

8 000

9 000

Public expenditure Private expenditure

USA

Nor

way

Switz

erla

ndHo

lland

Luxe

mbo

urg

Denm

ark

Cana

daAu

stria

Germ

any

Fran

ceBe

lgiu

mSw

eden

Irela

ndAu

stra

liaUn

ited

King

dom

Icel

and

Finl

and

Spai

nJa

pan

New

Zea

land

Italy

Gree

cePo

rtuga

lSl

oven

iaIs

rael

Slov

akia

Sout

h Ko

rea

Czec

h Re

publ

icHu

ngar

yPo

land

Esto

nia

Chile

Mex

ico

Turk

ey

a Or the last year for which data was available.

Source: Own research based on www.oecd.org/health/, (accessed on 31 Aug 2012).

A considerably lower level of spending on healthcare in Poland, both in relation to GDP and per capita, than in other OECD states, together with a high dynamics of their growth, is indicative of a great development potential of the healthcare sector in Poland.

Over the last years the healthcare sector in Poland has been developing intensively, with a dynamics clearly higher than the OECD member states’ average. Nonetheless, Poland is still a country that has a lot to do in the area of healthcare; the level of spending on that sector in relation to GDP remains low when compared to other countries. A systematic and substantial increase in public healthcare expenditure shows that there is political will to develop this sector. Having regard to the above, and to the fact that in all developed countries the dynamics of healthcare expenditure clearly exceeds the GDP growth, it may be expected that in the years to come the current trend will remain unchanged and Poland’s healthcare sector will continue its intensive growth.

Offshoring of medical services 17

Barbara LiberskaInstitute of Economics, Polish Academy of Sciences

oFFsHorinG oF mediCal serviCes

The ICT revolution, progress in medicine and globalisation processes have created new opportunities to provide number of professional medical services. The mode of organisation and operation of many medical facilities also changed. Recently, there has been a dynamic growth of the process of relocating some medical services abroad, i.e. offshoring or offshore outsourcing7. Escalating costs of health care in developed countries result in the search for opportunities of their reduction via commissioning some functions, procedures and research (currently no direct doctor−patient contact is required)8 to be performed in countries where their costs are lower. Innovations in medicine and development of telemedicine, in particular teleradiology, make it possible for a picture taken at any location to be send in an electronic form to another country for analysis and diagnosis9.

Healthcare institutions in developed countries more and more often decide to move some functions related to hospital operations, including business (e.g. accounts, insurance) and medical services (e.g. radiological diagnostics) to developing countries (mainly to the ‘emerging’ markets). These contries have modern medical technology and large number of highly specialised professionals, which guarantee adequate quality of services performed at a significantly lower cost.

The scope of offshoring of modern medical services continues to expand. It includes numerous research and diagnostic procedures that may involve radiology, i.e. reading and describing an image, such as ultrasound exam, computed tomography or magnetic resonance results. The image may be rapidly moved with the use of a computer and the internet from anywhere in the world to a country where such service will be performed. Progress in medical technology and continuously improving results yielding high quality images increase opportunities for offshoring use. Apart from radiological diagnostics, it may include histopathology or haematology. The choice of location for a given service depends mainly on availability of high level professionals, time and costs of its performance, and whether relevant standards of realising such a service (inclusive of registering, processing, archiving, proper data format and safety) are met.

Contemporary healthcare avails of various forms of offshoring. The first one involves highly specialised services in the field of medical diagnostics; the second refers to the so-called medical tourism, i.e. services for patients who leave for treatment to countries other than their countries of residence10. The third form is relocating scientific entities and conducting scientific research (R&D) out of the country, which includes both new medical technologies and introduction of medicines and research procedures.

Specialists from emerging countries, such as: India, China, or Brazil, provide their services in branch offices of international corporations. They also build their own enterprises, which provide medical services on the global markets. Their own research and development centres spare no effort to create modern medical equipment directed at healthcare improvement for people of low income. Innovations are to contribute to

7 Services may be performed abroad, in a branch of a given company, or in another local company.

8 New medicine allows one to separate numerous individual medical procedures − scanning, reading, describing, diagnosing.

9 Telemedicine includes, amongst others: transferring medical data to a different location, diagnostics, therapy, patient monitoring.

10 See also texts by: E. Szymańska and N. Grądzka and K. Kasner in this Report.

Barbara Liberska18

development of less complicated devices and processes that fulfil basic functions but are better suited to special consumer groups.

Processes of globalisation had an important influence upon the current nature and manner of providing medical services. Liberalisation and opening of economies gave way to internationalisation of medical facilities (many international hospitals in different countries were established) and standardisation of a number of services around the world. Whereas, offshoring of medical services became possible when comparable systems of educating physicians and specialising in certain fields were created, and when the application of international standards and procedures to the utilisation of specialist medical equipment became common practice. The number of specialists in individual countries varies; there are also large discrepancies in doctors’ wages between different countries. In 2005 for example, an average radiologist’ remuneration in the USA was at the level of USD 300,000, while in India it was USD 35,00011.

The processes of globalisation contributed to dynamic growth of the international market of medical services. In many emerging countries private hospitals and companies geared towards providing services to institutions and patients from developed countries are established. Developed countries are undergoing growth of demand for specialised medical services (aging societies and the necessity to take care of a growing group of the chronically ill); there is a need for educating more and more specialists, fast diagnosis and increase of medical services availability through service cost cuts.

Formation of a global market of specialists in the field of medicine and access to state-of-the-art technology let numerous developing countries provide services in places from which physicians used to emigrate. Some countries conduct a special policy of giving medical specialists help to return and supporting development of medical services on the global market. Many doctors, encouraged by conditions of work and possibility to provide services over a distance, decides to return to their country of origin after they have specialised in a chosen field in foreign centres.

For some countries, such as India, service offshoring is one of the vital elements of country development. India has attained a considerable comparative advantage in terms of professional services provision in many domains, including medicine. Over the last few years, due to developed IT infrastructure, low wages and a large number of well-educated specialists, often with foreign internship experience and good command of English, India has become one of the main global offshoring centres. It turned out that it may provide similar-quality services faster and cheaper than in affluent countries. India is a country where traditionally large numbers of students are educated to become doctors – they rank second globally, just behind the USA. The following factors contributed to the development of the sector: high educational standards, government and private investment in IT infrastructure development and programmes supporting local companies in their effort to develop services for global markets. Indian enterprises sprang up, inclusive of Infosys, Wipro, One Source, WNS, which specialise in providing numerous services to the world’s markets. The main seat of the companies in the modern, professional service sector is the city of Bangalore. India greatly benefits from medical services offshoring as it contributed to the establishment of thousands of well-paid jobs, income from services export grew (trade surplus), and finally the base for the local sector of medical services grew.

Other countries (in Asia and Latin America) undertook offshoring medical services development programme despite the fact that their state of healthcare is not very much developed. Nevertheless, they may offer many highly specialised professionals, which guarantees high quality services offered at considerably lower prices.

11 Thousands of foreign students are enrolled in medical universities and educated in hospitals in the USA; simultaneously, American students study in numerous other countries, too.

Offshoring of medical services 19

Global tendencies indicate that the directions of providing medical services are changing. In the past the affluent people from developing countries used to go for treatment to developed countries in anticipation of high quality service that is not available at home ; nowadays, an increasing number of people from developed countries seeks medical services in developing countries because they cannot afford them in their homelands. Some insurance companies offer less expensive service packages in hospitals abroad. In 2010, more than 6 million Americans availed of medical services abroad. At the same time, the majority of American hospitals utilises offshoring and moves several medical services out of the country.

Recently, a global market of medical services has emerged. Health care facilities in many countries, like other enterprises, use international supply chain and offshoring of services for cost reduction. Global demand for medical services will continue to growth due to i the aging society, occurrence of many civilisation-related diseases and prolongation of the life span of people who often require constant care. These challenges need to be answered with medical technology and organisation of medical services.The development of modern technology and advances in the field of medical diagnostics should contribute to cost reduction and increase in availability of medical services. Offshoring of medical services can bring benefits both to the countries which relocate their services abroad as well as to those countries which could provide that services at a distance. The scope and forms of modern offshoring of medical services will continue to expand. Poland should take advantage of the process of globalisation of medicine and of global tendencies in order to develop a competitive sector of modern medical services offshoring.

Iwona Nowicka20

Iwona NowickaMinistry of Science and Higher Education

mediCal issues in tHe polisH ForesiGHt projeCts

Health care in Europe is currently a major social problem due to the widespread aspiration to improve the quality of life, where health is a key factor, and due to the problem of an aging population. These issues have been continuously present in Poland and in the majority of industrialised countries around the world. In order to solve the healthcare-related problems of the society, one needs to pay special attention to vital concerns in the field of medicine involving identification of the primary classification of diseases and the analysis and choice of key medical technologies for prophylaxis, diagnostics, treatment and rehabilitation12.

An opportunity to select principal technologies and to determine possible future long-term development scenarios is provided by Foresight, which invites a wide range of social actors: scientists, entrepreneurs, public administration representatives, non-governmental and social organisations, politicians and the media to a shared debate on the future.

Realisation of Foresight projects in Poland began in 2003 with a Pilot Foresight Health and Life Project. Even back then, the health and life protection issues were priorities because of a strong social support for the subject matter, progressing changes in the demographic structure of the Polish society resulting from its aging, and seeking a niche on the Polish pharmaceutical and medical market.

The main outcome of the Pilot Foresight Health and Life Project was a selection of 26 directions of research and technology development in the areas of prophylaxis, healthcare and health promoting education, and those aimed at assuring proper nutrition and its safety. Top priorities in the area of medicine include13:

Construction of effective screening systems.��

Development of perinatal care, early detection of genetic defects and developmental ��

disorders.Development of methods and techniques of first-aid services.��

Development of methods and technologies for the purpose of universal health ��

promotion.Development of methods and techniques of prophylaxis, diagnostics and therapy ��

of infectious diseases and infections important from the point of view of public health. Development of methods and techniques of prophylaxis, diagnostics and therapy ��

of aging-associated diseases. Research on stress and development of methods of stress reduction.��

Development of methods and techniques of rehabilitation in somatic and psychic ��

disorders of a great social meaning.One of the most important Foresight projects related to medical technologies in

Poland was the following: The System of Medical Technologies Monitoring and Scenarios Development in Poland, realised in 2008 by the ROTMED consortium. The

12 ROTMED Consortium: The system of medical technologies monitoring and scenarios development in Poland [in Polish], J.M. Wójcicki, P. Ładyżyński (ed.), Drukarnia Platin, Warsaw 2008, p. 19.

13 Pilot Foresight Health and Life Project Brochure [in Polish], Pentor Research International, Warsaw 2005.

Medical issues in the Polish foresight projects 21

outcomes of the project included scenarios of development of medical technologies in Poland till 2020 and a selection of key medical technologies.

The results of project analyses indicated technologies with the highest chance of being implemented in medicine (healthcare) and industry, including14:

Telemetry.��

The analysis of bio-medical signals acquired by on-body and environmental ��

sensors.Bio-materials for the treatment of skeletal system diseases in humans.��

Development of technologies improving the quality of life of the sick, the disabled, ��

and the elderly.A remote tele-medical assistance for endoscopic and laparoscopic therapy and ��

diagnostics.Automatic systems of threat detection and warning.��

Ultrasound characteristics of the tissue structure. ��

Technology of production of devices supporting patients with sensory ��

impairment.New structural composite materials for external prostheses and rehabilitation ��

equipment.In addition to projects directly focused on medicine-related issues, there have

been multiple regional Foresight projects accomplished in Poland that dealt with said subject matter. For example, the project entitled Monitoring and projecting key, innovative technologies for a sustained development of the Mazovieckie Province, as part of projected development scenarios of technologies concerning the standard of living of the society, lays down technologies supporting prophylaxis, diagnostics, constant medical care, surgical interventions and first aid, including but not limited to the following medical imaging technologies: MRI (magnetic resonance imaging), fMRI (functional magnetic resonance imaging), PET (positron emission tomography)15.

Practicable technologies in the area of medicine and health to be implemented in the Małopolskie Province were designated in the consecutive Foresight project entitled: Technology Perspective Kraków-Małopolska 2020 and these are16:

Selective anti-cancer medicines and technologies. ��

Facilitation of the treatment process based on data analysis. ��

In silico �� research in medicine development. Monitoring and control of medical conditions (telemedicine). ��

Research and development of therapies based on stem cell analyses. ��

Tissue engineering, immunotherapy, artificial muscles and tissues. ��

Advanced methods of diagnosing and surgery.��

The next Foresight project with research priorities set in the areas of biotechnology and pharmacy vital for the Lower Silesia region is the project entitled Identification of the potential and resources of Lower Silesia in the field of science and technology for the benefit of quality of life improvement, and setting directions for development. Research based on Foresight methods. A positive scenario projected implementation of the following priorities in the Lower Silesia region:

Development and implementation of simple and inexpensive diagnostic methods, ��

mainly concerned with diseases of civilisation.

14 ROTMED Consortium: The system of medical technologies monitoring and scenarios development in Poland [in Polish], J.M. Wójcicki, P. Ładyżyński (ed.), Drukarnia Platin, Warsaw 2008, pp. 332−333 (project’s website http://rotmed.ibib.waw.pl/index.html).

15 Foresight of the Mazowieckie Province. A cross-sectional analysis of impacts, development scenarios, priority technologies [in Polish], Industrial Research Institute for Automation and Measurements, Warsaw 2008, pp. 124−130 (project’s website http://www.formazovia.pl/).

16 Technology Perspective Kraków-Małopolska 2020. Developmental challenges [in Polish], Krakowski Park Technologiczny, Cracow 2010, p. 50 (project’s website http://foresight.kpt.krakow.pl).

Iwona Nowicka22

New selective anti-cancer medicines.��

Development of transplantology and application of biotechnology in the production ��

of tissues and cells for transplantation and regeneration of damaged organs. Application of bacteriophages in the treatment of infectious diseases.��

Establishment of a regional Cancer Bank.��

Creation of a biotechnological and pharmaceutical cluster.��

The last of the selected examples of Foresight projects focusing on medical issues is a regional Foresight project of the Silesian Province entitled Priority technologies for a sustainable development of the Silesian Province. The identified project identified emerging trends in the field of medicine, such as: telemedicine, artificial organs, micro- and nanotechnology for medicine, and advanced diagnostic and therapeutic tools. Another result of the project was a list of 30 key technologies in the area of medical engineering for the Silesian Province. Below are 10 top key technologies on the list17:

Blood substitute based on genetic technologies and cell cultures. 1. Construction of stent valves and other tools for transcatherer heart disease 2. treatment. Synthesis of biodegradable polymers. 3. Tele-monitoring of patient’s condition, including bedridden patients staying out of 4. hospital.Advanced systems of medical modelling based on virtual technologies.5. ICT system of medical data transfer.6. Programmable, implantable, high-integrity, low-power-design diagnostic tools 7. with a wide array of communication options.Stem cell cultures, highly specialised cell type cultures for therapeutic purposes.8. Completely implantable, permanent use artificial heart. 9. Surgical tele-operators, such as Robin Heart.10. The results of Foresight projects in the area of medicine, both accomplished and

in progress, should mainly be directed at representatives of central and local authorities responsible for financing of scientific research; with the transfer of scientific research findings also to the sector of enterprises and institutions responsible for the quality of life and healthcare.

In addition, outcomes of such projects might prove useful for18:Research and development centres.��

Companies manufacturing medical equipment and materials.��

Companies selling medical technologies.��

Service companies operating in the area of healthcare.��

Healthcare facilities.��

Institutions funding the healthcare area.��

Insurance companies.��

Patients using the healthcare system.��

17 Priority technologies for a sustained development of the Silesian Province [in Polish], K. Czaplicka-Kolarz, A. Karbownik (ed.), Part 3, Trade development scenarios for the Silesian Province [in Polish], Główny Instytut Górnictwa Katowice, Katowice, 2008 (project’s website http://www.forsilesia.polsl.pl/).

18 ROTMED Consortium: The system of medical technologies monitoring and scenarios development in Poland [in Polish], J.M. Wójcicki, P. Ładyżyński (ed.), Drukarnia Platin, Warsaw 2008, p. 23.

Medical issues in the Polish foresight projects 23

Grażyna K. NiedbalskaThe Science of Science Committee of the Polish Academy of Science

HealtH-related r&d primary indiCators and measurement problems

Over the recent years, highly developed countries observe growing demand for statistical data concerning research and development activity (R&D), in the scope that is referred to, in international literature, as health-related R&D. Such data constitutes an ever more important component of a set of statistical data used in decision-making processes in the fields of economic, as well as scientific and technical policies (topics of special interest according to the Frascati Manual 2002)19.

The measurement of resources earmarked for research and development activities performed in areas related to the broadly understood healthcare is one of the most difficult challenges that the R&D statistics faces today. Official R&D activity statistics are based on the so-called Frascati system (methodology), i.e. a set of methodological definitions and recommendations discussed in the Frascati Manual (hereinafter FM) drawn up 50 years ago under the auspices of the Organization for Economic Cooperation and Development (OECD).

In its current, sixth edition, the Frascati Manual 2002 (FM 2002) devotes one of the chapters of Annex 420 to the issue of collecting statistical data concerning health-related R&D. The chapter is titled Deriving data on health-related R&D from regular R&D statistics. The difficulties faced when estimating health-related R&D stem from the fact that the standard classifications used in the Frascati system do not offer a possibility to directly single out the value in question.

The most frequently used and the most easily accessible data relates to R&D by major field of science − Medical sciences. The basic indicators concern the absolute value, the share that the medical sciences expenditure has in the total R&D spending (total R&D spending is referred to, in R&D statistics, as GERD – Gross Domestic Expenditure on R&D), and the number of personnel employed in this field of science.

According to data published by GUS (Główny Urząd Statystyczny – Central Statistical Office), expenditure on medical sciences (medical and health-related sciences) accounted, in Poland, over the past years, for approximately 10 per cent of all R&D expenditure, i.e. the aggregate known as GERD (10.5 per cent in 2009, 10.3 per cent in 2010). In absolute values, we are dealing with the amount of approximately PLN 1 billion here (PLN 953.3m in 2009, PLN 1,073.5m in 2010)21.

The GUS data is based on an R&D survey conducted pursuant to the Frascati methodology. The survey covers R&D performers.

Data concerning R&D activity performed in the field of medical sciences constitutes the core category of health-related R&D. This approach, however, fails to include the

19 Proposed Standard Practice for Surveys of Research and Experimental Development – Frascati Manual, OECD, first edition 1963, sixth edition 2002 (http://www.uis.unesco.org/Library/Documents/OECDFrascatiManual02_en.pdf), pp. 26–27.

20 Frascati Manual 2002, Annex 4, R&D Related to Health, Information and Communication Technology (ICT) and Biotechnology.

21 Polish Statistical Yearbook 2011, GUS, Warsaw 2011, pp. 411-412 (http://www.stat.gov.pl/gus/5840_2844_PLK_HTML.htm). In the structure of R&D expenditure by scientific discipline (natural, technical, medical, agricultural, social sciences and humanities), technical sciences visibly predominate, accounting for over 40% of total R&D expenditure in Poland (44.2% in 2009 and 47% in 2010).

Grażyna K. Niedbalska24

health-related R&D performed in other fields of science (genetics, bacteriology, etc.), as well as technical or social sciences.

Another source of official statistical data concerning health-related R&D is a survey of the resources earmarked by the government for R&D activity according to socio-economic objectives (GBAORD – Gross Budget Appropriations or Outlays on R&D, by socio-economic objectives). In Poland, the said survey, performed in line with the requirements of EU legislation, is conducted by the Ministry of Science and Higher Education.

Unlike with the GUS-conducted survey that covered the entities performing R&D activity, the survey concerned with the structure of the aggregate referred to as GBAORD, by socio-economic objectives, is a survey that covers the “providers” of R&D funding – it is the so-called funders’ report. The funder/performer distinction is one of the fundamental principles on which the Frascati methodology is based.

The socio-economic objectives of R&D activity are defined based on the NABS classification – Nomenclature for the Analysis and Comparison of Scientific Programmes and Budgets. The current version of this classification, known as NABS 200722, distinguishes the total of fourteen socio-economic objectives, or SEO. R&D activity related to the protection of health is classified under the “Health” objective. However, health-related R&D elements are also included in the category General advancement of knowledge.

In 2009, approximately 8 per cent of the total amount of budget funding earmarked in Poland for R&D activity was classified, under NABS 2007, as “Health” expenditure23.

In the United States, a country that is currently the world’s leader in terms of health-related R&D, the share of funding earmarked for the objective classified as “Health” accounts to approximately 25 per cent of GBAORD, i.e. the total resources appropriated by the federal government for R&D activity (26.7 per cent in 2009)24. The objective referred to above is the most important civil socio-economic objective for which R&D budgetary resources are earmarked by the United States federal government (over half of the funding earmarked by the federal government for R&D activity is appropriated to defense – approx. 52 per cent in 2009).

When analyzing the official statistical data concerning R&D activity, one has to bear in mind that they constitute – due to the great degree of difficulty posed by R&D measurements – only a more or less accurate estimate of the actual values, which applies, in particular, to health-related R&D.

In the conclusions to the aforementioned Annex 4 to the “Frascati Manual” a need has been identified to rely, in practice, on numerous varying sources while estimating the health-related R&D, and, in particular, on an indicator referred to as GERD for health. Other data sources may be relied upon as well, such as reports of medical charities, health research councils and funds, and reports of the pharmaceutical industry associations25.

As far as health-related R&D is concerned, one of the most serious methodological challenges is posed by the measurement of expenditure on clinical trials. Such trials aim to identify whether a given medicine which is to be introduced to the market is effective and safe for patients. Clinical trials last for a number of years, and in the case of some medicines – even more than 10 years. It is estimated that the cost of

22 NABS 2007 classification can be found at Eurostat RAMON – Eurostat’s Metadata Server, accessible also from GUS website http://www.stat.gov.pl/Klasyfikacje/.

23 Total GBAORD by NABS 2007 Socio-economic Objectives, Eurostat, Statistics Database (http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do)

24 Science and Engineering Indicators 2012, National Science Foundation.25 Detailed information on international statistics and examples of methodological solutions

used in countries attempting to estimate health-related R&D expenditures can be found in OECD publication Measuring Expenditure on Health-related R&D, OECD, Paris 2001, http://browse.oecdbookshop.org/oecd/pdfs/free/9201061e.pdf.

Health-related R&D primary indicators and measurement problems… 25

clinical trials accounts, on average, to approximately 2/3 of the costs involved in the development of new medicinal preparations26.

Clinical trials consist of four phases. The first, second and third phase occur prior to the manufacturer’s obtaining the market authorization, while the fourth – after the authorization has been granted and production commenced. Frascati Manual 2002 assumes that the first, second and third phase of clinical trials should be considered, in statistical surveys, as R&D activity.

In practice, due to various reasons, it is very difficult to obtain exhausting data in this filed. Various countries adopt differing solutions, which exerts a negative impact on the international comparability of statistical data concerning medical sciences - and health-related R&D.

In Poland, clinical trials are usually performed by pharmaceutical companies within the framework of international projects. In January 2010 “Rzeczpospolita” daily informed that according to unofficial sources clinical trial-related expenditure may amount to as much as over USD 1bn per year27. According to the “Clinical trials in Poland – Key Challenges, November 2010” report drawn up by PricewaterhouseCoopers (PwC) to the order of the Association for Good Clinical Practice in Poland (GCPpl), the value of the clinical trials market in Poland amounts to approximately PLN 860 million, with a vast majority of those funds originating from abroad. According to the same report, 469 new clinical trials were registered in Poland in 2009, which accounts to approximately 2.5–3 per cent of all new trials registered worldwide28.

One of the data sources that may prove useful for analyzing health-related R&D is an undertaking of the European Union, i.e. The EU Industrial R&D Investment Scoreboard, presenting data from company reports and accounts published up to 31 July.

According to data published in the subsequent editions of The EU Industrial R&D Investment Scoreboard, it is the Pharmaceuticals & biotechnology sector that is currently the world’s leader in terms of R&D expenditure, based on the ICB Industry Classification System.

In the World Top 1400 Companies ranking, as published in The 2011 EU Industrial R&D Investment SCOREBOARD29, five out of the 10 businesses leading, in the 2010 fiscal year, in the terms of R&D expenditure, are pharmaceutical companies (ICB category: Pharmaceuticals 4577). Two out of those are Swiss businesses (Roche and Novartis), while three come from the United States (Pfizer, Merck US and Johnson & Johnson). The world’s leader in terms of R&D expenditure borne in 2010 is the Swiss Roche, which earmarked, for R&D purposes, approximately EUR 7.2 billion.

The top ten of the 2010 R&D ranking of the top 1000 EU companies includes three pharmaceutical enterprises: the French Sanofi-Aventis (ranked 4th with the 2010 R&D expenditure of EUR 4.4 billion) and two British companies: GlaxoSmithKline and AstraZeneca (ranked 5th and 9th respectively). As far as enterprises from new EU Member States are concerned, the highest position in the ranking measuring R&D-related expenditure is occupied by the Hungarian pharmaceutical corporation of Gedeon Richter (ranked 196th) and the Slovenian company of Krka (ranked 207th)30.

No in-depth analysis of R&D activity has been conducted in Poland that would relate to health-related R&D or GERD for health. It is high time a research project of this type was commenced, which project shall aim at and result in introducing, in Poland, a comprehensive system for monitoring health-related R&D activity.

26 The procedure of introducing generic medicines to the market is much shorter and cheaper. It involves investigations aimed at confirming bioequivalence of generics and original medicines.

27 „Rzeczpospolita” 2010, No. 7 (8518) of January 9–10.28 Report in Polish and English available at: http://www.gcppl.org.pl/index.php/aktualnoci/128-

raport-pwc-badania-kliniczne-2010-#, pp. 2, 3.29 The 2011 EU Industrial R&D Investment Scoreboard (http://iri.jrc.ec.europa.eu/research/

scoreboard_2011.htm).30 For comparison, the highest scoring Polish firm in the „R&D ranking of the top 1000 EU

companies” – ComArch (category ICB „Computer services 9533”) ranked 463.

Beata Kwiecińska26

Beata KwiecińskaInstitute of Economics, Polish Academy of Sciences31

innovativeness and FinanCinG oF tHe HealtH Care seCtor From tHe eu Funds

Healthcare sector in the European Union (EU) differs in terms of research and development (R&D) intensity from other regions in the world, such as the USA. Clustering of individual entities of the medical sector is much less intensive in the EU than in the USA. Clusters increase innovativeness, as companies composing them create more innovations that they would working separately. Relatively poor commercialization of R&D and non-technological innovation in the EU seems to be even more serious a problem than the state of the R&D sector per se. The EU should therefore put more attention to fostering basic research in order to create new ideas, and to create the right business conditions for new technologies and innovations to be developed and commercialised on the market. As the importance of services in most OECD countries has steadily increased over time, entreprises using knowledge- intensive business services32 have become ever more important.33

The R&D development in line with the Lisbon Strategy, supporting innovation defined in technological and process terms in the Oslo Manual34, is becoming gradually more visible in a number of the EU actions. This trend illustrates an increasing share of the Structural Funds allocated to the health care in its broad sense.35 According to the information provided by the European Commission, nearly EUR 5 billion were allocated in the European Regional Development Fund (ERDF) programming period 2007–2013 to the health care infrastructure, while in the ESF it represented only 10% of EUR 7.6 billion. So far these resources have been primarily aimed at modernisation of facilities and equipment used in the health care sector, and at medical staff training. The financial resources available to support health care are very crucial for operational programmes and research projects aimed at improving the technology innovation and medical entities.36

Funding of health care projects can be achieved within the regional or countrywide operational programmes. Depending on the region, EU funding covers from 30% to 85% of the project costs.

Research and development of medical technologies are important issues in the health care policy. Two EU programmes are the closest to those goals: Health, implemented under TEN (e-Trans-European Network) Network and the Framework Programme (FP). Programme e-Health was launched in year 2000 under the eEurope initiative. Its aim is to support technology areas, including medical informatics, telemedicine and ICT. e-Health is one of the programmes within eTEN and is focused on improving access, quality and cost effectiveness of health policy on the Trans-European level.37

31 The opinions expressed in the article are those of the author. 32 Defined in accordance with NACE classification. 33 European Competitiveness Report 2011, European Commission, EU 2011, p. 22.34 Oslo Manual, OECD, 2005.35 In programming period 2007−2013 from ERDF (European Regional Development Fund) and

ESF (European Social Fund) only 2−3,6% of resources were directed to health care related projects.

36 More on the subject in: Report on Innovativeness of the Polish Economy in 2011, T. Baczko (ed.), INE PAN, Warsaw 2012.

37 More on e-Health see: http://ec.europa.eu/information_society/activities/health/policy/index_en.htm

Innovativeness and financing of the health care sector from the EU funds 27

The Framework Programme has been already launched for the seventh time. Its budget compared to the previous editions has been increased to EUR 53.2 billion for the whole programming period 2007–2013.38 Health care is one of the major areas of the FP7, together with information technology and nanotechnology. The budget assigned to health related projects amounts to EUR 6 billion.

Co-financing of projects has an impact on economic performance on the international and national level. Figure 1 shows the spending of the Visegrad Group (V4) on health care, as a percentage of GDP. Bringing an example of V4 is not accidental, since the impact of health care financing on GDP is similar. Its increasing trend reflects, among the other factors, the impact of the pre-accession funds, and, after EU accession in 2004, increased EU funding. Co-financing the projects from the EU funds allowed the V4 countries to reduce systematically the gap between them and the EU-15 (the “old” EU Member States). Increasing the amount of funds supporting health care in the new programming period launched in 2007 gave a further boost for project funding.

The economic crisis started in 2008 was also not neutral for the health care, largely funded form public resources. Execution of the budget for 2008 allowed for further continuation of the growth until the end of the year. Changes in the future spending planning were reflected in fluctuations in the trend starting from 2009. Comparing with the preceding year 2008, Poland, Czech Republic and Slovakia reported a reduction of spending on health care. Despite the fluctuations discussed above the cohesion policy funds coming from the EU budget have still significant impact of on the health care.39

Figure 1

Health care expenditure in v4 countries

9,5

9,0

8,5

8,0

7,5

7,0

6,5

6,0

5,5

5,0

4,5 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010Year

% P

KB

HungaryCzech Republic

PolandSlovakia

Source: Health Expenditure and Financing, OECD, 2011 (http://stats.oecd.org/Index.aspx?DataSetCode=SHA).

38 http://ec.europa.eu/research/fp7/index_en.cfm?pg=understanding 39 More on the subject in: Evaluation of benefits to the EU-15 countries resulting from the

implementation of Cohesion Policy in the Visegrad Group countries, MRR, Warsaw 2011.

Beata Kwiecińska28

Analysing figure 1, it may be pointed out that it is economically profitable to apply for financing from the structural funds for projects in the health sector.40

Poland, similarly to the other Visegrad Countries (Hungary, Czech Republic and Slovakia), developed a trend of increased spending on health care and financing the growing number of innovative projects. Steadily increasing funding for innovative projects is important both for Poland and for the other EU-27 Member States which later on may potentially contribute to increasing the density and quality of research and development.

Therefore, together with the preparation of the new programming period 2014–2020, it will be important to increase spending on R&D including the health sector. In addition, it is important for the sector development to develop the above-mentioned research and development base to support the service sector expansion.

Interaction of individual business sections (such as health care, industry, education, information and communication) on theoretical and practical level is also significant and may prove to be an optimal solution for the market’s demand.

Although the health sector participants face a number of challenges and are in need of steadily increasing funding, it still faces good prospects for development. Despite the number of EU guidelines and complicated process of acquiring EU co-financing, the economic data confirm that obtaining the EU funds is necessary and crucial when supporting the activities in the health sector. Various available funding resources and cooperation between sectors using potential innovative solutions become the basis for creating new projects at the regional, national and transnational level.

40 An example of the report presenting innovative Project in health care is: Innovation in Healthcare Without Borders, Research Media Ltd, Issue 14, Bristol 2012.

Medical sector universities and institutes which received eu funds for innovation 29

Joanna PęczkowskaInstitute of Economics, Polish Academy of Sciences

mediCal seCtor universities and institutes wHiCH reCeived eu Funds For innovation

As part of the Operational Programme Innovative Economy in Poland 106 scientific entities and 42 tertiary education institutions received support. Overall, they carried out 484 projects worth nearly to PLN 8.5 billion, out of which almost PLN 7 billion was EU funding. This group of beneficiaries comprised 36 scientific entities and 20 higher education institutions, which accomplished more than 130 innovative projects in the field of medicine. The total value of these projects exceeded PLN 2.2 billion, out of which more than PLN 1.7 billion41 was funded by EU. The largest number of projects was accomplished as part of the first and second priority axes, i.e. Research and development of new technologies and R&D infrastructure. A few projects were carried out also as part of the fourth and fifth priority axes, i.e. Investment in innovative undertakings and Diffusion of innovation.

It is worth noting here that the analysis included projects the subject matter of which was closely related to the medical sector. Identification of all projects connected with health care is extremely difficult as medical issues are frequently only a small part of projects with a much more extensive scope. There are numerous projects that are interdisciplinary in nature and thus realised by scientific consortia comprising among others units which may be included in the widely understood medical sector.

When analysing EU-funded projects, it is worth noting that a large group thereof were innovative projects in the field of medical diagnostics, new medicines and therapies development, including but not limited to:

cancer detection and therapy realised by: the Medical University of Gdańsk, the ��

Pharmaceutical Research Institute in Warsaw, the Institute of Bioorganic Chemistry, Polish Academy of Sciences, the Poznań University of Technology, the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences in Wrocław, the Jagiellonian University in Cracow, Centre of Oncology – the Maria Skłodowska-Curie Institute, Gliwice Branch, the Pomeranian Medical University in Szczecin, the Institute of Atomic Energy POLATOM in Otwock-Świerk, the University of Łódź; diagnostics and development of innovative cardiac and cardiovascular system ��

disease carried out by: the Cardinal Stefan Wyszyński Institute of Cardiology in Warsaw, the Silesian Centre for Heart Diseases in Zabrze, the Professor Zbigniew Religa Foundation of Cardiac Surgery Development in Zabrze, the Institute of Bioorganic Chemistry, Polish Academy of Sciences, the Pharmaceutical Institute, the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, the Institute of Medical Technology and Equipment in Zabrze, the Jagiellonian University, the Medical University in Łódź, the Nicolaus Copernicus University in Toruń; treatment of diabetes and prevention of complications related thereto – the ��

Jagiellonian University, the Institute of Biotechnology and Antibiotics in Warsaw, the Medical University of Białystok;

41 Developed on the basis of: List of beneficiaries of the Innovative Economy Operational Programme – as of 31 December 2011, based on KSI SIMIK 07–13 [in Polish] (www.funduszeeuropejskie.gov.pl/).

Joanna Pęczkowska30

development of antibiotics and other bactericides – Ludwik Hirszfeld Institute of ��

Immunology and Experimental Therapy, Polish Academy of Sciences, the National Institute of Public Health – the National Institute of Hygiene in Warsaw; new methods of therapies of disorders of the nervous system and mental diseases, ��

inclusive of depression and schizophrenia – the Institute of Pharmacology, Polish Academy of Science in Cracow; development of bird flu vaccine – the Institute of Biotechnology and Antibiotics;��

the use of implants in the treatment of osseous tissue deficiencies – the Warsaw ��

University of Technology, the AGH University of Science and Technology in Cracow, and the treatment of abdominal hernias – the Medical University of Gdańsk;new methods of wounds and burns treatment – the Centre of Polymer and Carbon ��

Materials, Polish Academy of Science in Zabrze;development of specialist biosensors for pathological processes detection in a body, ��

e.g. complications of diabetes or an early stage of Alzheimer disease – the Institute of Biochemistry and Biophysics, Polish Academy of Sciences in Warsaw, development of endothelium-targeted therapeutics – the Jagiellonian University, ��

the Medical University of Warsaw;the application of stem cells in medicine – the Pomeranian Medical University, the ��

Institute of Bioorganic Chemistry, Polish Academy of Sciences;electrical muscle stimulation after trauma and long-term immobilisation – the ��

Łódź University of Technology;development of home assistance for disabled and elderly people – the Gdańsk ��

University of Technology.Moreover, research was conducted in the areas of genetics, molecular medicine,

ophthalmology and there were projects involving development of specialist medical equipment.

7 scientific entities and 3 tertiary education institutions realised projects related to receiving a patent protection for their inventions. An absolute leader amongst these bodies is the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, which accomplished 13 projects. The Institute of Bioorganic Chemistry ranks second (7 projects) and the Pomeranian Medical University third (5 projects).

EU funds were also allotted to realisation of numerous projects aiming at development of IT systems and scientific platforms supporting scientific research and allowing knowledge exchange. The entities conducting works in said fields are: the Jarosław Dąbrowski Military University of Technology in Warsaw, the Centre of Oncology – the Maria Skłodowska-Curie Institute in Warsaw, the Pomeranian Medical University in Warsaw, the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, the Children’s Memorial Health Institute in Warsaw, the Military Medical Institute in Warsaw, the Nofer Institute of Occupational Medicine in Łódź, the Cardinal Stefan Wyszyński Institute of Cardiology, the Institute of Physiology and Pathology of Hearing in Warsaw, and the Poznań University of Technology.

Moreover, structural funds helped to establish multiple laboratories and research centres, including but not limited to:

the Centre for Preclinical Research and Technology – the Medical University of ��

Warsaw,the Jagiellonian Centre for Experimental Therapeutics – the Jagiellonian ��

University, the Centre for Micro- and Nanotechnologies MINOS – the Institute of Electronic ��

Materials Technology in Warsaw, the Centre of Radiochemistry and Nuclear Chemistry for the purposes of nuclear ��

power and nuclear medicine − the Institute of Nuclear Chemistry and Technology in Warsaw,

Medical sector universities and institutes which received eu funds for innovation 31

International Centre for Research and Treatment of Partial Deafness − Institute ��

of Physiology and Pathology of Hearing, the Małopolska Centre of Biotechnology − Jagiellonian University,��

the Bronowice Cyclotron Centre – Gantry Treatment Room – the Henryk ��

Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences in Cracow,the National Centre for Hadron Radiotherapy, Phase 1: the Bronowice Cyclotron ��

Centre – the Henryk Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences,NeoLek – Integrated Laboratory of Experimental Oncology and Innovative ��

Technologies – Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences,the National Centre for Diagnostics and Treatment of Familial Hypercholesterolemia ��

– the Medical University of Gdańsk,WROVASC – Integrated Centre of Cardiovascular Medicine – Voivodeship Specialist ��

Hospital in Wrocław,the Centre of Morphologic Images Archiving and Digital Database of Microscopic ��

Pictures – the Poznań University of Medical Sciences. Furthermore, the Ochota Biocentre Consortium was established in Warsaw,

comprising: Institute of Biochemistry and Biophysics, Polish Academy of Sciences, the Nałęcz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, the Nencki Institute of Experimental Biology, Polish Academy of Sciences, the Mossakowski Medical Research Centre, Polish Academy of Sciences in Warsaw, the Institute of Fundamental Technological Research, Polish Academy of Sciences in Warsaw, and the International Institute of Molecular and Cell Biology in Warsaw.

Polish scientific entities conducting research in the field of medicine have outstanding potential, which is frequently not utilised due to lack of financial resources. Therefore, structural funds are a key element of support to their research and development activity. Probably many of the innovative and costly research would have never been initiated without support from the EU. Despite the fact that most effects cannot be measured yet, we may say that structural funds have largely contributed to growing competitiveness of Polish scientific centres, both on the domestic and global markets.

It is well worth stressing that high research potential of Polish scientific entities in the medical sector has been seen. This is reflected by participation of Polish institutes in EU Framework Programmes, among others, of the following: the Nałęcz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences42, the Medical University of Warsaw, the International Institute of Molecular and Cell Biology in Warsaw, the Intercollegiate Faculty of Biotechnology, the University of Gdańsk – the Medical University of Gdańsk, and the Medical University in Łódź.43

42 Compare the text by J.M. Wójcicki in this Report. 43 Website http://www.nauka.gov.pl/ministerstwo/aktualnosci/aktualnosci/artykul/rekordowe-

dotacje-dla-polskich-centrow-badawczych-1/ (accessed on 10.09.2012).

Urszula Skorupska32

Urszula SkorupskaInstitute of Economics, Polish Academy of Sciences

tHe private HealtH insuranCe market in poland

Two areas of the Polish healthcare sector are developing simultaneously: the public area, where health benefits are funded by the Polish National Health Fund (Narodowy Fundusz Zdrowia, NFZ), and the private one, where the payers are private individuals, enterprises, not-for-profit organisations and insurance companies other than NFZ. The public sector, as measured by the share of public payers’ spending in the total spending on healthcare in Poland accounted for 71.7% in 2010. It should be noted that NFZ is a major but not the only public payer on the health services market – its share in public healthcare expenditure is 86.2%44. Other payers include local self-governments and the state budget, which covers expenditure related to the functioning of the State Sanitary Inspection (Państwowa Inspekcja Sanitarna), health policy programmes, and highly specialised and other benefits. Shortage of public funding in the healthcare system is supplemented with household budgets, not-for-profit organisations, and enterprises spending, both obligatory – set forth in the Labour Code, and optional – a part of employers’ social policy. It should be noted that lack of legal regulations opening way to private insurance development has contributed to their marginal significance. Private insurance constitutes barely 2% of the private sector healthcare expenditure (cf. Fig. 1).

Figure 1

private sector: healthcare payers structure in 2009 (in %)

households

enterprises

non-profit institutions

private insurance

abroad

79,9

13,6

3,6 2,10,8

Source: Based on: Health and healthcare in 2010 [in Polish], GUS, Warsaw, pp. 270–273.

Lack of possibility of taking out health insurance outside the public system contributes to households bearing the major cost of private spending on healthcare. Household expenditure covers mostly health benefits that are not provided for by the general health insurance or only partially funded, for instance medicines and health benefits guaranteed by NFZ but with limited availability or of insufficient, according

44 Data based on the Announcement of the President of the Central Statistical Office (GUS) of 26 June 2012 on the National Health Account for 2010 (http://www.stat.gov.pl/gus/5840_13087_PLK_HTML.htm).

The private health insurance market in Poland 33

to patients, quality. It is a gap which could be filled by private insurers. In 2010, 31.2% of households used medical services which were not funded by NFZ. The most common reasons of covering the costs individually involve setting faraway appointment dates by sub-contracted NFZ entities or employing better specialists in outpatient clinics that are not part of the public healthcare system. Detailed data is presented in Figure 2.

Figure 2

the reasons behind the use of medical services not funded by nFZ by households in 2010 (in %)

49,3

24,3

7,5

4,8

4,4

9,7 faraway date of appointment as part of NFZ

better doctors in clinics not funded by NFZ

lack of doctors specialising in particular fields in NFZ-funded clinics

better equipment and medical materials in non-NFZ-funded clinics

better patient treatment in non-NFZ-funded clinics

other

Source: Based on: Healthcare in households in 2010 [in Polish], p. 129 (http://www.stat.gov.pl/cps/rde/xbcr/gus/zo_ochrona_zdrowia_w_gospodarstwach_domowych_2010.pdf).

In the general health insurance system, patients are required to co-finance the purchase of medicines and other medical products, which deems most therapies unsuccessful without financial involvement of the insured45. In Poland, pharmaceuticals expenditure are covered primarily with individual incomes – households finance circa 62% of medicines spending in total; whereas, in the majority of European systems the main burden is carried on the shoulders of the public system. For example, in France ca. 73%, in Czech Republic ca. 69% and in Germany ca. 73% of pharmaceuticals expenditure is covered with public funds. The system that is typical of Poland facilitates marketing activities of pharmaceutical companies, the promotional campaigns of which are not verified on the market by specialists but by patients, whose medical knowledge is largely limited. The gross of households spending on healthcare goes to the costs of pharmacotherapy and dental services. This means that more than 80% of household healthcare expenditures ensues from legislative norms. The remaining expenses involve services which are potentially available as part of the public system. The distribution of said expenses is presented in Figure 3.

Certain scope of the private sector on the healthcare market was specified in the Labour Code through a duty laid upon employers and employees involving preventive medical tests, which are paid for in full by the employer, hence, they fall outside the public financing system. Employers in particular pay the costs of preliminary tests, follow-up and periodical exams, the costs of health benefits as part of preventive-therapeutic subscriptions, and the costs of workers’ group health insurance. The employer may refer the employee to a public Health Care Centre (ZOZ) or use services of private companies offering services in the field of occupational medicine. Workers’ tests are a small portion of the health services market (less than 2% of the private sector current spending), which exists only within the framework set forth by the Labour Code, without any greater prospects of development. Apart from obligatory

45 Mainly older generation medicines and generic medicines (developed on the basis of innovative medicines past their patent protection period) are subsidised; therefore, pharmacological treatment with modern agents is largely funded by the patients.

Urszula Skorupska34

contracts on providing services in the field of occupational medicine, employers may also conclude agreements concerning the provision of medical services as part of so-called medical subscriptions46 or workers’ health insurance covering various scopes of health services. This market segment is undergoing dynamic development. It means that despite lack of rules or regulations supporting private health insurance market development, a so-called quasi-health insurance market has emerged, where medical packages or subscriptions directed at enterprises (workers; medical subscriptions) and individual patients are offered. They are very frequently sold not through insurance companies but directly by service providers.

Figure 3

the structure of household healthcare expenditure in 2009 (in %)

0,0 20,0 40,0 60,0 80,0 100,0

0,2

Pharmaceuticals and medical equipment

Dentistry

Outpatient clinics (POZ) and specialist care

Hospital services

Nursing care services

66,8 15,5 14,9 2,6

Source: Based on: Health and healthcare in 2010 [in Polish], GUS, Warsaw 2012, pp. 270-273.

Quasi-health insurance, which accounted for almost 6% of the private healthcare market in Poland in 2009, served to partially fill the gap in the Polish healthcare system related to shortage of private, supplementary health insurance, despite existing demand for it. Experience of numerous countries demonstrate that development of the health insurance market, both state and private, is a positive stimulant for the whole healthcare sector development. So far, Poland has not taken advantage of other European countries’ experience in reforming the sector, where an essential element of health policy was the establishment of legal institutions for the functioning of private health insurance. Poland, Hungary and Greece find themselves at the low end of the list of European countries in terms of private health insurance expenditure per capita47.

46 Medical subscriptions are viewed primarily as an element of employer’s human resources policy, directed ate employee motivation (as part of remuneration) but they also bring additional benefits including better working time organisation through shortening of the diagnostic process, which means shortening the time of workers’ sick absences at the same time.

47 Cf.: European Insurance in Figures, CEA Statistics No. 44, December 2011 http://www.insuranceeurope.eu/uploads/Modules/Publications/european-insurance-in-figures-2011.pdf.

Innovative character of health tourism 35

Elżbieta SzymańskaBiałystok University of Technology

innovative CHaraCter oF HealtH tourism

Health tourism innovation is a rather unusual topic of scientific investigation48. Although there is no comprehensive study on innovation in health tourism, scientists more and more often undertake research on selected areas thereof. Major monographs in the field were published by the Institute of Tourism, Polish Information and Foreign Investment Agency, Central Statistical Office (GUS), and as post-conference publications of the Polish Health Resorts Congresses.

J. Wolski defines health tourism as “a conscious and voluntary movement to a place other than one’s place of residence in one’s free time with a purpose of recuperation of the body thanks to active, physical and mental, relaxation”49. Health tourism is a type of tourism with health improvement or maintenance as its main objective50.

Figure 1

Health tourism and its scope

Health Tourism

SPA & wellness Health resorttherapy

Therapeutic tourism

Health tourism aiming at aesthetic medicine

treatments

Health tourism related to disease prevention

and health improvement

Health tourism related to treatment

Source: Own research.

As seen in Figure 1, health tourism includes offers directed both at sick people and related to their treatment, and at healthy individuals. In the case of the former, one may speak of therapeutic tourism. Whereas, people wishing to improve their wellbeing or prevent any potential disorders have a wide range of spa and wellness services, or aesthetic medicine services, at their disposal51. Wellness tourism, which is one of the most popular forms of health tourism can be, however, directed at both groups.

48 These issues are addressed. among others, in: A.-M. Hjalager, Repairing Innovation Defectiveness in Tourism, Tourism Management 1999, No. 23; E. Dziedzic, Prospects for tourism under conditions of innovation-based development [in Polish], in: Tourism and new phenomena in global economy [in Polish], Oficyna Wydawnicza Szkoły Głównej Handlowej w Warszawie, Warsaw 2011, pp. 339-360; Innovations in tourism development [in Polish], M. Jalinik (ed.), Wydawnictwo Politechniki Białostockiej, Białystok 2008; E. Szymańska, Innovative character of tourist companies in Poland [in Polish], Oficyna Wydawnicza Politechniki Białostockiej, Białystok 2009.

49 Humanist aspects of rehabilitation, tourism, recreation and sport [in Polish], W. Żukow, R. Muszkieta, E. Prystupa, M. Górny, M. Napierała (ed.), ORSiE, Poznań 2010, p.109.

50 Health tourism [in Polish], M. Bartoszuk (ed.), Wyższa Szkoła Turystyki i Hotelarstwa w Gdańsku, Gdańsk 2010.

51 Cf. J. Kordasiewicz, Medical tourism in practice [in Polish], electronic document available at: http://www.equilibrium-med.com/news/turystyka-medyczna-w-praktyce.html (accessed on 06Aug2012).

Elżbieta Szymańska36

According to GUS data, in 2010 there were 158 health and wellness resorts in Poland, offering a total of 31,815 beds. 612,000 people availed of said accommodation, which means that circa 7.6 million nights were spend in these objects52. Moreover, it is worth focusing on the increase in the number of hotels offering spa services; their growth is estimated at several dozen percent yearly53. According to the International Spa Association, a spa is a place where one’s wellbeing improves through a variety of services that encourage the renewal of mind, body and spirit54. What is more, the idea of wellness, relating to wellbeing and improvement of one’s mental and physical state55, is in use on the market of services comprising health tourism.

According to estimates, the value of the health tourism segment in 2011 in Poland amounted to approximately PLN 800 million, while the number of foreign patients reached approximately 300 thousand56. The Institute of Tourism data reveal that each year Poland is visited for health purposes by approximately 3 million foreigners. The reasons why patients from abroad took interest in Polish medicine include, apart from high quality services, differences in prices, which could be as high as 80% in relation to United Kingdom, Germany or USA. The number of individuals participating in this form of tourism keeps growing, also in the area of domestic tourism, as demonstrated by the Institute of Tourism statistical data. The proportion of the health tourism of the Poles in long-term journeys abroad is on the rise; between 2008 and 2009 3% declared they had chosen this purpose, whereas in the consecutive years (2010-2011) this number grew to 4%57.

“Oslo Manual”58 distinguishes four types of innovations, namely: product, organisational, marketing, and process innovations. Examples of innovations parting line with this classification are presented in Table 1.

Nowadays technological and marketing innovations seem to be of particular importance. As demonstrated by research conducted in Spain, 78% of all innovations implemented in every tourist and spa and wellness enterprise in that country are technological innovations, led by information technologies (49%) and environmental technologies (19%)59. According to studies conducted by the Stockholm Network (a London-based Institute involved in public opinion studies in the European countries), more than 50% of the Germans and more than 70% of the British, Dutch and Swedish are willing to use healthcare systems of neighbouring countries60. The newest project of the Ministry of Economy (a part of sub-activity 6.5.1 of the Innovative Economy Operational Programme), which allotted PLN 4 mln to the global promotion of the Polish medical tourism sector as a sector with high export potential61, can help to accomplishm that goal.

52 Tourism in 2010 [in Polish], GUS, Warsaw 2011, p. 73.53 The term is an acronym of the Latin sanus per aquam – health through water; in:

M. Turkowski, Hotel services marketing [in Polish], PWE, Warsaw 2010, p. 76. 54 M. Sachs, R. Sachs, Ayurvedic Spa: Treatments for Large and Small Spas as Well as Home Care

to Help Everyone Become Healthy, Happy, and Feel Inspired, Lotus Press, Wisconsin 2007, p. 381.55 C.A. Miller, Nursing for Wellness in Older Adults, Lippincott Williams & Wilkins, 2009, p. 2. 56 Information available at: http://www.rynekestetyczny.pl/medycyna-estetyczna-skorzysta-na-

programie-promocji-turystyki-medycznej/ (accessed on 22Jul2012).57 Data available on the Institute of Tourism website, http://www.intur.com.pl/polacy.

php?o=5&t1=3 (accessed on 06Aug2012).58 Oslo Manual, Eurostat/OECD, Paris 2005.59 Cf.: www.finetraturistica.org 60 S. Ostrowska, Medical tourism in the Podkarpackie Province – a threat or opportunity? [in

Polish], in: Innovations in tourism development, M. Jalinik (ed.), ed. cit., p. 78.61 Website http://www.paiz.gov.pl/20120417/paiiiz_promuje_turystyke_medyczna (accessed on

06Aug2012).

Innovative character of health tourism 37

table 1

innovations in health tourism

innovation examples (realor suggestions) source

product

CollHeal collagen dressing by Euroimplant JSC

Report on innovativeness of the Polish economy in 2010 [in Polish], T. Baczko (ed.), Institute of Economics, Polish Academy of Sciences, Warsaw 2011, pp. 328– –329.

Regional products and ingredients use in the spa cosmetics production.

D. Dryglas, Product innovations of wellness tourism, in: Innovative trends in the development of wellness tourism and wellness health services [in Polish], 18th Polish Health Resorts Congress, Ministry of Sport and Tourism 2009, pp.169–173.

process

New medical equipment and devices;New software;Technological innovations in health tourism offer for the disabled in particular.

E. Wyrwicz, Tourism development trend till 2015, with special attention to wellness tourism [in Polish], in: Innovative trends in the development of wellness tourism and wellness health services [In Polish], ed. cit., p. 95.

The idea of medicalwellness combining the notion of wellness with preventing health threats.

C.A. Miller, Nursing for wellness in older adults, Lippincott Williams & Wilkins, 2009.

organisational

Changes related to the privatisation of health resorts.

Congress organised by the Association of Polish Spa Communities, the Polish Health Resorts Association and the Economic Chamber “Polish Health Resorts” (http://suup.pl/kongres.html – accessed on 25Jul2012).

marketing

The Polish Agency of Information and Foreign Investment engaged in an EU-financed programme of Polish health tourism promotion around the world. The Agency will be in charge, among others, of participation of Polish companies in foreign events.

Trendbook Poland 2010, The Polish Agency of Information and Foreign Investment, Warsaw 2010, pp. 43-47.

Combining aesthetic medicine and art.

Aesthetic medicine conference with art in the background, which took place on 16 June 2012 with a motto Aesthetic Medicine vs The Arts of Renaissance.

Participation in non-governmental organisations and clusters as a form of seeking customers (associating, network creation), a synergy effect.

A. Żołnierski, A concept of demand driven approach to innovation in the production of medical equipment in the light of quality testing [in Polish] in: Report on innovativeness of the Polish economy in 2010 [in Polish], T. Baczko (ed.), ed. cit., p. 190.

Loyalty programmes.

Source: Own research based on the sources listed in the Table and websites. http://www.sgurp.pl/Dokumenty/Kongres%20Muszyna/publikacja.pdf (accessed on 29Jul2012); http://www.sgurp.pl/Dokumenty/Kongres%20Muszyna/publikacja.pdf (accessed on 29Jul2012) ; http://www.paiz.gov.pl/20120417/paiiiz_promuje_turystyke_medyczna (accessed on 02Aug2012); http://www.paiz.gov.pl/publikacje/jak_prowadzic_dzialalnosc_gospodarcza_w_polsce (accessed on 06Aug2012); http://www.rynekestetyczny.pl/warszawa-konferencja-medycyny-estetycznej-ze-sztuka-w-tle/, (accessed on 03Aug2012).

Nela Grądzka, Kamil Kasner38

Nela Grądzka, Kamil KasnerInstitute of Economics, Polish Academy of Sciences

aestHetiC mediCine in poland

Allowing private investors a lot of leeway on the medical market led to their concentration on the basic healthcare services. The segment recorded the fastest growth in 2007-2009, thanks to meeting patients’ expectations regarding queues reduction and increase of access to primary healthcare62. Inefficiency of the public health service in the area of satisfying citizens’ needs contributed to non-public medical facilities development; whereas, people’s growing expectations − to the formation of other branches of medicine, amongst them, of aesthetic medicine. It is a branch of medicine focusing on aesthetic desires of patients, and unlike plastic surgery, it is based on non-surgical treatments, which do not require an operating table or presence of an anaesthesiologist63.

Doctors involved in aesthetic medicine are becoming more popular than plastic surgeons. And this is a worldwide tendency. The number of plastic surgeries in the United States fell by more than 20% − from 1.9 mln in 2000 to 1.5 mln in 2009, while the quantity of non-invasive procedures did just the opposite − it rose by approximately 100% during the same time period, from 5.5 to 11 mln. No one keeps thorough statistics in Poland; the only known data is that beauty is corrected by about one million people a year, out of whom 3% choose the operating table64. Increasing demand for aesthetic medicine services is met with growing supply. More than one thousand doctors are involved in this type of medicine, of whom one hundred in Warsaw, and the market is worth around PLN 2-4 billion per year65. It is estimated that approximately 0.5 million Poles undergo beautifying treatments every year, the absolute majority of whom are women66. Market development entailed growth of demand for specialist knowledge and its diffusion. In December 2002, a Postgraduate School of Aesthetic Medicine67 was established in Poland. The school is intended only for medical graduates. The institution cooperates with the International School of Aesthetic Medicine in Rome, Aesthetic Medicine School in Spain under the auspices of the International Association of Aesthetic Medicine and the International Association of Aesthetic Medicine (UIME) in Paris68. Aesthetic Medicine Clinic69, which deals with the diagnostics and therapy of individual aesthetic medicine-related problems, operates at the School of Aesthetic Medicine.

62 M. Byrt, Healthcare sector attractive for investors [in Polish], in: Report 2012. Medical market in Poland [in Polish], July 2012, p. 12.

63 The American Institute of Aesthetic Medicine.64 Aesthetic medicine on the Polish market [in Polish], http://www.estetykaciala.pl/artykuly/

medycyna-estetyczna-na-polskimrynku.html, 7 February 2011.65 Aesthetic medicine in Poland: express botox at a dentist’s [in Polish] http://biznes.

gazetaprawna.pl/artykuly/483077,medycyna_estetyczna_w_polsce_ekspresowy_botoks_u_stomatologa.html, 15 April 2011.

66 The ABC of plastic surgeries safety [in Polish], http://www.rynekestetyczny.pl/abc-bezpieczenstwa-operacji-plastycznych/, 21 October 2011.

67 Website: http://www.ptl.org.pl/Left-Menu/DzialalnoscNaukowa/MedycynaEstetyczna.aspx 68 Website: http://psme.waw.pl 69 It also conducts research activity promoting state-of-the-art, fail-safe methods of diagnosing

and treatment, the value of which was scientifically confirmed and documented in world’s medical literature.

Aesthetic medicine in Poland 39

Research conducted by TNS OBOP70 revealed that aesthetic medicine has the most proponents amongst young women71. Results covering particular body parts may be used as a forecast for individual segment and service development in the sector of aesthetic medicine72.

Projections of the medical market growth and slight cyclic fluctuations contributed to the establishment of funds that specialise in investments on the Polish medical services market. Domestic and foreign investors more and more actively express their interest in entering with capital into the widely understood medical industry. According to the representatives of private equity and venture capital (PE/VC) funds, the market systematically increases in value, whereas demand for capital in the medical sector is going to rise. Such favourable conditions might have been created by great systemic changes that are ahead of us: introduction of additional health insurance and intensification of the process of commercialisation and privatisation of public hospitals73.

The above may help to explain why Poland has become a popular health and medical tourism destination for Western Europeans. The main objectives of the visits are plastic surgery interventions, aesthetical surgery procedures, aesthetical dermatology procedures, rehabilitation or dentistry – all performed in private Polish clinics. Our country’s attractiveness lies mainly in price differences. In Poland, and in other Central and Eastern European countries, the prices of said services may be 60-80% below those in the UK or Germany74. Commercial (more and more medical companies are debuting on the Warsaw Stock Exchange and NewConnect markets) and scientific development of the aesthetic medical market in Poland results in the rise of trust in services, and translates consequently into growing number of customers, both domestic and foreign.

The growth in the number of foreigners visiting Poland in order to purchase medical services is referred to as health-related travel75. It is defined as goods and services bought by a person travelling abroad for medical purposes. Data available for OECD countries show that the value of exports and imports connected with travel for health reasons in 2009 exceeded USD 6 billion in both cases76. These values are probably largely underestimated due to insufficient data in these countries. Expenditure on goods and services include spending on medical services, healthcare, food, accommodation and local transportation. A balance of payments of a given country reflects transactions related to goods and services between the residents and non-residents in a given period. The report concerning the HealthCare System77 of the

70 TNS OBOP Report: a female Pole and aesthetic medicine [in Polish], http://www.wellderm.pl/wp-content/uploads/WellDerm-OBOP-Polka-i-medycyna-estetyczna.pdf, 2011, p.9

71 Interest in the ways and methods which allow one to stay young longer is expressed by as much as 92% of women aged 19-29. As a counterbalance, the least interested in such solutions would be women more than fifty years old (74% of women in the 50–55 y. group and 77% aged > 60).

72 To the question regarding readiness to improve one’s facial appearance, female Poles most often indicated the condition of the skin (66% of the polled). Nevertheless, nearly every fourth respondent (23%) claims that she would not change anything in her face. While analysing willingness to change one’s figure, female Poles most readily selected the change of their belly (43%) and thighs (24%). A little less than every fifth (19%) respondent would not change anything.

73 And yet growth [in Polish], http://www.rynekzdrowia.pl/Rynek-Zdrowia/A-jednak- wzrost,115969,drukuj.html, 24 January 2012.

74 The Polish medical market is more and more attractive for investors [in Polish], http://www.twojeinnowacje.pl/polski-rynek-medyczny-coraz-bardziej-atrakcyjny-dla-inwestorow, 11 August 2011.

75 According to the Manual on Statistics of International Trade in Services 2010 (MSITS 2010), Department of Economic and Social Affairs, Geneva, Luxembourg, Madrid, New York, Paris and Washington D.C. 2012, p. 14.

76 Health at a Glance 2011, OECD Indicators, http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2011_health_glance-2011-en, p. 158.

77 A System of Health Accounts (SHA) provides systematic overviews of financial flows related to the consumption of healthcare-related goods and services. According to SHA, many countries


OECD countries includes import in the current spending on health defined as import of medical goods and services for final consumption. Export is defined as a purchase of medical services and goods by patients-residents during a stay abroad.

As demonstrated in Figure 1, expenditure on health-related travel of residents of most countries per total health expenditure of a given country is insignificant; however, it has been growing over the last five years. Germans, for example, have recorded the highest import in terms of money-expressed value, but it constitutes a mere 0.5% of state expenditure on current health spending.

Smaller countries, such as Iceland or Portugal, have recorded an increased movement of residents-patients, but it is only 1% in their health expenditure. Luxembourg is a special case of a country where a large proportion of the insured live and consume health services in its neighbouring countries78.

Figure 1

imports of healthcare-related services as a share of total health expenditure in 2009 and the annual growth rate in 2004-2009

* Refers to balance-of-payments concept of health-related travel.

Greece*

2009 Change 2000–09

Sweden

United Kingdom*

Canada* Czech RepublicSlovak Republic

Austria

United States*

NorwayEstoniaFrance*

DenmarkIreland* Poland

Italy* SloveniaMexico*

Korea

Turkey* Hungary

LuxembourgIcelandPortugal

NetherlandsBelgium*Germany

0,04 0,05

0,06 0,06 0,07 0,08 0,10

0,13 0,14 0,14 0,14 0,14

0,16 0,18

0,20 0,20 0,21 0,24

0,30 0,44 0,47

0,59 0,89

1,02 1,11

0,0 0,5 1,0 1,5 2,0 % of total health expenditure

8,4

–4,0 3,0

–5,4

–4,4 23,6

2,0

–6,4 19,7

4,6 13,2

6,2 48,6

1,0 40,0

23,5 7,3

–3,9 1,7

5,5

–6,8

–20 0 20 40 60 Annual growth rate (%)

9,49 //

58,1

12,2

–10,0

–14,0

13,0

Source: OECD Health Data 2011 and OECD-Eurostat Trade in Services Database.

experience difficulties or does not report export and import in a sufficient manner. currently, SHA is not registering the exports; thus, there are difficulties when it comes to drawing comparisons between countries. More and more countries is implementing improvements in their own health systems pursuant to SHA guidelines. This will allow one to receive more detailed data in the future, which will lead to better comparisons.

78 Ibid, p. 158.

Aesthetic medicine in Poland 41

Despite the fact that American exports in 2009 amounted to around USD 2.3 billion, it plays a minor role (0.11%) in comparison with the total health expenditure79. As demonstrated in Figure 2, the Central and Eastern European countries are growing in popularity amongst foreign patients. Health-related travel exports in 2009 were 3.6% in Czech Republic, 2.1% in Hungary, and 1.6% in Poland (a percentage of the total health spending of a given country). Out of said countries, the highest growth over the course of the last five years was observed in Czech Republic (28%) and Poland (42%). Poland recorded the highest increase among all the listed countries. The above data indicate that foreign patients are satisfied with medical services they receive in Poland.

Figure 2

exports during healthcare-related travel as a share in total health expenditure in 2009 and the annual growth rate in 2004-2009

* Information on data for Israel: http://dx.doi.org/10.1787/888932315602

Czech RepublicHungaryPoland

SloveniaGreece

Luxembourg

AustriaIceland

FranceKoreaIsrael*

United StatesItaly

Canada

2009 Change 2000-09

United KingdomNew Zealand

TurkeyBelgiumEstoniaMexico

0,02 0,03 0,06 0,06 0,08 0,08 0,11 0,13 0,15 0,15 0,19 0,20

0,48

0,84 0,98

1,15 1,62

2,08 3,58

0 1 2 3 4 % of total health expenditure

–6,0 5,7

–1,7 2,4

5,2 0,7

6,9 –5,2

8,9 0,6

–7,7

–1,3 9,9

–2,0 3,5

41.9 –3,6

27,8

–20 0 20 40 Annual growth rate (%)

60

35,7

–13,5

0,67

Note: Health-related travel exports occur when domestic providers supply medical services to non-residents travelling for medical reasons.

Source: OECD-Eurostat Trade in Services Database.

A key feature of medical tourism of the 21st century is a rising number of people travelling for medical purposes. The patients’ movement originates in the richer, more developed countries and leads to the less developed states. It is mainly a result of lower costs of medical care, affordable flights and access to readily available information on the internet80. These data may serve as an indicator for investors

79 Ibid, p. 158.80 N. Lunt, R. Smith, M. Exworthy, S.T. Green, D. Horsfall, R. Mannion, Medical Tourism:

Treatments, Markets and Health System Implications: A Scoping Review, http://www.oecd.org/els/healthpoliciesanddata/48723982.pdf, 2011, p. 6.


interested in Poland. Wise use of Polish potential, promotion of Polish medical tourism abroad at times of economic slowdown, and patients searching for less expensive medical services could result in marked, positive transformations across the Polish health service.

REIMBURSEMENT LAW vs. R 43

Paweł KrzywinaPolfinas Sp. z o.o.

reimbursement law vs. r&d FinanCinG

As of 1 July 201281, all provisions of the Act of 12 May 2011 on medicines, foodstuffs intended for particular nutritional uses, and medical devices reimbursement82 (hereinafter referred to as Reimbursement Law) came into effect. The dynamics of changes occurring within the matter regulated by said provisions may be evidenced by the fact that there have already been two amendments to the act since 12 May 201183. By passing Reimbursement Law, the legislator intended to attain three major goals84. First of all, to transform the reimbursement system so that it conformed to the current social needs in terms of medicine supply, to the extent the available, always insufficient, financial means allow. Secondly, to clearly regulate relations between business entities comprising the domestic market in said scope. Thirdly, to meet the requirements of the Council Directive 89/105/EEC85. Despite omitting the scientific research aspect in the key goals of Reimbursement Law, the legislator decided to incorporate it elsewhere in the Act. In Article 13 of Reimbursement Law, it is established that the Minister of Health takes the below criteria into consideration when setting the official selling price of a medicine, foodstuff intended for particular nutritional use, and a medical device, for which no substitute is reimbursed in a given indication86:

position of the Economic Committee, 1) recommendation of the President of the Agency for Health Technology Assessment 2) (AOTM), price competitiveness,3) taking into consideration the balancing of interests of payees and entrepreneurs 4) involved with the manufacturing and marketing of medicinal products, foodstuffs intended for particular nutritional uses, and medical devices, payment capabilities of the entity obliged to finance benefits with public funds and scientific research and investment activity of the applicant regarding healthcare within the Republic of Poland and in other European Union member states or European Free Trade Agreement member states. One should proceed in a similar fashion when establishing the official selling price

of a medicinal product, foodstuff intended for particular nutritional uses provided as part of guaranteed benefits, with the inclusion of the following criteria87:

position of the Economic Committee, 1) minimum net selling price obtained in the Republic of Poland within one year 2) prior to submitting an application for a requested dose and package size,

81 Art. 63 point13 of Reimbursement Law.82 Dz. U. [J. of Laws] of 2011 No. 122, Item 696.83 Art. 1 of the Act of 13 January 2012 on amending the Act on the medicines, foodstuffs

intended for particular nutritional uses, and medical devices reimbursement and some other acts Dz. U. of 2012 No. 95, Art. 7 of the Act of 14 June 2012 on amending the Act on therapeutic activity and some other acts Dz. U. of 2012 No 742.

84 Website http://orka.sejm.gov.pl/Druki6ka.nsf/0/1FC5453A46485EFAC12577C2002BFA21?OpenDocument

85 Council Directive of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems (EC Off. Journal L 40 of 11.02.1989, p. 8; EU Off. Journal, Polish special edition, Chapter. 5, vol. 1, p. 345).

86 Art. 13 of Reimbursement Law.87 Art. 13(8) of Reimbursement Law.

Paweł Krzywina44

minimum net selling price obtained in individual EU member states or EFTA 3) member states as part of funding from public funds of said countries, within one year prior to submitting an application, converted to Polish zlotys at an average National Bank of Poland conversion rate from the month preceding the month of application; in case when the subject of the application is not financed from public funds in a given country, free market prices are considered respectively, official selling price of medicines with the same international name, or other 4) international names but with similar therapeutic action, and foodstuffs intended for particular nutritional uses, with the application of the following criteria:

identical indications or purposes,��

similar efficiency,��

taking into consideration the balancing of interests of payees and entrepreneurs88, payment capabilities of an entity obliged to finance benefits of public funds, and scientific research and investment activity of the applicant regarding healthcare within the Republic of Poland and in other European Union member states or EFTA member states.

Apart from the above described procedure for the establishment of an official price, scientific research activities and investment activities of the applicant are also taken into consideration in case of investigating applications89 regarding, amongst others:

including a medicine, foodstuff intended for particular nutritional use, medical 1) device in a reimbursement scheme; allowing increase of the official selling price of a reimbursed medicine, foodstuff 2) intended for particular nutritional use, medical device; allowing reduction of the official selling price of a reimbursed medicine, foodstuff 3) intended for particular nutritional use, medical device; The above conclusions are examined by the Economic Committee at the Ministry

of Health, which conducts negotiations in the panel of five, in consideration of the following criteria90:

recommendation of the President of the Agency for Health Technology Assessment 1) (AOTM), including but not limited to results of the analysis of the cost to health outcomes ratio;minimum and maximum net selling price obtained in the Republic of Poland 2) within one year prior to submitting an application for a requested dose and package size, which is the subject of said application, if applicable;maximum and minimum net selling price obtained in individual EU member states 3) or EFTA member states, as part of funding from public funds of said countries, within one year prior to submitting the application91, information concerning rebates, discounts or price agreements in other EU 4) member states or EFTA member states;therapy cost with the application of the requested medicine, foodstuff intended for 5) particular nutritional use, medical device in comparison with other medical technologies available in a particular health condition, which may be replaced with said medicine, foodstuff intended for particular nutritional use, medical device;influence on the budget of the entity obliged to finance benefits with public 6) funds;

88 Manufacturing or marketing medicines, foodstuffs indented for particular nutritional use.89 Art. 24.1 of Reimbursement Law.90 Art. 19(1) of Reimbursement Law.91 Converted to Polish zlotys at an average National Bank of Poland conversion rate from the

month preceding the month of application; in case when the subject of the application is not financed from public funds in a given country, free market prices are considered respectively.

Reimbursement law vs. R&D financing 45

threshold level of the quality-adjusted life year established as three times the 7) Gross Domestic Product per capita92.

Information regarding scientific research activities and investment activities of the applicant in relation to healthcare in the Republic of Poland and in other European Union member states or EFTA member states is one93 of documents to be attached to the application.

The above quoted provisions require only information regarding scientific research activities and investment activities to be provided. There is no need to enter any additional criteria that would favour certain applicants, e.g. those investing specific percentage into such research, when establishing official prices. It leaves some space for creative interpretations of presented data and may discourage applicants from micro, small and medium enterprises, who invest relatively large sums in research in relation to their capabilities.

Article 1194 of the bill, according to which an applicant who is included in the reimbursement scheme shall transfer, every year, the amount equal 3% of the value of the medicine reimbursed in a given calendar year to the current income account of the minister with responsibility for health-related matters, was removed in the legislation process. Financial resources raised in such manner were to be allotted, among others, to clinical trials, which could have supported conducting research on new drugs.

There are numerous challenges in the field in every aspect – economic, medical, and legal. Communications between various interested actors is crucial here. Further legal solutions are needed, which will, on the one hand, secure the interests of the Polish National Health Fund (Narodowy Fundusz Zdrowia, NFZ), and, on the other hand, provide new financial means for research and development.

92 “which are set forth in Article 6(1) of the Act of 26 October 2000 on the method of calculating the yearly gross domestic product, or whenever it is impossible to evaluate – the cost per life year gained” – Art. 19.2 point.7.

93 Art. 25 of Reimbursement Law.94 Website http://orka.sejm.gov.pl/proc6.nsf/0/DC5C9F5F784CF3C0C12577D1004F4F91?OpenD

ocument-sciezkalegislacyjna

Development of pharmaceutical industry in Poland 47

Marek NiechciałNational Bank of Poland

development oF pHarmaCeutiCal industry in poland

Poland, together with Hungary and Yugoslavia, was one of the Eastern Bloc countries in which pharmaceutical industry developed prior to 198995. Has this experience in pharmaceuticals production been properly taken advantage of in Poland, particularly when compared to the above mentioned countries?

Maintaining a long-term competitive advantage in the pharmaceutical industry is connected with conducting research regarding new medicines and medical products. It results from the global reach of the pharmaceutical industry.

The pharmaceutical industry, constituting a part of the medical market, features high degree of internationalisation. In contrast to many other industries, here the transportation costs do not pose a barrier to the flow of products. The existing barriers are mainly institutional in nature96. They include, among others, diverse systems of subsidizing medicines prescribed by physicians (prescriptions) and matters related to medicines patent protection97. The importance of institutional differences in the pharmaceutical-medical sector is highlighted by the World Health Organisation (WHO)98. Barriers to entry are the costs of clinical trials involving new medicines and the time of conducting such research. In addition, in case of smaller companies, such barriers involve also generic drugs99. Advertising and marketing, indispensable to enter a given market, may also pose a problem to small enterprises. Specific features of the global pharmaceutical market make Polish pharmaceutical companies think and act globally, too. One evidence of such strategy are pharmaceutical companies R&D-related expenses.

According to the latest European Union data for the year 2010, among 1400 biggest R&D investors, as many as 89 are pharmaceutical companies; they also constitute a half of the top ten companies. Their total R&D expenses amounted to nearly EUR 78 billion (cf. Table 1). This allowed pharmacy (including biotechnology)

95 M. Adamkiewicz, From need to therapy [in Polish], in: European innovations. Theory and practice [in Polish], J. Babiak, T. Baczko (ed.), Warsaw-Brussels 2011, p. 198.

96 For other barriers, see the text by E. Puchała-Krzywina in this Report. 97 Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property,

WHO, Geneva 2011, p. 4.98 World Report on Knowledge for Better Health Strengthening Health Systems, WHO, Geneva

2004, p. 60.99 Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property,

WHO, Geneva 2011, p. 41.

miCroeConomiC analyses

Marek Niechciał48

to score first in the industrial R&D investment scoreboard100. A strong concentration of R&D expenses is observed therein. In 2010, the top five biggest R&D investors in the pharmaceutical industry spent a total of EUR 32 billion on that purpose. Nonetheless, economic analyses indicate that supporting the small and medium enterprises sector allows them to increase their R&D expenses. Such mechanism is particularly effective in the pharmaceutical sector101.

Scientific progress in the field of pharmacy is evidenced, apart from R&D investments and patent expenses, by the fact that since 2002, 200 new medical procedures have been implemented each year102. Their effective entry on the medical market requires cooperation with numerous institutions103.

table 1

r&d investment of selected industries worldwide in 2010 in comparison with scoreboard.

item no. sector/industry Qty. of

companies

r&d investment

(eur billion)

sales (eur billion)

intensity of r&d

activity* (%)

medical sector:

1 Pharmaceutical 89 77.9 525.8 14.8

2 Biotechnologies 57 9.5 45.4 20.9

3 Medical equipment manufacturers

58 9.4 153.4 6.1

total medical 204 96.8 724.6 13.4

other sectors (a selection):

4 Aviation and astronautics 44 16.2 406.9 4.0

5 Car production (excluding trucks) 90 68.6 1662.0 4.1

6 Truck production 27 7.9 233.9 3.4

7 Chemical industry 89 20.2 659.0 3.1

8 Computer production (hardware) 43 17.8 509.0 3.5

9 Computer industry (software) 25 10.5 204.4 5.1

10 Software production 82 21.6 154.5 14.0

11 Electronic equipment production 65 20.8 497.0 4.2

12 Semiconductors production (integrated circuits)

122 28.2 214.6 13.1

13 Telecom equipment (e.g. mobile phones)

60 27.4 233.5 11.7

* R&D investment to sales ratio

Source: Compiled from: http://iri.jrc.ec.europa.eu/research/scoreboard_2011.htm

100 The 2011 EU Industrial R&D Investment Scoreboard, European Commission and Joint Research Centre, Seville 2011, p. 31.

101 P. Voigt, P. Moncada-Paternò-Castello, Can a Faster Growth Of R&D-Intensive SMEs Close The EU R&D Intensity Gap Within One Decade?, Seville 2012, p. 20.

102 Innovative Technologies That Address Global Health Concerns. Outcome Of The Call Global Initiative on Health Technologies 2010, WHO, Geneva 2010, p. 7.

103 Health Technology Assessment of Medical Devices, WHO, Geneva 2011, p. 13.

Development of pharmaceutical industry in Poland 49

High position of pharmaceutical companies from Hungary and former Yugoslavia among the world R&D merits special attention104. The most important pharmaceutical companies in Hungary and former Yugoslavia (located in Slovenia and Croatia) were privatised as early as in the 90s. Relatively small-sized internal markets called for territorial expansion of the companies. It also implied large, long-term involvement in R&D activities. Data regarding the size of sales and involvement in R&D indicate that the Balkan-based companies have succeeded (cf. Tab. 2). In recent years, Gedeon Richter often ranked amongst 20 pharmaceutical companies with largest R&D investments.

table 2

pharmaceutical companies from Hungary, slovenia and Croatia present on the scoreboard for 2005 and 2010.

Company name Country

2005 2010r&

d in

vest

men

t (e

ur

mill

ion)

sale

s (e

ur

mill

ion)

inte

nsity

of r

&d

ac

tivity

(%)

r&d

inve

stm

ent

(eu

r m

illio

n)

sale

s (e

ur

mill

ion)

inte

nsity

of r

&d

ac

tivity

(%)

Gedeon Richter Hungary 50 680 7.4 98 989 9.9

Egis Pharmaceuticals Hungary 23 372 6.2 42 427 9.9

Krka Slovenia 40 554 7.2 91 1 010 9.0

Pliva Croatia 102 983 10.4 no data no data no data

Source: Compiled from: http://iri.jrc.ec.europa.eu/research/scoreboard_2011.htm and IRI.

In this context, the transformation of the Polish pharmaceutical industry is worth analysing. Prior to the year 1990, pharmaceuticals had been produced by various plants united in the Polfa group. These production plants based their sales predominantly on generic drugs, i.e. drug products which are substitutes for original products and which contain the same active ingredient. The legacy of the pre-1989 situation is the fact that nowadays more than half of medicines used in the country originate from Polish manufacturers. This translates into ca. PLN 12−13 billion of domestic producers’ revenues per year. Poland is ranked as one of the top ten pharmaceutics market in Europe. Unfortunately, R&D investments of the Polish pharmaceutical companies (in relation to sales) are a far cry from relations observed in other pharmaceutical companies included in the Scoreboard. Polish pharmaceutical companies are planning to spend PLN 461 million in the year 2012 on R&D and development of new generic drugs105, which accouts for barely 3-4% of their income. It is a few times belowthe world standards for pharmaceutical companies (cf. Tab. 1 and 3). This ratio is also lower than for the above described Hungarian, Slovenian or Croatian companies. There are no Polish pharmaceutical companies in subsequent Scoreboards.

104 See also the text by G.K. Niedbalska in this Report.105 M. Adamkiewicz, From need to therapy [in Polish], in: European innovations. Theory and

practice [in Polish], J. Babiak, T. Baczko (ed.), Warsaw-Brussels 2011, p. 198.

Marek Niechciał50

table 3

Geographical distribution of pharmaceutical companies from the scoreboard for 2010.

item no. Country Qty. of companies

r&d investment (eur million)

sales (eur million)

intensity of r&d (%)

1 Belgium 1 701 3 218 21.8

2 Denmark 4 1 735 11 000 15.8

3 Finland 1 79 850 9.3

4 France 4 4 702 34 266 13.7

5 Greece 1 32 89 36.1

6 Spain 2 153 1 036 14.7

7 India 4 272 3 831 7.1

8 Ireland 2 283 2 845 9.9

9 Israel 1 696 12 017 5.8

10 Japan 22 11 837 68 370 17.3

11 Canada 1 51 881 5.8

12 South Korea 1 42 556 7.6

13 Luxembourg 1 212 3 111 6.8

14 Germany 5 4 083 24 302 16.8

15 Slovenia 1 91 1 010 9.0

16 Switzerland 4 13 709 79 729 17.2

17 Sweden 1 40 750 5.4

18 USA 25 30 628 214 248 14.3

19 United Kingdom 4 8 121 60 573 13.4

20 Hungary 2 140 1 416 9.9

21 Italy 2 215 1 743 12.3

Source: Compiled from: http://iri.jrc.ec.europa.eu/research/scoreboard_2011.htm

Therefore, it may be said that in contrast with Hungarian and former Yugoslavian companies, the Polish pharmaceutical industry took advantage of its initial competitive position to a lesser degree. Such failure may be attributed to a few factors of institutional nature, including:

failure to create a powerful, national pharmaceutical group in the 1990s on the ��

basis of a selected Polfa group enterprises,lack of or delays in the pharmaceutical industry companies privatisation process,��

A relatively large internal market and the need to expand marked developmental trends in the modern pharmaceutical industry in Poland106.

106 Numerous examples of pharmaceutical industry expansion are included in List of the most innovative medical sector enterprises in Poland in 2010 and Information on a selection of innovative enterprises of the medical sector in Poland, included in this Report.

Barriers impeding innovative actions in the medical sector enterprises 51

Ewa Puchała-KrzywinaInstitute of Economics, Polish Academy of Sciences

barriers impedinG innovative aCtions in tHe mediCal seCtor enterprises

The environment in which innovative enterprises operate in Poland is subject to dynamic changes. Studies carried out at INE PAN, covering nearly 80 innovative companies, revealed that they come across multiple barriers impeding, or even preventing, successful accomplishment of innovative projects, both ongoing and planned107. This also concerns companies operating in the medical sector. However, based on the responses of the enterprises in this sector108, it cannot be explicitly determined whether they experienced problems with innovative projects realisation in 2010, as half of them answered that a project had not even started. One of the companies from the Mazowieckie Province was compelled to discontinue an innovative project that had already began. The analysed enterprises varied in terms of their perception of the influence of individual factors on their innovative activities.

According to the examined medical sector companies, economic barriers had a moderate influence on their innovativeness109 (see Fig.1). Lack of internal finance and access to external funds affected their innovativeness to a greater extent than for all surveyed companies in Poland. However, barriers related to innovation costs were seen in quite a different way. A barrier regarding excessive costs of innovation was felt by all innovative companies in Poland110; whereas, for the medical sector companies, its meaning was somewhat smaller. Still, the medical sector enterprises, similarly to other analysed companies in Poland, experienced an impediment of high R&D costs (a slightly stronger impact of this factor may be observed in the medical sector companies). This barrier was felt most strongly when studying all of the analysed enterprises in Poland.

107 The analysis was based on research questionnaires sent to INE PAN for List of 500 most innovative enterprises in Poland in the year 2010 by companies from the service and industry sector. See E. Puchała-Krzywina, Barriers to entrepreneurial innovation in 2007-2010 [in Polish], in: Report on innovativeness of the Polish economy in 2011 [in Polish], T. Baczko (ed.), INE PAN, Warsaw 2012. For more information regarding methodology of innovative activity analysis used by the Central Statistical Office (GUS), see E. Puchała-Krzywina, Factors limiting innovative activity of enterprises in 2007-2009, in: Report on innovativeness of the Polish economy in 2010 [in Polish], T. Baczko (ed.), INE PAN, Warsaw 2011.

108 The analysis included 6 medical sector enterprises, which submitted their questionnaires to INE PAN. Therefore, the results of this study may not be treated as an average of the whole sector. Nevertheless, they should be regarded as a signal of certain tendencies and trends in perceiving barriers by some innovative companies of the medical sector.

109 In case of one company from the Lubuskie Province in the analysed sector, financial impediments were not an issue.

110 Industry and services sector enterprises analysed by GUS also deemed high costs of innovations as the most significant factor impeding innovative activity in the years 2008–2010. See. Innovative activities of enterprises in 2008–2010 [in Polish], GUS, Statistical Office in Szczecin, Information and Statistical Analyses, Warsaw 2012, pp. 81–83, http://www.stat.gov.pl/cps/rde/xbcr/gus/nts_dzialanosc_innowacyjna_2008-2010.pdf

Ewa Puchała-Krzywina52

Figure 1

economic factors impeding innovative actions in the medical sector and the general sample of innovative companies in poland in 2010

0,0

0,5

1,0

1,5

2,0

2,5

lack of own financial resources

medical sector Poland

lack of external financial resources

excessive costsof innovation

high costs of B+R

2,22,0

2,4 2,4

2,11,9

2,5

1,8

Note: Degree of influence: 1 – high (significant), 2 – average (moderate), 3 – low, 4 – insignificant. It was assumed that the lower the number, the more severe the barrier for enterprises. Individual digits stand for an averaged degree of influence of a given factor on innovative activities of the medical sector companies in comparison with Poland.

Source: Based on research questionnaires submitted to INE PAN by enterprises for List of 500 most innovative enterprises in Poland in the year 2010.

Research conducted among the most innovative companies in Poland revealed that in the year 2010, in comparison with 2007, a barrier which mounted the most concerned finding partners for cooperation in the field of innovative activity. According to the analysed companies in the medical sector, this impediment was also one of the factors with the greatest impact on their innovations. Medical sector enterprises felt the effects of such barrier more intensively than average surveyed innovative enterprises in Poland. The impact of other barriers was relatively less significant. Lack of information regarding markets and technologies constituted a barrier which only slightly affected innovativeness of the surveyed medical sector companies, noticeably less then their counterparts in other industries. The sampled medical sector enterprises demonstrated a weaker perception of the lack of qualified staff than other companies in the survey (see Fig.2).

The effect of market-related factors was felt relatively more strongly by the analysed medical sector companies than the other analysed innovative companies in Poland. The degree of influence of the above impediments was perceived as average. Innovative enterprises of the medical sector were as much afraid of uncertain demand as of other companies dominance. In comparison with the general sample results, the medical sector companies were more afraid of dominant enterprises taking over the market (see Fig. 3).

Even though uncertain demand, according to the polled medical sector companies, was one of the factors with the greatest impact on their innovative activities, these enterprises regard the influence of demand shortage as not that important for innovations111. The assessment of lack of the need to conduct innovative activities due to past-years innovations by the sector’s innovative companies was very low. The demand barrier is not felt so strongly by the analysed medical sector companies yet.

111 The barrier may be interpreted by companies in two ways – as lack of demand on the part of consumers or employees of the company.


This may result from the fact that the importance of competitive advantage development on the basis of user driven innovation112 is not clearly seen yet.

Figure 2

knowledge-related factors impeding innovative actions in the medical sector enterprises and the general sample of innovative companies in poland in 2010

0,0

0,5

1,0

1,5

2,0

2,5


3,03,2

2,72,8 2,7

2,4

3,3

2,0

lack of qualifiedstaff

lack of information regarding technology

lack of information regarding the market

difficulties with finding cooperation partners

3,0

3,5

Note: Degree of influence: 1 – high (significant), 2 – average (moderate), 3 – low, 4 – insignificant. It was assumed that the lower the number, the more severe the barrier for enterprises. Individual digits stand for an averaged degree of influence of a given factor on innovative activities of the medical sector companies in comparison with Poland.

Source: Based on research questionnaires submitted to INE PAN by enterprises for List of 500 most innovative enterprises in Poland in the year 2010.

Figure 3

market factors impeding innovative actions in the medical sector enterprises and the general sample of innovative companies in poland in 2010

0,0

0,5

1,0

1,5

2,0

2,5

market domination


uncertain demand

2,0 2,0

2,52,2

Note: Degree of influence: 1 – high (significant), 2 – average (moderate), 3 – low, 4 – insignificant. It was assumed that the lower the number, the more severe the barrier for enterprises. Individual digits stand for an averaged degree of influence of a given factor on innovative activities of the medical sector companies in comparison with Poland.Source: Based on research questionnaires submitted to INE PAN by enterprises for List of 500 most innovative enterprises in Poland in the year 2010.

112 For more information, see texts of the following: N. Grądzka, W. Burzyński, W. Pander and A. Żołnierski in Reports on innovativeness of the Polish economy in 2008, 2009, 2010, 2011 [in Polish], T. Baczko (ed.), INE PAN, Warsaw 2009, 2010, 2011, 2012.

Ewa Puchała-Krzywina54

Despite an array of instruments supporting innovative processes, the medical sector companies struggle with numerous barriers113: institutional, legal, new medical technologies-related barriers, etc. Among major barriers to innovativeness in 2010, the analysed companies of the sector listed the following: high cost of R&D, lack of external funding, difficulties with finding partners for cooperation in the field of innovative activity, market taken over by dominant enterprises, and uncertain demand.

It is typical that acquiring EU funds affects the way in which barriers are perceived by a given company. It may be illustrated by a comparison of current data with the 2004-2006 results for companies where information on barriers is available114. A company which received a grant from EU funds participated in both studies. In comparison with a preceding period, in 2010 there was a pronounced weakening of the financial barriers perception by said company, which was mainly related to lack of external funding and market impediments. Shortage of information on technologies and markets was felt to the same degree as difficulties with finding partners for cooperation in the area of innovative activity. At the same time, the analysed company indicated growing problems related to finding qualified staff in 2010 comparing with the period 2004-2006.

According to the analysed medical sector companies115, in order to reduce impediments to innovation, public institutions should focus, among others, on simplifying the procedures for EU funded projects settlement. The importance of effective tax incentives for R&D activities was also emphasized. What is more, attention was drawn to tax cuts with relation to business activity and costs of employment. According to the studied companies, public institutions should also distinguish between scientific innovations and process innovations applied in industries. Support instruments should be betted adapted to the realities of economic turnover and R&D work characteristics. The analysed companies called for a rise in innovation funding (the company size issue was highlighted) and for abolition of the need to abide by the public procurement law in the case of conducting scientific research.

Promotion of innovation in the medical sector is highly important. The needs reported by innovative companies of this sector may serve as a form of diagnosis of barriers to innovativeness, and may help in their identification. An innovation strategy for Poland should be concerned with modifications of the current institutional framework, change of regulations, and facilitation of external financing for all companies. Another significant issue is complementarity and substitution116 of barriers to innovation and differentiation of the perception of impediments in relation to company’s age. Scientific institutions117 do not always recognise the needs of companies, and therefore, cooperation between science and business is of key importance. Information regarding carried out scientific projects and possibilities of their practical application should be presented on internet sites of scientific research institutes and academic websites. Another vital matter is the institution of a knowledge broker, which provides a linkage between companies, academies, and scientific research institutes.

113 See also publications of M. Niechciał and A. Chaberski in the same Report.114 See. E. Krzywina, Barriers impeding innovation in medical technologies enterprises [in

Polish], in: Foresight. The system of medical technologies monitoring and scenarios development in Poland. Results of economic panel analyses [in Polish], T. Baczko (ed.), ROTMED Consortium, INE PAN, Warsaw 2008.

115 Based on selected information from questionnaire data submitted by the companies to INE PAN for List of 500 most innovative enterprises in Poland in the year 2010.

116 For more information see: A. Wziątek-Kubiak, On the methodology of research of barriers to innovation [in Polish], in: Report on innovativeness of the Polish economy in 2011 [in Polish], T. Baczko (ed.), INE PAN, Warsaw 2012.

117 For more information see: T. Baczko, G. Gierszewska, E. Puchała-Krzywina, The functions of scientific research units in the transfer of new knowledge to enterprises [in Polish], in: The influence of EU structural funds on the transfer of knowledge to enterprises [in Polish], J. Kotowicz- -Jawor (ed.), INE PAN, Key Text, Warsaw 2012.


Jan Maria WójcickiThe Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences

Nałęcz INstItute of BIocyBerNetIcs aNd biomediCal enGeneerinG oF tHe polisH aCademy oF sCienCes

Field of researchIn recent years biomedical engineering has been developing very quickly around the world. It plays a very important role not only in the production of modern medical equipment but first and foremost in the development of medical diagnostics and new therapies, awaited by patients.

Nowadays, biomedical engineering research makes use of a wide range of technologies, from nanotechnology to teleinformatics, including their diverse applications e.g. in physiological processes modeling, microsensors and artificial organs construction, biological imaging, information processing and storage, homecare monitoring and patient safety etc.

the institute The Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences (IBBE PAS) was established in 1975. It is the biggest research centre in biomedical engineering in Poland. IBBE PAS, as one of two institutions in Poland, is entitled to confer the title of Doctor and Assistant Professor of biomedical engineering.

At present, the Institute employs about 140 people, including 9 professors, 14 associate professors, 20 assistant professors (adjuncts) and 16 assistants. Its latest structure comrises five Departments: Department of Hybrid Microbiosystem Engineering, Department of Biomedical Systems and Technologies, Department for Biophysical Measurements and Imaging, Department for Mathematical Modelling of Physiological Processes, Department of Engineering of Nervous and Muscular System.

The International Advisory Committee has existed at the Institute since 2008. The Committee members are:

Prof. Dov Jaron, Calhoun Distinguished Professor of Engineering in Medicine, ��

Drexel University, USA, Prof. Jos Van der Sloten, Head of Division, Katholieke Universiteit Leuven, ��

Chairman of the Leuven Medical Technology Centre, Belgium, Prof. J. Vienken, vice President of the Department of Bioscience, Fresenius Medical ��

Care, Germany.

Jan Maria Wójcicki56

IBBE PAS runs doctoral studies. In 2011, there were 20 PhD students. Since 2011 our institute takes part in the PAS Interdisciplinary Doctoral Study in computer science and information science.

The Institute publishes English language journal “Biocybernetics and Biomedical Engineering”, which is indexed by Thomas Reuters in the Science Citation Index Expanded (SciSearch), in the Journal Citation Reports/Science Edition, and in Elsevier’s SCOPUS and EMBASE bibliographical data bases.

research activityThe subject matter of IBBE PAS focuses on such domains as: biomeasurements, computer data processing and

analysis for medical diagnostics, and supporting and replacing lost body functions by technical and technical-biological means. The third domain covers the mathematical and physical modelling of physiological processes and their computer simulation.

Between 2008 and 2011 one hundred twenty five original works were published in journals included in the Philadelphian List, eleven patents were obtained, including one USA patent, 13 patent applications were submited, including two foreign patent applications. Ten senior researchers have Hirsh-index between 9 and 21. The Institute employees’ publications were cited 330 times in 2011.

Apart from statutory research, 31 research projects (including 10 international ones) were carried out in the Institute last year.

Research of the institute is implemented in many medical centers in the country.In the past four years, 28 original diagnostic and therapeutic systems have been

clinically verified. Eight biomedical systems were implemented in 2011. Main implementation achievements are:

Measurement and control oculomotor activity research systems used to diagnose ��

the early stage of central and peripheral nervous system diseases, to rehabilitate and to examine the human factor in aviation (diagnostic system SACCADOMETER, XY-MRI Oculometer, X-Stimuli Oculometer, system Jazz-novo).Time–resolved optical scanner used for oxygenation and blood supply brain tissue ��

assessment.TeleDiaFoS system for monitoring of the diabetes foot syndrome patients.��

New controlling system used for independent /artificial lung ventilation.��

Simulators used for supporting cardiovascular and pulmonary/respiratory ��

systems.External counter pulsation system for support cardiovascular system.��

Spirometry simulation system.��

Optimization of algorithm of adaptation of atrioventricular delay, depending on ��

stimulation frequency of patients treated by Dual Chamber Rate Adaptive Pacemaker (DDDR) method.

Nałęcz Institute of Biocybernetics and Biomedical Engeneering of the Polish Academy of Sciences 57

Dynamic method of optimization of atrioventricular delay (AV) with the use of ��

plethysmography.New method of image segmentation for quantitative analysis of dyed tissue ��

fragments.

activity for scientific communityThe Institute set up the centre of excellence for Artificial and Hybrid Internal Organs used for supporting meta-bolism.

IBBE PAS coordinates the national scientific network carrying out research in the field of biomedical engineering (BIOMEN).

In 2008 IBBE PAS joined BIOCENTRUM Ochota - newly formed consortium associating about 1500 researchers and doctoral students, grouping the following research units: the Institute of Experimental Biology PAS, the Institute of Biochemistry and Biophysics PAS, the Institute of Experimental and Clinical Medicine PAS, the Institute of Fundamental Technological Research PAS and the Institute of Molecular and Cell Biology PAS.

As part of common research at Biocentrum a research network BIOWIZJA was established for studying the visualization of biomedical phenomena and the development of methods of visualization of biological phenomena. The project “Information technology infrastructure for the development of the strategic areas of biology and medicine” has been carried out at BIOCENTRUM, since 2009.

The scientific network Micro- and Nano- Structure Applied Science Network (MINAS) for interdisciplinary applications in electronics, telecommunication, environment protection, molecular biology, diagnostics and medical therapy, was established in 2005.

The Centre for Preclinical Research and Technology CePT has been active since 2007. The aim of this project is to create a scientific centre in Warsaw consisting of closely cooperating environmental research centers, performing basic interdisciplinary research and research concerning new diagnostic and therapeutic methods with reference to cardiovascular diseases, nervous system, cancer and age-related diseases. Research covers structural and functional analysis of proteins, physicochemistry and nanotechnology of biomaterials, nanomedicine, biomedical engineering, molecular biotechnology, genomics, neurobiology, biochemis-try, physiology, pharmacology, pharmacodynamics, pharmacogenomics and pharmacognosis.

In 2006-2008 IBBE PAS coordinated a national Foresight project entitled “System of monitoring and scenarios for the development of medical technologies in Poland”, carried out by the ROTMED consortium. The project concluded with a monograph including abstracts in Polish and English.

In 2009 IBBE PAS became a member of Technical Committee of Polish Committee for Standardization for Medical Materials and Biomaterials.

In 2009 IBBE PAS set out to establish standards in research on the appliances supporting inefficient cardiovascular and respiratory systems. To this purpose the hybrid simulators for supporting cardiovascular

Jan Maria Wójcicki58

system constructed at the Institute were given to proper institutions such as: FCS in Zabrze, AGH University of Science and Technology, Jagiellonian University, Cracow and Warsaw University of Technology. Parallel research has been conducted on new standards in the assessment of respiratory failure in patients suffering from chronic obstructive pulmonary disease.

international cooperationThe institute boasts excellent premises for the organization of conferences and scientific seminars. In 1988, the International Centre of Biocybernetics (ICB) started operating,at the Institute. Till the end of 2011, 119 seminars and 3 European congresses were held, with over 6,000 participants (1,600 from abroad) from 47 countries, mainly from: Japan (293), Germany (163), USA (114), Great Britain (104), Italy (95), Sweden (68), Holland (62) and Russia (44). After two decades of its activity, ICB is a well known meeting spot for biomedical engineering research experts.

Between 2008 and 2011 the institute carried out 11 joint research projects together with international institutions.

Senior researchers of IBBE PAS take active part in managements of over 20 international organizations connected with biomedical engineering, including International Federation for Medical and Biological Engineering, European Alliance for Medical and Biological Engineering and Sciences, American Institute for Medical and Biological Engineering, European Society for Artificial Organs, International Faculty of Artificial Organs, International Association for Information and Management Sciences, International Federation of Information Processing, Baltic Society for Integrated Psychobiology, European Society for Engineering in Medicine, International Academy for Medical and Biological Engineering.

Innovative family companies of the medical sector 59

Artur ChaberskiInstitute of Economics, Polish Academy of Sciences

innovative Family Companies oF tHe mediCal seCtor

Innovation, which has almost always been interrelated with medical technologies, is one of characteristic features of medical technologies. The contemporary pace of change in medical technologies, referred to as a revolution, until recently had been regarded as evolutionary. Medicine and pharmacy are domains of exceptional innovative activity because of pressures exerted upon them by the society, willing to take advantage of the most effective and up-to-date technologies in diagnosing, treatment and rehabilitation. These pressures require that international experiences and funding be applied to global research aimed at development of new medical technologies and evaluation of their effectiveness.

In some cases, in genetic research for instance, such research is limited to the world of medicine, whereas in others, it focuses on the application of the already available technologies to specific medical uses118. It then becomes necessary to create novel forms of cooperation between enterprises, public administration, and scientific research institutes. The flexibility of cooperation linkages has become, according to Bożena Lublińska-Kasprzak, the President of the Polish Agency for Enterprise Development (PARP), a universal quality of the currently developing complex organisational and economic systems. High risk associated with innovative projects and their implementation costs forced the followers of the innovation policy to increase flexibility and develop new co-operative relations as part of R&D cooperation119. Analysis of the pharmaceutical sector conducted in 2011 by PwC120 reveals that nearly 450 pharmaceutical companies operate in Poland, out of which 62 are innovative enterprises. Ten largest enterprises on the pharmaceuticals market account for nearly 50% of its value. There are eight innovative companies and three biggest companies operating in Poland in the top ten on the list. The leading three companies have their production plants located in Poland, and accout for nearly 23% of the value of the pharmaceuticals market121.

The analysis of research questionnaires regarding innovation in the medical sector sent to INE PAN in 2010 shows that more than half of the enterprises are innovative family companies or businesses controlled by families. They include both international and Polish innovative family undertakings, such as the German Wiki Met Ltd. and Stolter Ltd. Among the better known Polish family companies or businesses controlled by families enumerated in the Report there are: Adamed of the Adamkiewicz family, Curtis HealthCaps of the Niemczyccy family, or Bioton controlled by Ryszard Krauze. The PwC report includes the Starak family-owned Polpharma, right next to Adamed and international giants such as Novartis, Sanofi, Roche, GlaxoSmithKline, Krka, and Teva, in the Top 10 players on the Polish pharmaceutical market. Two out of ten

118 W. Ponikło, Innovations in technologies [in Polish], Służba Zdrowia 2009, no. 9-12 (3810-3813) of 9 February, p. 2.

119 A meeting devoted to innovations in the medical and pharmaceutical sector on 19 October 2011, statement made by the President of PARP Bożena Lublińska–Kasprzak (http://www.parp.gov.pl/index/more/23614).

120 Impact of the innovative pharmceuticala industry on the Polish economy [in Polish], PwC Report, September 2011.

121 Impact of the innovative pharmaceutical industry on the Polish economy [in Polish], PwC Report, September 2011, p. 6.

Artur Chaberski60

largest corporations of the pharmaceutical industry in Poland are Polish innovative family companies (cf. Fig. 1).

Figure 1

market share of top 10 pharmaceutical corporations in poland in 2010

value

Sanofi-grupa

Nonartis

GlaxoSmithKline

Polpharma

Roche

Servier

Merck & Co

Pfizer

Teva

Astrazeneca

Other

0% 20% 40% 60%

8,5

8,2

6,1

5,2

4,6

3,9

3,8

3,4

3,1

3,1

50,1

Polpharma

Sanofi-grupa

Nonartis

GlaxoSmithKline

Teva

Servier

Valeant Pharma

Adamed Poland

KRKA

Gedeon Richter

Other

0% 20% 40% 60%

46,0

10,8

7,6

7,3

7,3

5,1

4,6

3,9

3,5

3,2

2,9

volume

Source: Impact of the innovative pharma industry on the Polish economy [in Polish], PwC Report, September 2011, p.26

One of the seven priority research tendencies on the medical and pharmaceutical market shall be diseases of civilisation, new medicines and regenerative medicine. State spending on research and development of the Polish science in 2011 accounted for 0.9% of GDP. The result is better than in 2006, when the ratio in question was as low as 0.56% of GDP. At that time, Sweden spent thirteen times more on research and development, calculated on a per capita basis, than Poland. However, in the opinion of professor Andrzej Górski, Vice-President of the Polish Academy of Sciences, (...) the level of innovative research financing, particularly in the sector of medical sciences, is appalling, and we are a long way behind the level of the “old EU member states”122. According to professor Jan Lubiński, an oncologist and geneticist from the Pomeranian Medical University in Szczecin, who set up the Read-Gene company, the initiation of cooperation between scientists and business is a positive symptom and support for innovative ideas. Also pharmaceutical companies see the situation in a positive light as, according to the authors of the report prepared for Poland by the Polish Association of Pharma Industry Employers, (...) the dynamics of research and development in the national pharmaceutical industry exceeds dynamics in other branches of the chemical industry. There are some more patents, mainly related to manufacturing processes in pharmacy; our biotechnology also begins to flourish. Some companies, Adamed for example, are working on new psychopharmaceuticals, reported Cezary Śledziewski, President of the Polish Association of Pharma Industry Employers. Andrzej Włodarczyk, Vice-Minister of Health, referred to the pharmaceutical sector as an unquestionable leader when it comes to the number of innovative enterprises123.

122 K. Boczek, An innovative jump [in Polish], Służba Zdrowia 2011, no. 24(110), p. 2.123 K. Boczek, An innovative …op. cit., p. 4.

Innovative family companies of the medical sector 61

Companies and scientists willing to join forces to create a patent have many more financing opportunities than a few years ago. In addition, programmes of the Polish Agency for Enterprise Development that compel scientists-business cooperation are another example of a significant support. More and more companies reach out for money to the public market − NewConnect. According to professor J. Lubiński, whose company obtained this type of funding, NewConnect constitutes a chance to attract funds necessary for ideas development. European funds and their use, based on the Adamed instance, help to change the situation and serve as a positive example of innovation development in the medical and pharmaceutical sector. The requirement to possess one’s own financial contribution constitutes a barrier to acquiring such type of financial support of development. Another possible form of financing an innovative activity may be private equity seed capital124, which is an interesting proposition for start–up companies125.

Barriers126 to medical sector development in Poland include: lack of a long-term strategy of industry development, insufficient incentives for development of scientific research activity, and lack of legal stabilisation. The sector “...has got a great potential and may become a strong pillar of the Polish economy”, as it was stated in the Report on innovativeness of the Polish pharmaceutical and medical sector, which was a result of initiative of the entities operating on the medical and pharmaceutical market and associated with the Initiative Group Go Global! Polish Pharma127. The Report stresses that “... in terms of the number of research centres participating in clinical trials, Poland occupies 10th position in the world and it is the leader of the so-called emerging markets. Moreover, Poland has well qualified doctors and a wide range of up-to-date students interested in biotechnology”. As phrased by M. Adamkiewicz, a member of the Initiative Group Go Global! Polish Pharma, “... engaging all stakeholders of the pharmaceutical and medical market in the establishment of one common goal which all entities would be pursuing. Its accomplishment will allow for a construction of healthy competition between Polish and foreign companies. In addition, it will also guarantee stabilisation, significant from the point of view of constructing an innovative pharmaceutical and medical market, and in a long run it will lead to levelling of position of Polish companies on international market”s128. As indicated in the PwC report, nowadays the regions of high growth of the pharmaceutical and medical market are Asian countries, the Commonwealth of Independent States and the Middle East. A high growth rate of these markets may result from low baseline values and does not need to last in a long-term because sponsors seek countries where clinical research environment is more predictable (e.g. having more rigorous principles of patent protection and more friendly, stable legal framework). Since factors motivating to take part in clinical research grow weaker as markets mature, developed countries initiated a series of actions aimed at maintaining the increase and number of researches conducted there. These actions comprise administrative facilitation, shorter registration time and transparent principles of agreements conclusion. Poland and other countries need to consider implementation of similar initiatives if they wish to compete with more rapidly developing markets. Conducted research indicates that the level of ownership concentration129 may favour innovation in family businesses. This concerns also the medical sector and should be the basis for further, more in-depth analyses.

124 See also the article by N. Grądzka, K. Kasner in this Report.125 One example may be the Medical Technologies Capital Fund − MedFund, instigated by the

Małopolska Agency of Regional Development. The main task of the project is a search for innovative solution and establishing new, thriving companies in the medical sector on the basis thereof.

126 See also the articles by: M. Niechciał and E. Puchała-Krzywina in this Report.127 Go Global! Polish Pharma (www.goglobalpolishpharma.pl) is an initiative of entities operating

on the pharmaceutical and medical market. 128 Stakeholders understood as the government, the legislator, entrepreneurs and scientists.129 See. A. Chaberski, The analysis of family companies innovation and innovative property

concentration, [in Polish] in: Report on innovativeness of the Polish economy in 2011 [in Polish], T. Baczko (ed.), INE PAN, Warsaw 2012.

63

S.N

. C

ompa

ny n

ame

Pla

ce

Res

earc

h an

d de

velo

pmen

t act

ivity

(R&

D)

Net

sal

es re

venu

esN

et P

rofit

/ Lo

ss

2010

ch

ange

20

10/2

009

chan

ge

2010

/200

820

10

chan

ge

2010

/200

9ch

ange

20

10/2

008

2010

thou

sand

PL

N%

%th

ousa

nd

PLN

%%

thou

sand

PL

N

Tota

l val

ue

192

729

297.

27

35.4

2 4

936

537

48.0

2 24

.92

698

608

num

ber o

f com

pani

es u

sed

for c

alcu

latio

n 36

30

26

3635

35

36

1Za

kład

y Fa

rmac

euty

czne

Pol

phar

ma

(Pha

rmac

eu-

tical

Wor

ks P

olph

arm

a JS

C) S

taro

gard

Gda

ński

64

632

(I)18

.64

11.1

1 1

119

752

11.8

6 6.

80

207

256

2Bi

oton

(JSC

) W

arsz

awa

44 2

92(I)

3.59

–1

1.05

37

8 59

5 74

.59

13.5

7 11

7 18

0

3Ad

amed

Sp.

z o

.o. (

Ltd.

) C

zosn

ów

39 8

87(I)

–17.

78

50.3

7 39

6 59

6 31

.51

1.90

12

870

4W

ojew

ódzk

i Szp

ital S

pecj

alis

tycz

ny w

e W

rocł

a-w

iu (W

rocł

aw S

cien

tific

and

Tec

hnol

ogic

al M

edi-

cal P

ark)

Wro

cław

7

515(I)

44.6

3 85

.63

160

941

13.3

4 12

.68

12 8

92

5Se

lvita

S.A

. (JS

C) K

rakó

w

6 02

2(I)10

2.69

57

.40

8 84

7 16

7.41

29

1.29

–1

611

6Re

ad-G

ene

S.A

. (JS

C) S

zcze

cin

5 19

4(I)

36

4 –6

3.08

18

3.20

–3

99

7Pr

zeds

iębi

orst

wo

Farm

aceu

tycz

ne L

ek-A

m S

p. z

o.o.

(P

harm

aceu

tical

Com

pany

Lek

-Am

Sp.

Ltd

.) Z

akro

czym

4

293(II

)0.

39

–14.

18

176

823

12.0

8 8.

67

7 91

5

8Bi

ofar

m S

p. z

o.o

. (Lt

d.)

Poz

nań

3 11

4(II)

58.2

6 20

.21

284

342

6.55

21

.85

13 9

10

9Sw

issm

ed C

entru

m Z

drow

ia S

.A. (

Swis

smed

He

alth

Cen

tre (J

SC)

Gda

ńsk

1 95

0(II)

48 0

54

5.97

22

.76

–463

10Bi

oMax

ima

S.A

. (JS

C) L

ublin

1

850(I)

7 17

9 7.

46

7.52

53

9

11Po

lfarm

ex S

.A. (

JSC)

Kut

no

1 80

1(II)

–23.

06

–11.

89

171

734

10.2

8 24

.03

23 2

59

LIST

OF

LARG

EST

INVE

STOR

S IN

R&

D IN

MED

ICA

L SE

CTOR

IN

POL

AN

D IN

201

0

Report on Innovativeness of the Health Sector in Poland in 201264

SN

Com

pany

nam

e P

lace

Res

earc

h an

d de

velo

pmen

t act

ivity

(R&

D)

Net

sal

es re

venu

esN

et P

rofit

/ Lo

ss

2010

ch

ange

20

10/2

009

chan

ge

2010

/200

820

10

chan

ge

2010

/200

9ch

ange

20

10/2

008

2010

thou

sand

PL

N%

%th

ousa

nd

PLN

%%

thou

sand

PL

N

12W

arsz

awsk

ie Z

akła

dy F

arm

aceu

tycz

ne P

olfa

S.A

. (W

arsa

w P

harm

aceu

tical

Wor

ks P

olfa

JSC

) W

arsz

awa

1 30

5(II)

–46.

57

–34.

99

364

388

13.3

2 4.

11

44 4

47

13M

edan

a Ph

arm

a S.

A. (

JSC)

Sie

radz

1

219(II

)–2

8.62

–2

1.90

16

4 94

0 24

.96

14.6

6 64

483

14Lf

C Sp

. z o

.o. (

Ltd.

) Z

ielo

na G

óra

1 03

8(I)19

.31

–22.

63

6 42

7 –2

.22

–0.6

8 69

5

15PZ

HTL

S.A

. (JS

C) W

arsz

awa

983(II

)35

7.44

14

4.04

31

476

4.

98

10.1

9 6

039

16Tr

icom

ed S

.A. (

JSC)

Łód

ź 90

9(I)77

.89

72.9

2 5

729

1.94

6.

04

–581

17Ta

rcho

miń

skie

Zak

łady

Far

mac

euty

czne

Pol

fa S

.A.

(Tar

chom

in P

harm

aceu

tical

Wor

ks J

SC)

War

szaw

a 83

5(II)

–10.

39

–52.

07

214

947

–5.6

7 –0

.97

–17

415

18Bi

omed

Lub

lin W

ytw

órni

a Su

row

ic i

Szcz

epio

nek

S.A

. Bio

med

Lub

lin S

era

and

Vacc

ines

Pla

nt J

SC)

Lub

lin

809(II

)0.

55

58.2

1 33

624

4.

18

5.55

2

541

19M

edic

algo

rithm

ics

S.A

. (JS

C) W

arsz

awa

797(II

)37

.98

4

107

1 31

4.85

19

9.25

1

748

20He

rbap

ol L

ublin

S.A

. (JS

C) L

ublin

74

0(II)

225

814

7.71

7.

93

19 5

16

21As

cor S

.A. (

JSC)

War

szaw

a 69

8(II)

8 32

5.87

39

7.65

12

378

18

.78

19.3

8 20

6

22In

styt

ut B

iote

chno

logi

i Sur

owic

i Sz

czep

ione

k Bi

o-m

ed S

.A. (

Biot

echn

olog

y In

stitu

te o

f Ser

a an

d Va

ccin

es B

iom

ed J

SC)

Kra

ków

62

4(II)

163.

10

32.3

5 43

184

–8

.77

8.71

17

516

23Fa

rmac

euty

czna

Spó

łdzie

lnia

Pra

cy G

alen

a (P

har-

mac

eutic

al C

oope

rativ

e Ga

lena

) W

rocł

aw

511(II

)–5

2.58

–2

7.88

34

174

22

.94

–1.7

2 –1

056

24Fa

bryk

a Ap

arat

ury

Elek

trom

edyc

znej

Fam

ed Ł

ódź

S.A

. (Fa

ctor

y of

Med

ical

App

arat

us J

SC)

Łód

ź 43

6(II)

–26.

38

84.5

9 6

765

1.53

–0

.98

–936

25US

Pha

rmac

ia S

p. z

o.o

. (Lt

d.)

Wro

cław

31

7(II)

488

162

100

010

26PZ

Cor

may

S.A

. (JS

C) Ł

omia

nki

244(II

)–6

.87

61

940

61

.09

41.1

6 6

130

27To

war

zyst

wo

Prze

mys

łow

o Ha

ndlo

we

Secf

arm

Sp

. z o

.o. (

Indu

stria

l and

Com

mer

cial

Com

pany

Se

cFar

m L

td.)

War

szaw

a 18

4(II)

–12.

50

62

6 –5

3.82

–6

3.67

–2

63

28Pr

zeds

iębi

orst

wo

Yavo

Sp.

z o

.o. (

Com

panz

Zav

o Lt

d.)

Beł

chat

ów

182(II

)–5

0.00

–4

2.26

9

464

–10.

21

–4.0

6 50

2

List of largest investors in r&d in medical sector in Poland in 2010 65

29Pr

zeds

iębi

orst

wo

Farm

aceu

tycz

ne J

elfa

S.A

. (P

harm

aceu

tical

Com

pany

Jel

fa J

SC)

Jel

enia

Gór

a 15

8(II)

–41.

61

–35.

71

351

637

3.99

2.

87

64 3

12

30Sp

ółdz

ieln

ia M

echa

nikó

w S

MS

(Mec

hani

cs

Coop

erat

ive

SMS)

War

szaw

a 72

(II)

–50.

00

–42.

27

10 8

49

8.54

8.

70

255

31De

ntal

Nan

otec

hnol

ogy

Sp. z

o.o

. (Lt

d.)

Kat

owic

e 39

(II)

135.

46

318.

88

1 47

4 8.

15

26.7

8 57

32Po

znań

skie

Zak

łady

Zie

lars

kie

Herb

apol

S.A

. (He

r-ba

l Pla

nts

Pozn

an J

SC H

erba

pol)

Poz

nań

29(II

)16

.07

83

795

–2

.03

–0.2

3 2

786

33Ch

emap

ol S

.C. (

JSC)

Ust

roń

21(I)

61.5

4 62

.02

633

–14.

80

2.54

24

6

34Bi

o-Ks

el S

p. z

o.o

. (Lt

d.)

Gru

dzią

dz

17(II

)

–72.

10

4 91

8 10

.72

6.71

31

6

35Ad

amed

Con

sum

er H

ealth

care

S.A

. (JS

C) T

uszy

n 10

(II)

–46.

15

13

591

3.

07

–1.9

9 –6

179

36M

obile

x Sp

. z o

.o. (

Ltd.

) Ł

ódź

2(II)

–92.

90

–85.

47

8 26

9 –1

0.54

–1

2.42

–1

15

(I) –

dat

a of

cap

italiz

ed v

alue

in R

&D; (

II) –

dat

a of

inve

stm

ent i

n R&

D in

ass

ests

stru

ctur

e.


S.N

.Co

mpa

ny n

ame

Plac

eN

ACE

co

de

Net sales 2010

Sales growth 2010/2009

Source

Research and deve-lopment activity

(R&D) 2010

R&D activity/ sales 2010

National patents

UE contracts

Market innovation

Process innovation

Investment on innovation activity

Patents

UE contracts

thou

sand

PL

N%

thou

sand

PL

N%

1Lf

C Sp

. z o

.o. (

Ltd.

)Zi

elon

a Gó

ra32

50Z

6 4

27

–2.2

1

1 0

38

16.

15

2 C

AA

AA

2Se

lvita

S.A

. (JS

C)Kr

aków

7211

Z 8

847

16

7.4

1 6

022

6

8.07

9

AC

AA

A

3Ad

amed

Sp.

z o.

o. (L

td.)

Czos

nów

2120

Z 3

96 5

96

31.5

1

39

887

10.

06

2 4

AC

AA

A

4W

ojew

ódzk

i Szp

ital S

pecj

alis

tycz

ny w

e W

rocł

awiu

(W

rocł

aw S

cien

tific

and

Tec

hnol

ogic

al M

edic

al P

ark

Wro

cław

8610

Z 1

60 9

41

13.3

1

7 5

15

4.6

7 1

AB

AC

B

5PZ

Cor

may

S.A

. (JS

C)Ło

mia

nki

3250

Z 6

1 94

0 61

.1

3 2

44

0.3

9 2

BB

CN

A

6Pr

zeds

iębi

orst

wo

Farm

aceu

tycz

ne L

ek-A

m S

p. z

o.o.

(P

harm

aceu

tical

Com

pany

Lek

-Am

(Ltd

.) Za

kroc

zym

2120

Z 1

76 8

23

12.1

6

4 2

93

2.4

3 4

CC

BN

A

7Bi

oton

S.A

. (JS

C)W

arsz

awa

2110

Z 3

78 5

95

74.6

4

44

292

11.

70

1 B

CB

NC

8M

edic

algo

rithm

ics

S.A

. (JS

C)W

arsz

awa

7219

Z 4

107

1.

314.

9 6

797

1

9.41

2

CC

BN

B

9Tr

icom

ed S

.A. (

JSC)

Łódź

3250

Z 5

729

1.

9 1

909

1

5.87

1

BC

AC

N

10W

arsz

awsk

ie Z

akła

dy F

arm

aceu

tycz

ne P

olfa

S.A

.(JSC

)W

arsz

awa

2110

Z 3

64 3

88

13.3

6

1 3

05

0.3

6 C

BB

NN

11M

edan

a Ph

arm

a S.

A. (

JSC)

Sier

adz

2120

Z 1

64 9

40

25.0

6

1 2

19

0.7

4 C

BB

NN

12He

rbap

ol L

ublin

S.A

. (JS

C)Lu

blin

1089

Z 2

25 8

14

7.7

6 7

40

0.3

3 C

BB

NN

13Ol

imp

Labo

rato

ries

Sp. z

o.o

. (Lt

d.)

Dębi

ca10

86Z

125

244

25

.8

5

3

CB

NN

A

14Ch

emap

ol S

.C.

Ustro

ń46

69Z

633

–1

4.8

1 2

1 3

.32

CA

BC

N

15Bi

ofar

m S

p. z

o.o

. (Lt

d.)

Pozn

ań21

20Z

284

342

6.

6 6

3 1

14

1.1

0 3

NC

BN

B

16Bi

oMax

ima

S.A

. (JS

C)Lu

blin

2120

Z 7

179

7.

5 4

1 8

50

25.

77

CC

BN

C

LIST

OF

ThE

MOS

T IN

NOV

ATIV

E CO

MPA

NIE

S OF

ThE

MED

ICA

L SE

CTOR

IN P

OLA

ND

IN 2

010

List of the most innovative companies of the medical sector in Poland in 2010 67

17Po

lfarm

ex S

.A. (

JSC)

Kutn

o21

20Z

171

734

10

.3

6 1

801

1

.05

CC

BN

N

18Pr

zeds

iębi

orst

wo

Farm

aceu

tycz

ne J

elfa

S.A

. (P

harm

aceu

tical

Com

pany

Jel

fa J

SC)

Jele

nia

Góra

2120

Z 3

51 6

37

4.0

6 1

58

0.0

4 1

NB

CC

C

19De

ntal

Nan

otec

hnol

ogy

Sp. z

o.o

. (Lt

d.)

Kato

wic

e86

90E

1 4

74

8.1

6 3

9 2

.63

CC

CN

C

20Bi

o-Ks

el S

p. z

o.o

. (Lt

d.)

Grud

ziądz

3250

Z 4

918

10

.7

6 1

7 0

.35

CB

CN

N

21Ch

M S

p. z

o.o

. (Lt

d.)

Juch

now

iec

Kośc

ieln

y32

50Z

29

666

41.7

5

1 C

BN

NB

22Oś

rode

k Ba

daw

czo-

Prod

ukcy

jny

Polit

echn

iki Ł

ódzk

iej

Iche

m S

p. z

o.o

. (Ce

ntre

for R

esea

rch

and

Prod

uctio

n Lo

dz T

echn

ical

Uni

vers

ity Ic

hem

Ltd

.) Łó

dź46

46Z

217

848

8.

5 5

1 C

BN

NB

23Sw

issm

ed C

entru

m Z

drow

ia S

.A. (

JSC)

Gdań

sk86

21Z

48

054

6.0

3 1

950

4

.06

CN

BN

C

24Bi

omed

Lub

lin W

ytw

órni

a Su

row

ic i

Szcz

epio

nek

S.A

. (J

SC)

Lubl

in21

20Z

33

624

4.2

6 8

09

2.4

0 N

CB

NC

25As

cor S

.A. (

JSC)

War

szaw

a32

50Z

12

378

18.8

6

698

5

.64

CC

BN

N

26Fa

rmac

euty

czna

Spó

łdzie

lnia

Pra

cy G

alen

a (P

harm

aceu

tical

Coo

pera

tive

Gale

na)

Wro

cław

2120

Z 3

4 17

4 22

.9

6 5

11

1.4

9 C

NB

NC

27Sp

ółdz

ieln

ia M

echa

nikó

w S

MS

(Mec

hani

cs

Coop

erat

ive

SMS)

War

szaw

a32

50Z

10

849

8.5

6 7

2 0

.66

CC

CN

N

28Ce

lon

Phar

ma

Sp. z

o.o

. (Lt

d.)

Łom

iank

i21

20Z

39

253

14.8

5

14

CC

NN

A

29Am

erca

n He

art o

f Pol

and

S.A

. (JS

C)Us

troń

8610

Z 1

41 7

68

13.9

5

2 C

CN

NB

30St

olte

r Sp.

z o

.o. (

Ltd.

)St

olno

3250

Z 6

4 56

0 9.

2 5

CB

NN

C

31St

erip

ack

Med

ical

Pol

and

Sp. z

o.o

. (Lt

d.)

Jelc

z La

skow

ice

8292

Z 1

3 86

8 9.

1 5

1 C

BN

NC

32PZ

HTL

S.A

. (JS

C)W

arsz

awa

3250

Z 3

1 47

6 5.

0 6

983

3

.12

NC

BN

N

33In

styt

ut B

iote

chno

logi

i Sur

owic

i Sz

czep

ione

k Bi

omed

S.

A. (

Biot

echn

olog

y In

stitu

te o

f Ser

a an

d Va

ccin

es

Biom

ed J

SC)

Krak

ów21

20Z

43

184

–8.8

6

624

1

.45

NC

BN

N

34Pr

zeds

iębi

orst

wo

Yavo

Sp.

z o

.o. (

Com

panz

Zav

o Lt

d.)

Bełc

ható

w32

50Z

9 4

64

–10.

2 6

182

1

.93

1 N

CC

NC

35Fr

ey S

p.J.

Pias

eczn

o32

50Z

6 9

36

27.1

5

1 C

CN

NC

36M

elis

a Ol

ga C

herk

asov

a Sp

.K. (

Lim

ited

Partn

ersh

ip)

Pozn

ań86

21Z

152

15

.6

5

C

BN

NN

37Za

kład

y Fa

rmac

euty

czne

Pol

fa Ł

ódź

S.A

. (P

harm

aceu

ital W

orks

Pol

fa Ł

ódź

JSC)

Łódź

2120

Z 4

3 34

2 5.

0 5

2 N

CN

NA

S.N

.Co

mpa

ny n

ame

Plac

eN

ACE

co

de

Net sales 2010


Source


(R&D) 2010


National patents

UE contracts

Market innovation

Process innovation


Patents

UE contracts

thou

sand

PL

N%

thou

sand

PL

N%


38Ba

lton

Sp. z

o.o

. (Lt

d.)

War

szaw

a32

50Z

76

648

1.3

5

4

NC

NN

A

39Re

ad-G

ene

S.A

. (JS

C)Sz

czec

in72

19Z

364

–6

3.1

4 5

194

1

NN

BN

C

40US

Pha

rmac

ia S

p. z

o.o

. (Lt

d.)

Wro

cław

2120

Z 4

88 1

62

6 3

17

0.0

7 N

CC

NN

41N

euro

reha

Sp.

z o

.o. (

JSC)

Opol

e86

90E

206

82

.2

5

C

CN

NN

42Te

lem

edyc

yna

Pols

ka S

.A. (

JSC)

Kato

wic

e86

22Z

2 1

86

54.9

5

BC

NN

N

43Gl

axoS

mith

Klin

e Ph

arm

aceu

tical

s S.

A. (

JSC)

Pozn

ań21

20Z

3 4

73 5

84

22.7

5

CC

NN

N

44Ca

rint S

p. z

o.o

. (Lt

d.)

Krak

ów86

21Z

13

772

22.0

5

CC

NN

N

45Vo

xel S

.A. (

War

saw

Pha

rmac

eutic

al W

orks

Pol

fa J

SC)

Krak

ów86

22Z

36

635

16.9

5

1 C

CN

NC

46Or

gani

zacj

a Po

lski

ch D

ystry

buto

rów

Fa

rmac

euty

czny

ch S

.A. (

Orga

nisa

tion

of th

e Po

lish

Phar

mac

eutic

al D

istri

buto

rs J

SC)

War

szaw

a46

46Z

536

735

15

.3

5

C

CN

NN

47Sa

lus

Inte

rnat

iona

l Sp.

z o

.o. (

Ltd.

)Ka

tow

ice

4646

Z 5

22 4

66

14.6

5

CC

NN

N

48Ce

ntra

la F

arm

aceu

tycz

na C

efar

m S

.A. (

JSC)

War

szaw

a46

46Z

1 0

14 6

62

11.0

5

CC

NN

N

49Ro

che

Diag

nost

ics

Pols

ka S

p. z

o.o

. (Lt

d.)

War

szaw

a47

74Z

467

132

10

.4

5

C

CN

NN

50He

rban

ordp

ol G

dańs

k Sp

. z o

.o. (

Ltd.

)N

owy

Staw

2120

Z 9

92

8.8

5

C

CN

NN

51N

euca

S.A

. (JS

C)To

ruń

4646

Z 4

622

720

8.

6 5

CC

NN

N

52N

ovo

Nor

disk

Pha

rma

Sp. z

o.o

. (Lt

d.)

War

szaw

a46

46Z

483

804

8.

2 5

CC

NN

N

53Pe

lion

S.A

. (JS

C)Łó

dź46

46Z

5 7

95 3

83

6.8

5

C

CN

NN

54Ta

rcho

miń

skie

Zak

łady

Far

mac

euty

czne

Pol

fa S

.A.

(Tar

chom

in P

harm

aceu

tical

Wor

ks J

SC)

War

szaw

a21

20Z

214

947

–5

.7

6 8

35

0.3

9 N

NB

NN

55Fa

bryk

a Ap

arat

ury

Elek

trom

edyc

znej

Fam

ed Ł

ódź

S.A

. (F

acto

ry o

f Med

ical

App

arat

us J

SC)

Łódź

3250

Z 6

765

1.

5 6

436

6

.44

NN

BN

N

56To

war

zyst

wo

Prze

mys

łow

o Ha

ndlo

we

Secf

arm

Sp.

z o.

o.

(Indu

stria

l and

Com

mer

cial

Com

pany

Sec

Farm

Ltd

.) W

arsz

awa

4646

Z 6

26

–53.

8 6

184

2

9.48

N

NB

NN


57Po

znań

skie

Zak

łady

Zie

lars

kie

Herb

apol

S.A

. (He

rbal

Pl

ants

Poz

nan

JSC

Herb

apol

)Po

znań

2120

Z 8

3 79

5 –2

.0

6 2

9 0

.03

NC

CN

N

58Ad

amed

Con

sum

er H

ealth

care

S.A

. (JS

CTu

szyn

2120

Z 1

3 59

1 3.

1 6

10

0.0

7 N

NC

NC

59Pr

zeds

iębi

orst

wo

Zaop

atrz

enia

Far

mac

euty

czne

go

Cefa

rm K

ielc

e S.

A. (

Phar

mac

eutic

al S

uppl

y Co

mpa

nz

Cefa

rm K

ielc

e JS

C)Ki

elce

4646

Z 5

29 3

13

25.1

5

CC

NN

N

60Sa

nofi

Aven

tis L

td.

War

szaw

a21

20Z

1 7

98 0

51

24.6

5

CC

NN

N

61Pf

izer T

radi

ng P

olsk

a Sp

. z o

.o. (

Ltd.

)W

arsz

awa

4646

Z 5

56 5

05

17.4

5

CC

NN

N

62Ce

farm

Wro

cław

Cen

trum

Zao

patrz

enia

Fa

rmac

euty

czne

go S

.A. (

Phar

mac

eutic

al S

uppl

y Ce

ntre

(JSC

)W

rocł

aw46

46Z

494

154

11

.3

5

C

CN

NN

63Cu

rtis

Heal

th C

aps

Sp. z

o.o

. (Lt

d.)

Pozn

ań21

20Z

8 8

43

10.6

5

1 C

NN

NC

64Fa

rmac

ol S

.A. (

JSC)

Kato

wic

e46

46Z

4 9

53 8

85

7.2

5

C

CN

NN

65JZ

O Sp

. z o

.o. (

Ltd.

)Je

leni

a Gó

ra32

50Z

55

959

3.6

5

N

BN

NN

66

Przy

chod

nia

Leka

rska

Med

eo H

enry

ka M

ikuł

a Te

leng

a To

mas

z M

atec

ki B

arba

ra E

lżbie

ta S

chm

idt J

acek

Sz

yman

iak

Sp.J

. (Cl

inic

al S

urge

ry U

nit M

edeo

He

nryk

a M

ikuł

a Te

leng

a, T

omas

z M

atec

ki, B

arba

ra

Elżb

ieta

Sch

mid

t, Ja

cek

Szym

ania

k Ge

nera

l Pa

rtner

ship

)

Pozn

ań86

21Z

4 9

50

2.0

5

N

BN

NN

67

Nie

publ

iczn

y Za

kład

Opi

eki Z

drow

otne

j Pra

ktyk

a Ze

społ

u Le

karz

a Ro

dzin

nego

Zdr

ovita

Mic

hnie

wic

z-N

owak

, Ról

ka, W

iśni

ewsk

a-Pr

ałat

, Śni

eg. S

p.P.

(Hea

lth C

entre

Inde

pend

ent H

ealth

care

Cen

tre (N

ZOZ)

Fa

mily

Doc

tor P

ract

ice

Grou

p Zd

rovi

ta

Kros

no

Odrz

ańsk

ie86

21Z

2 0

82

–0.2

5

NB

NN

N

68

Nie

publ

iczn

y Za

kład

Opi

eki Z

drow

otne

j Prz

ycho

dnia

Le

kars

ka Z

drow

ie A

.Gra

czyk

-Dud

a E.

Rac

zyńs

ka

A W

alor

ski S

p.P.L

. (He

alth

care

Cen

tre (N

ZOZ)

M

edic

al H

ealth

Cen

tre A

.Gra

czyk

-Dud

a E.

Racz

yńsk

a A

Wal

orsk

i

Grod

ków

8621

Z 1

463

–2

.1

5

N

BN

NN

69Hu

rtap

S.A

. (JS

C)Łę

czyc

a46

46Z

737

555

–2

3.9

5

N

CN

NC

70M

obile

x Sp

. z o

.o. (

Ltd.

)Łó

dź47

74Z

8 2

69

–10.

5 6

2

0.0

3 N

NC

NN

71Te

map

harm

Sp.

z o

.o. (

Ltd.

)W

arsz

awa

4646

Z

5

2

NN

NN

B

72M

abio

n S.

A. (

JSC)

Kutn

o72

11Z

3 0

85

3 38

5.8

5

C

NN

NN

S.N

.Co

mpa

ny n

ame

Plac

eN

ACE

co

de

Net sales 2010


Source


(R&D) 2010


National patents

UE contracts

Market innovation

Process innovation


Patents

UE contracts

thou

sand

PL

N%

thou

sand

PL

N%


73Pr

o Pl

us S

p. z

o.o

. (Lt

d.)

War

szaw

a32

50Z

731

16

0.9

5

C

NN

NN

74Ph

arm

aGea

Sp.

z o

.o. (

Ltd.

)Ka

tow

ice

4773

Z 4

615

13

.6

5

C

NN

NN

75

Cent

raln

y Sz

pita

l Klin

iczn

y M

inis

ters

twa

Spra

w

Wew

nętrz

nych

i Ad

min

istra

cji w

War

szaw

ie (C

entra

l Cl

inic

al H

ospi

tal o

f the

Min

istry

of I

nter

nal A

ffairs

and

Ad

min

istra

tion

in W

arsa

w)

War

szaw

a86

10Z

321

361

7.

4 5

CN

NN

N

76Za

kład

y Fa

rmac

euty

czne

Pliv

a Kr

aków

S.A

. (P

harm

aceu

tical

Wor

ks P

liva

Krak

ów J

SC)

Krak

ów21

20Z

586

766

2.

9 5

NC

NN

N

77Pr

zeds

iębi

orst

wo

Zaop

atrz

enia

Far

mac

euty

czne

go

Cefa

rm S

zcze

cin

S.A

. (Ph

arm

aceu

tical

Sup

ply

Ente

rpris

es C

efar

m S

zcze

cin

JSC)

Szcz

ecin

4646

Z 4

72 6

53

1.5

5

N

CN

NN

78W

rocł

awsk

ie Z

akła

dy Z

iela

rski

e He

rbap

ol S

.A.

(Wro

cław

Her

bal W

orks

Her

bapo

l JSC

)W

rocł

aw21

20Z

98

989

–0.2

5

NC

NN

N

79Ni

epub

liczn

y Za

kład

Opie

ki Zd

row

otne

j Med

icor

Sp.

z o.

o.

(Inde

pend

ent H

ealth

Car

e Ce

ntre

Ltd

.)W

rocł

aw86

21Z

1 4

54

–1.0

5

NC

NN

N

80Ce

ntru

m S

łuch

u i M

owy

Sp. z

o.o

. (He

arin

g an

d Sp

eech

Cen

tre L

td)

War

szaw

a86

90E

10

184

–1.3

5

1 N

CN

NC

81W

iki M

et S

p. z

o.o

. (Lt

d.)

Kępn

o32

50Z

48

083

–1.9

5

NC

NN

N

82Kr

ka P

olsk

a Sp

. z o

.o. (

Ltd.

)W

arsz

awa

4646

Z 6

24 6

63

–2.3

5

NC

NN

N

83Ch

ema

Elek

trom

et S

półd

zieln

ia P

racy

(Che

ma

Elek

torm

et C

oope

rativ

e)Rz

eszó

w21

20Z

16

614

–3.3

5

NC

NN

C

84Kr

akow

skie

Zak

łady

Zie

lars

kie

Herb

apol

w K

rako

wie

S.

A. (

Herb

al P

lant

Com

pany

Cra

cow

in K

rako

w J

SC

Herb

apol

) Kr

aków

2120

Z 1

9 12

4 –3

.9

5

N

CN

NC

85M

PW M

ed In

stru

men

ts S

półd

zieln

ia P

racy

War

szaw

a32

50Z

11

647

–3.9

5

NC

NN

N


86N

iepu

blic

zny

Zakł

ad O

piek

i Zdr

owot

nej Z

drow

ie S

p.P.L

. Be

ata

Duda

-Che

łsto

wsk

a i P

artn

erzy

(Ind

epen

dent

He

alth

care

Cen

tre)

Ostró

da86

21Z

2 0

77

–7.0

5

NC

NN

N

87To

mog

raf S

p. z

o.o

. (Lt

d.)

Toru

ń86

90E

5 4

81

–11.

8 5

NC

NN

N

88Ce

farm

Bia

łyst

ok S

.A. (

JSC)

Biał

ysto

k46

46Z

222

849

–2

2.7

5

N

CN

NN

89An

phar

m P

rzed

sięb

iors

two

Farm

aceu

tycz

ne S

.A.

(Anp

harm

Pha

rmac

eutic

al C

ompa

ny J

SC)

War

szaw

a21

20Z

241

541

–3

4.4

5

N

CN

NN

90Ja

rmed

Sp.

z o

.o. (

Ltd.

)Rz

eszó

w32

50Z

37

–60.

7 5

NC

NN

N

91Te

chno

phar

ma

Sp. z

o.o

. (Lt

d.)

War

szaw

a46

46Z

5

NC

NN

N

92Za

kład

Bad

awcz

o-W

droż

enio

wy

Ośro

dka

Salm

onel

la

Imm

unol

ab S

p. z

o.o

. (Re

sear

ch a

nd Im

plem

enta

tion

Depa

rtmen

t Im

mun

olab

Sal

mon

ella

Cen

tre L

td.)

Gdyn

ia21

20Z

5

NN

NN

C

93Le

k S.

A. (

JSC)

Stry

ków

2120

Z 1

598

413

3.

7 5

NC

NN

N

94Ba

yer S

p. z

o.o

. (Lt

d.)

War

szaw

a46

90Z

1 2

65 0

64

0.6

5

N

CN

NN

95Sa

mod

zieln

y Pu

blic

zny

Zakł

ad O

piek

i Zdr

owot

nej

Szpi

tal U

niw

ersy

teck

i w K

rako

wie

(Ind

epen

dent

Pub

lic

Heal

th C

are

Univ

ersi

ty H

ospi

tal i

n Kr

akow

)Kr

aków

8610

Z 4

16 3

53

–1.5

5

NN

NN

C

96Gl

axoS

mith

Klin

e Co

nsum

er H

ealth

care

Sp.

z o

.o. (

Ltd.

)W

arsz

awa

4646

Z 7

99 0

72

–2.9

5

NC

NN

N

97Pr

ospe

r S.A

. (JS

C)W

arsz

awa

4646

Z 1

886

221

–5

.2

5

N

NN

NC

98Ph

ytop

harm

Dob

rzyc

a Sp

. z o

.o. (

Ltd.

)Do

brzy

ca21

20Z

2 0

52

–30.

9 5

NC

NN

N

99W

rocł

awsk

i Med

yczn

y Pa

rk N

auko

wo-

Tech

nolo

gicz

ny

Sp. z

o.o

. (W

rocł

aw S

cien

tific

and

Tec

hnol

ogic

al

Med

ical

Par

k Lt

d.)

Wro

cław

7219

Z

5

1

NN

NN

C

100

Nyc

omed

Pha

rma

Sp z

o.o

. (Lt

d.)

War

szaw

a46

46Z

5

NN

NN

C

Sour

ce –

1 –

dat

a fro

m c

ompa

nies

rece

ived

in s

urve

ys o

f the

MSN

Sci

entif

ic N

etw

ork

and

INE

PAN

, inv

estm

ent R

&D a

ccor

ding

to O

ECD

i CSO

(Cen

tral S

tatis

tical

Offi

ce G

US);

2 –

data

from

com

pani

es

rece

ived

in s

urve

ys o

f the

MSN

Sci

entif

ic N

etw

ork

and

INE

PAN,

inve

stm

ent i

n R&

D ac

cord

ing

to IA

S 38

sta

ndar

d; 3

– d

ata

from

repo

rts o

f the

com

pani

es lis

ted

on G

PW (W

arsa

w S

tock

Exc

hang

e), i

nves

tmen

t in

R&D

acc

ordi

ng to

IAS

38 s

tand

ard;

4 –

dat

a fro

m re

ports

of t

he c

ompa

nies

list

ed o

n GP

W, i

nves

tmen

t in

R&D

acco

rdin

g to

the

2011

EU

Indu

stria

l R&D

Inve

stm

ent S

core

boar

d, E

urop

ean

Com

mis

sion

, JRC

/DG

RTD

; 5 –

dat

a fro

m fi

nanc

ial r

epor

ts o

f the

com

pani

es b

ased

on

KRS

(Nat

iona

l Cou

rt Re

gist

ry);

6 –

data

from

fina

ncia

l rep

orts

of t

he c

ompa

nies

bas

ed o

n KR

S, in

vest

men

t in

R&D

acco

rdin

g to

IAS

38

stan

dard

; I –

dat

a of

inve

stm

ent i

n R&

D in

a c

ost s

truct

ure;

II –

dat

a of

inve

stm

ent i

n R&

D in

ass

ets

stru

ctur

e.


ALPhABETICAL LIST OF COMPANIES

Company Name Place on the list

Adamed Sp. z o.o. (Ltd.) 3Adamed Consumer Healthcare (JSC) 58Amercan Heart of Poland S.A. (JSC) 29Anpharm Przedsiębiorstwo Farmaceutyczne S.A. (Anpharm Pharmaceutical Company JSC) 89Ascor S.A. (JSC) 25Balton Sp. z o.o. (Ltd.) 38Bayer Sp. z o.o. (Ltd.) 94Biofarm Sp. z o.o. (Ltd.) 15Bio-Ksel Sp. z o.o. (Ltd.) 20BioMaxima S.A. (JSC) 16Biomed Lublin Wytwórnia Surowic i Szczepionek S.A. (JSC) 24Bioton S.A. (JSC) 7Carint Sp. z o.o. (Ltd.) 44Cefarm Białystok S.A. (JSC) 88Cefarm Wrocław Centrum Zaopatrzenia Farmaceutycznego S.A. (Pharmaceutical Supply Centre JSC) 62Celon Pharma Sp. z o.o. (Ltd.) 28Centrala Farmaceutyczna Cefarm S.A. (JSC) 48Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie (Central Clinical Hospital of the Ministry of Internal Affairs and Administration in Warsaw) 75Centrum Słuchu i Mowy Sp. z o.o. (Hearing and Speech Centre Ltd) 80Chema Elektromet Spółdzielnia Pracy (Chema Elektormet Cooperative) 83Chemapol S.C. 14ChM Sp. z o.o. (Ltd.) 21Curtis Health Caps Sp. z o.o. (Ltd.) 63Dental Nanotechnology Sp. z o.o. (Ltd.) 19Fabryka Aparatury Elektromedycznej Famed Łódź S.A. (Factory of Medical Apparatus JSC) 55Farmaceutyczna Spółdzielnia Pracy Galena (Pharmaceutical Cooperative Galena) 26Farmacol S.A. (JSC) 64Frey Sp.J. 35GlaxoSmithKline Consumer Healthcare Sp. z o.o. (Ltd.) 96GlaxoSmithKline Pharmaceuticals S.A. (JSC) 43Herbanordpol Gdańsk Sp. z o.o. (Ltd.) 50Herbapol Lublin S.A. (JSC) 12Hurtap S.A. (JSC) 69Instytut Biotechnologii Surowic i Szczepionek Biomed S.A. (Biotechnology Institute of Sera and Vaccines Biomed JSC) 33Jarmed Sp. z o.o. (Ltd.) 90JZO Sp. z o.o. (Ltd.) 65Krakowskie Zakłady Zielarskie Herbapol w Krakowie S.A. (Herbal Plant Company Cracow in Krakow JSC Herbapol) 84Krka Polska Sp. z o.o. (Ltd.) 82Lek S.A. (JSC) 93LfC Sp. z o.o. (Ltd.) 1Mabion S.A. (JSC) 72Medana Pharma S.A. (JSC) 11Medicalgorithmics S.A. (JSC) 8Melisa Olga Cherkasova Sp.K. (Limited Partnership) 36Mobilex Sp. z o.o. (Ltd.) 70MPW Med Instruments Spółdzielnia Pracy 85

Alphabetical List of Companies 73

Neuca S.A. (JSC) 51Neuroreha Sp. z o.o. (Ltd.) 41Niepubliczny Zakład Opieki Zdrowotnej Medicor Sp. z o.o. (Independent Health Care Centre Ltd.) 79Niepubliczny Zakład Opieki Zdrowotnej Praktyka Zespołu Lekarza Rodzinnego Zdrovita Mich-niewicz-Nowak, Rólka, Wiśniewska-Prałat, Śnieg. Sp.P. (Health Centre Independent Healthca-re Centre (NZOZ) Family Doctor Practice Group Zdrovita) 67Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Lekarska Zdrowie A.Graczyk-Duda E. Raczyńska A.Walorski Sp.P.L. (Healthcare Centre (NZOZ) Medical Health Centre A.Graczyk- -Duda E. Raczyńska A.Walorski 68Niepubliczny Zakład Opieki Zdrowotnej Zdrowie Sp.P.L. Beata Duda-Chełstowska i Partnerzy (Independent Healthcare Centre (NZOZ) Medical Health Centre) 86Novo Nordisk Pharma Sp. z o.o. (Ltd.) 52Nycomed Pharma Sp. z o.o. (Ltd.) 100Olimp Laboratories Sp. z o.o. (Ltd.) 13Organizacja Polskich Dystrybutorów Farmaceutycznych S.A. (Organisation of the Polish Phar-maceutical Distributors JSC) 46Ośrodek Badawczo-Produkcyjny Politechniki Łódzkiej Ichem Sp. z o.o. (Centre for Research and Production Lodz Technical University Ichem Ltd.) 22Pelion S.A. (JSC) 53Pfizer Trading Polska Sp. z o.o. (Ltd.) 61PharmaGea Sp. z o.o. (Ltd.) 74Phytopharm Dobrzyca Sp. z o.o. (Ltd.) 98Polfarmex S.A. (JSC) 17Poznańskie Zakłady Zielarskie Herbapol S.A. (Herbal Plants Poznan JSC Herbapol) 57Pro Plus Sp. z o.o. (Ltd.) 73Prosper S.A. (JSC) 97Przedsiębiorstwo Farmaceutyczne Jelfa S.A. (Pharmaceutical Company Jelfa JSC) 18Przedsiębiorstwo Farmaceutyczne Lek-Am Sp. z o.o. (Pharmaceutical Company Lek-Am Ltd.) 6Przedsiębiorstwo Yavo Sp. z o.o. (Company Yavo Ltd.) 34Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm Kielce S.A. (Pharmaceutical Supply Companz Cefarm Kielce JSC) 59Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm Szczecin S.A. (Pharmaceutical Sup-ply Enterprises Cefarm Szczecin JSC) 77Przychodnia Lekarska Medeo Henryka Mikuła Telenga Tomasz Matecki Barbara Elżbieta Schmidt Jacek Szymaniak Sp.J. (Clinical Surgery Unit Medeo Henryka Mikuła Telenga, Tomasz Matecki, Barbara Elżbieta Schmidt, Jacek Szymaniak General Partnership) 66PZ Cormay S.A. (JSC) 5PZ HTL S.A. (JSC) 32Read-Gene S.A. (JSC) 39Roche Diagnostics Polska Sp. z o.o. (Ltd.) 49Salus International Sp. z o.o. (Ltd.) 47Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie (Indepen-dent Public Health Care University Hospital in Krakow) 95Sanofi Aventis Ltd. 60Selvita S.A. (JSC) 2Spółdzielnia Mechaników SMS (Mechanics Cooperative SMS) 27Steripack Medical Poland Sp. z o.o. (Ltd.) 31Stolter Sp. z o.o. (Ltd.) 30Swissmed Centrum Zdrowia S.A. (JSC) 23Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. (Tarchomin Pharmaceutical Works JSC) 54Technopharma Sp. z o.o. (Ltd.) 91


Telemedycyna Polska S.A. (JSC) 42Temapharm Sp. z o.o. (Ltd.) 71Tomograf Sp. z o.o. (Ltd.) 87Towarzystwo Przemysłowo-Handlowe Secfarm Sp. z o.o. (Industrial and Commercial Compa-ny SecFarm Ltd.) 56Tricomed S.A. (JSC) 9US Pharmacia Sp. z o.o. (Ltd.) 40Voxel S.A. (Warsaw Pharmaceutical Works Polfa JSC) 45Warszawskie Zakłady Farmaceutyczne Polfa S.A. (JSC) 10Wiki Met Sp. z o.o. (Ltd.) 81Wojewódzki Szpital Specjalistyczny we Wrocławiu (Wrocław Scientific and Technological Medical Park) 4Wrocławski Medyczny Park Naukowo Technologiczny Sp. z o.o. (Wrocław Scientific and Technological Medical Park Ltd.) 99Wrocławskie Zakłady Zielarskie Herbapol S.A. (Wrocław Herbal Works Herbapol JSC) 78Zakład Badawczo-Wdrożeniowy Ośrodka Salmonella Immunolab Sp. z o.o. (Research and Implementation Department Immunolab Salmonella Centre Ltd.) 92Zakłady Farmaceutyczne Pliva Kraków S.A. (Pharmaceutical Works Pliva Kraków JSC) 76Zakłady Farmaceutyczne Polfa Łódź S.A. (Pharmaceuital Works Polfa Łódź JSC) 37

Alphabetical List of Companies 75

ExPLANATION OF CODES FOR ThE SURVEyED GROUP OF SUBCLASSES OF NACE BASED POLISh CLASSIFICATION OF ACTIVITIES 20071

SN Sector name Subclasses PKD 2007

1 Research activites 7211Z – Scientific research and development works in biotechnology7219Z – Scientific research and development works in the natural sciences and engineering

2 Pharmaceuticals 1086Z – Production of homogenized and dietetic food1089Z – Production of other food articles, not classified elsewhere 2110Z – Production of basic pharmaceuticals2120Z – Production of medicines and remaining pharmaceuticals4646Z – Wholesale of pharmaceuticals and medical products4690Z – Non-specialized wholesale4773Z – Retail sale of pharmaceuticals in specialized stores

3 Medical equipment 3250Z – Production of equipment, instruments and medical devices, including dental4669Z – Wholesale of remaining machinery and equipment 4774Z – Retail sales of medical products, including orthopedic, in specialized stores 8292Z – Packaging activities

4 Hospital services and medical care

8610Z – Hospital activities 8621Z – General medical practice 8622Z – Specialized medical practice8690E – Remaining activites in health care, not classified elsewhere

1 Por. http://www.stat.gov.pl/klasyfikacje/pkd_07/pdf/2_PKD-2007-schemat_2.pdf


GLOSSARy TO ThE LIST OF MOST INNOVATIVE COMPANIES OF ThE MEDICAL SECTOR IN 2010

Company name – short name of the company allowing its identification.

Place – company headquaters.

NACE code – please refer to explanation of codes p. 75.

Net sales revenues and equivalents – (Form2 F-02 in 2010 Part II Section 2 line 01) or data from the MSN Scien-tific Network and INE PAN or data base of INE PAN.

Sales growth – calculated as the relation of change in sales revenues in 2010 to the previous year, to the sales revenues in 2009, as a percentage.

Source – 1 – data from companies received in surveys of the MSN Scientific Network and INE PAN, investment R&d according to OECD i CSO (Central Statistical Office GUS); 2 – data from companies received in surveys of the MSN Scientific Network and INE PAN, investment in R&D according to IAS 38 standard; 3 – data from reports of the com-panies listed on GPW (Warsaw Stock Exchange), investment in R&D according to IAS 38 standard; 4 – data from reports of the companies listed on GPW, investment in R&D according to the 2011 EU Industrial R&D Investment Sco-reboard, European Commission, JRC/DG RTD; 5 – data from financial reports of the companies based on KRS (National Court Registry); 6 – data from financial reports of the companies based on KRS, investment in R&D according to IAS 38 standard; I – data of investment in R&D in a cost structure; II – data of investment in R&D in assets structure.

Research and development (R&D) – PNT-02 form for industry or PNT-02/u form for services for the period 2008-2010 [Part. 3B line.10] or capitalized value of R&D (according to Act on Accounting) or in lack of data – data from MSN Scientific Network and INE PAN surveys or from INE PAN database.

R&D Activity/Sales – relation of investment in R&D activity to sales revenue as a percentage (specific position of statistical forms).

National patents – company obtained a patent (patents) in 2010 (data from Patent Office of the Republic of Poland) or data from MSN Scientific Network and INE PAN surveys.

EU contracts – number of signed contacts in the 7th Framework Programme of the European Union or in the Operational Programme Innovative Economy in 2008–2010.

Market innovativeness – by assessment, sales dynamics, export dynamics, employment dynamics and quality assessment of the most innovative product were taken into consideration.

Export – value of export sales (F-02 form in 2010 Part II Section 2 line 03) or data from MSN Scientific Network and INE PAN surveys.

Change in export – this is relation of change in export sales in 2010 to previous year, to export sales in 2009, as a percentage.

Employment – number of employees (as of end of reporting period) (F-01/I-01 form in 2010 Part. I Section. 1 Sup-plementary data line. 80) or from INE PAN database or from MSN Scientific Network and INE PAN surveys.

Change in employment – this is relation to change in number of employees in 2010 to the previous year, to num-ber of employees in 2009, as a percentage, if it was not possible to calculate the so-defined changes in employ-ment, then the change in employment for periods prior to time series was calculated.

Explanation of scoring in market innovation column max. 20 points): if 2 out of 3 dynamics indicators were higher (or equal) than its median values in population of companies – 15 points; if 1 out of 3 dynamics indicators were higher (or equal) than its median value – 10 points; if 2 or 3 dynamics indicators were lower than its median – 5 points; if there was lack of data for all values – from 1 to 5 points, and in case of lack of description – 0 points.

Explanation of letter signs A – 16 and more points, B – 11–15,99 points, C – 1–10,99 points, N – lack of data for all values.

Process innovation – when assessing the following financial indicators were taken into account: ROA in 2010, ROA dynamics, share of investments in total investment in innovativeness activity. ROA (net return on assests) – this is relation of net (positive) financial result total assests, as a percentage – F-02 form in 2010 [Section. II (Section. 2 item 65 minus 66/Section. 1 column. 2 item 59)*100] or data from MSN Scientific Network and INE PAN surveys. ROA dynamics – calculated as relation of change of ROA indicator in 2010 to previous, to ROA indicator in 2009 r., as a percentage.

2 This is reporting form of Central Statistical Office (GUS).

Glossary to the List of most innovative companies of the medical sector in 2010 77

Share of investment in fixed assets in investment on innovation activities in total – this is share of investment in fixed assets in investment on innovation activities in total, as a percentage – PNT-02 form for industry or PNT-02/u for services for 2008-2010 period [Section 3B (line 04/line 01)*100] or data from Scientific Network MSN and INE PAN surveys.

Explanation of scoring in process innovation column (max. 20 points): if 2 out of 3 dynamics indicators were higher (or equal) than its median values in population of companies – 15 points; if 1 out of 3 dynamics indicators were higher (or equal) than its median value – 10 points; if 2 or 3 dynamics indicators were lower than its median – 5 points; if there was lack of data for all values – 0 points; quality description of the most innovative product – from 1 to 5 points, in case of lack of description – 0 points.

Explanaion of letter signs : A – 16 and more points, B – 11–15,99 points, C – 1–10,99 points, N – lack of data for all values.

Investment in innovative activity – when assessing the following financial data were taken into consideration: r&D activity/sales, activity R&D/innovative activity in total. R&D activity/innovative activity in total – share of r&D activity in investment in innovative activity in total, as a percentage: PNT-02 form for industry or PNT-02/u for services for 2008-2010 period [Section. 3B (line 10/line 01)*100] or data from MSN Scientific Network and INE PAN surveys.

Explanation of scoring in innovation activity (max. 20 points): if 2 out of 3 dynamics indicators were higher (or equal) than its median values in surveyed population of companies – 15 points; if 1 out of 3 dynamics indicators was higher (or equal) than its median value in surveyed population of companies – 10 points; if 2 or 3 dynamics indicators were lower than its median in surveyed population of companies – 5 points; if there was lack of data for all values – 0 points, quali-ty description of most innovative product – from 1 to 5 points and in case of lack of description – 0 points.

Explanation of letter signs A – 16 and more points, B – 11–15,99 points, C – 1–10,99 points, N – lack of data for all values.

Patents (max. 20 points): national patents – in case of 1 patent, company receives 5 points; more than 1 patent – 10 points; international patents (European or American) – 15 points. In case, company had both national patents and international patents, only points for international patents were awarded. Quality assessment of the most innovative product from the side of patent applications – from 1 to 5 points, and in case of lack of description – 0 points. Quality assessment of the most innovative product from side of patent applications O – from 1 to 5, and in casoe of lack of product description – 0 points.

Explanaion of letter signs : A – 16 and more points, B – 11–15,99 points, C – 1–10,99 points, N – lack of data for all values.

EU contracts (total points – max. 20) – explanaion of letter signs: A – 16 and more points, B – 11–15,99 points, C – 1–10,99 points, N – lack of data for all values. Number of points for signed contracts in 7th Framework Pro-gramme of European Union or Operational programme Innovation Economy in w 2008-2010 period was: 15 points for 4 contracts and more, 10 points for 2–3 contracts, 5 points for 1 contract, 0 points for lack of contract.

Number of points for contracts financed form structural funds of European Union in 2008-2010 period: 5 points for 1 or more contracts, 0 points for lack of contracts. Companies that had signed contracts in national or international programmes, could obtain max. 20 points. In case of lack of data from MSN Scientific Network and INE PAN surveys, data comes from PNT statistical forms or from INE PAN database.

If companies received the same number of points, its order depended on investment in R&D activity in 2009, next from dynamics of sales revenues in 2010/2009.

Normal annual rate of change – refers to change of investment in research and development activity and net sales revenues in 2010/2009 period. Rate of change was calculate according to the formula:

change ‘10/’09 = 100*[A/B – 1]

whereA – value of investment in R&D activity or value of revenues in 2010,B – value of investment in R&D activity or value of revenues in 2009.

Two-year rate of change on an annual basis – refers to change of investment in research and development activity and revenues from net sales in 2010/2008 period. Change rate was calculated according to the formula:

change ‘10/’08 = 100*[((A/C)^0,5) -1]

where A – value of investment in R&D activity or sales revenues in 2010,

C – value of investment in R&D activity or sales revenue in 2008.

Developed by: Tadeusz Baczko, Ewa Puchała-Krzywina, Marek Szyl

Information on selected innovative companies of the medical sector 79

Adamed Sp. z o.o. Assessment with 5A System: ACAAA www.adamed.com.plPlace on the List of medical sector: 3 Established in: 1986Place on the 500’2010 List: 5 Company size: large Address: 05–152 Czosnów, ul. Pieńków 149

Voivodship: MazovianType of business: pharmaceuticalsDescription of business activity: Adamed is a Polish pharmaceutical and biotechnological company, one of the most innovative companies in Poland. It manufactures RX type medicines (prescriptions medicines), OTC medicines, dietary supplements and dermocosmetics. The company is an investor in research and development. During the 2008–2010 period, it spent more than PLN 106 mln for this purpose. The research and development works include innovative cancer medicines, as well as metabolic disorders and central nervous system diseases medicines. The research programmes are carried out in collaboration with leading universities, scientific institutes and private companies.Shareholders: Adamed Pharma ZF JSC – 100%

Finan

cial d

ata

(thou

sand

PLN

)

2005 2006 2007 2008 2009 2010Net sales revenues 299 397.5 340 771.3 381 332.6 381 940.5 301 565.0 396 596.0Net financial income (profit/loss) 98 478.9 82 235.9 19 131.7 39 046.3 –6 005.3 12 870.2Capitalized value of R&D expenses 1 071.2 4 935.0Intangible assets 8 696.0 12 651.4Total assets 307 658.2 399 375.4 433 517.6 505 280.6 508 399.4 473 135.8Equity 292 375.4 364 611.3 374 068.0 439 868.5 437 390.3 359 816.7

Description of innovative activity: According to the 5A methodology, the Adamed Ltd. company market innvativeness level is very highly rated and the process innovativeness level is highly rated. The company enjoys the highest rating of expenditures on innvative activity and ability of obtaining patents, as well as the highest rating of obtaining funds for innovative projects from the EU. The company assessment in the 5A system is ACAAA.Company status: innovative company, investor in research and development, patenting company, beneficiary of national operatio-nal programmes of the European Union

Adamed Consumer Healthcare S.A.Assessment with 5A System: NNCNC www.adamed.com.plPlace on the List of medical sector: 58 Established in: 1989Place on the 500’2010 List: not listed Company size: medium Address: 95–080 Tuszyn, ul. Starościańska 33

Voivodship: LodzType of business: pharmaceuticalsDescription of business activity: Adamed Consumer Healthcare JSC is a pharmaceutical company being a part of Adamed JSC group. Adamed Consumer Healthcare manufactures OTC medicines (medicines available without a prescription) and dietary supplements. The company has developed and patented innovative formula of dermocosmetics. Sales of all products of Adamed Consumer Healtcare have been carried out since 2010. The company invests in R&D.Shareholders: Adamed Pharma ZF JSC – 100%

Finan

cial d

ata

(thou

sand

PLN

)

2005 2006 2007 2008 2009 2010Net sales revenues 13 475.0 13 309.9 14 576.9 14 147.3 13 186.0 13 590.9Net financial income (profit/loss) 243.0 213.6 321.6 508.9 –645.8 –6 179.1Capitalized value of R&D expenses 3.2 18.9 10.2Intangible assets 5.2 0.8 8.5 25.4 966.7Total assets 19 460.4 19 535.7 21 099.3 20 234.0 19 112.6 14 517.6Equity 13 610.0 13 823.6 14 038.6 14 440.9 13 136.0 6 956.9

Description of innovative activity: According to the 5A methodology, the Adamed Consumer Healthcare JSC company innovati-ve activity investment as well as its ability of obtaining the financing of innovative projects from EU are both highly rated. The company assessment in the 5A system is NNCNC.Company status: beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

299.

4

340.

8

381.

3

381.

9

301.

6 396.

6

Net sales datafor the 2005–2010 period in mln PLN

05 06 07 08 09 10

13.5

13.3

14.6

14.1

13.2 13

.6


INFormATIoN oN SELECTED INNoVATIVE ComPANIES oF THE mEDICAL SECTor IN PoLAND

raport med ANG karty przedsiębiorstw.indd 79 2012-10-10 18:10:12


American Heart of Poland S.A.

Assessment with 5A System: CCNNB www.klinikaserca.plPlace on the List of medical sector: 29 Established in: 2000Place on the 500’2010 List: 457 Company size: medium

Address: 43–450 Ustroń, ul. Sanatoryjna 1Voivodship: Silesian

Type of business: hospital services and medical careDescription of business activity: The Polish American Heart Clinics – American Heart of Poland JSC is a network of interventional cardiology, angiology and cardiac surgery branches in Poland. In 2000 those clinics were founded on initiative of the renowned doctors from Poland and United States. The idea of their appointment was the implementation of the latest treatment methods of cardiovascular deseases. For more than 12 years of their activity, thanks to, among others: the huge potential, the excellent repu-tation of medical staff and the patient admissions guarantee, the Polish American Heart Clinics became respected and well-known branches in Poland and abroad.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 25 128.2 31 266.7 61 005.5 94 313.7 124 469.1 141 767.6

Net financial income (profit/loss) 5 991.0 5 888.4 14 394.1 18 045.7 21 349.2 19 356.1

Capitalized value of R&D expenses

Intangible assets 1 283.3 1 022.6 771.8

Total assets 21 341.8 30 292.8 43 750.1 77 799.4 110 343.0 240 181.1

Equity 10 499.8 13 456.8 24 906.7 35 811.3 48 137.7 67 549.5

Description of innovative activity: According to the 5A methodology, the market and process innovativeness level of the Ameri-can Heart of Poland JSC company are highly rated and the ability of obtaining funds for innovative projects from the EU is very highly rated. The company assessment in the 5A system is CCNNB.Company status: innovative company, beneficiary of the national operational programmes of the European Union

Anpharm Przedsiębiorstwo Farmaceutyczne S.A.

Assessment with 5A System: NCNNN www.anpharm.plPlace on the List of medical sector: 89 Established in: 1993Place on the 500’2010 List: not listed Company size: medium

Address: 03–236 Warszawa, ul. Annopol 6bVoivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Anpharm Pharmaceutical Company JSC is a pharmaceutical company manufacturing medicines in a form of tablets supplied on the Polish market and abroad. The company is a part of the global French research and development group SERVIER – the second French pharmaceutical company in the world.Shareholders: Biofarma S.A.S. (France) – 75.47%, Egis Pharmaceutrcals Ltd. (France) – 24.25%, Silver Polska Ltd. – 0.08%, others – 0.20%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 418 938.6 279 846.8 348 424.2 368 190.9 241 540.5

Net financial income (profit/loss) 51 486.1 22 756.8 87 983.7 46 798.9 20 958.3


Intangible assets 300.4 120.0 111.7 80.2 34.3

Total assets 255 144.2 263 384.6 318 937.5 320 303.0 274 896.0

Equity 228 827.8 251 584.6 262 625.8 309 424.7 250 383.0

Description of innovative activity: According to the 5A methodology, the company process innovativeness level of Anpharm Pharmaceutical Company JSC is highly rated. The company assessment in the 5A system is NCNNN.

05 06 07 08 09 10

25.1

31.3 61

.0 94.3 12

4.5

141.

8


05 06 07 08 09 10

418.

9

279.

8

348.

4

368.

2

241.

5




Ascor S.A.

Assessment with 5A System: CCBNN www.ascor.com.plPlace on the List of medical sector: 25 Established in: 1993Place on the 500’2010 List: 349 Company size: small

Address: 01–330 Warszawa, ul. Mory 8Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: Ascor JSC is a manufacturer and supplier of medical eqipment on the Polish market and abroad. The company manufactures the SEP and AP infusion pumps.This is a wide range of one-shot and double-shot pumps, as well as volumetric pumps. The company’s offer also includes medical tripods, infusion fluids and blood warmers. It employs a group of highly skilled specialists, whose goal is to develop, manufacture and sale of advanced medical devices and equipment. The pro-ducts quality is guaranteed by the implementation of standards and obtaining certificates of ISO 9001 and ISO 13485 systems.The quality of individual products is certified each time by the CE mark.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 657.8 157.4 745.6 211.5 587.4 206.3

Capitalized value of R&D expenses 224.8 160.5 28.2 8.3 698.4

Intangible assets 1 147.0 1 100.7 961.8 928.1 1 605.6

Total assets 4 475.0 4 665.0 5 060.7 5 578.5 5 752.0 7 016.1

Equity 2 268.3 2 925.7 3 942.6 4 154.1 4 741.5 4 947.8

Description of innovative activity: According to the 5A methodology, the company market and process innovativeness levels are highly rated and the expenditure on innovative activity is very highly rated.The company assessment in the 5A system is CCBNN.Company status: inovative company, investor in research and development

Balton Sp. z o.o.

Assessment with 5A System: NCNNA www.balton.plPlace on the List of medical sector: 38 Established in: 1994Place on the 500’2010 List: not listed Company size: large

Address: 00–496 Warszawa, ul. Nowy Świat 7, 14Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: Balton Ltd. company is a manufacturer of disposable medical equipment for anaesthesiology, dialysis, surgery, gynecology, cardiology, radiology and urology. One of the most important scientific, research and implementation achievements of the company is the production of stents for coronary and peripheral vessels, as well as self-expansible stents (these are author’s designs protected by patents). The company is the only designer and manufacturer of stents in Central and Eastern Europe. In production Balton cooperates with American, German, Russian nd Japanese companies. Balton has won nume-rous awards. The Balton products are protected not only by patents, but they are also certificated according to ISO 9001 and EC Design-Examination Certificate.Shareholders: Płowiecki Emil – 99.82%, Hurkała Leszek – 0.18%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 178.6 76.6


Total assets 73 037.3 88 644.6 95 787.3 100 444.0 109 798.9 118 463.0

Equity 69 189.4 81 694.5 89 060.7 92 729.8 102 770.9 111 085.4

Description of innovative activity: According to the 5A methodology, the Balton Ltd. company process innovativeness level is highly rated and the capability of obtaining European Union funds for financing innovative projects is the highest. The company assessment in the 5A system is NCNNA.Company status: innovative company, investor in research and development, beneficiary of the 7th Framework Programm of the European Union, beneficiary of the national operational programmes of the European Union

05 06 07 08 09 10

7.0

6.7

9.6

8.7 10

.4 12.4


05 06 07 08 09 10

54.6 63

.9

66.4

70.7

75.7

76.6




Bayer Sp. z o.o.

Assessment with 5A System: NCNNN www.bayer.com.plPlace on the List of medical sector: 94 Established in: 1993Place on the 500’2010 List: not listed Company size: large

Address: 02–326 Warszawa, ul. Al. Jerozolimskie 158Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The Bayer Ltd. company belongs to the German consortium Bayer AG, that operates in the health sector, in plant protection products and in highly specialized materials. The Polish consortium subsidiary has operated in Poland since 1957, and as the Bayer Ltd. company since 1994. Since 2000 there is the central management of the Bayer compa-ny in Warszawa covering the Central Europe territory including 4 countries such as Poland, Czech Republic, Slovakia and Hungary. The company offers the OTC medicines such as Tabcin, Aleve, Saridon, Rennie, Alka-Seltzer, Bepanthen, Elevit and also dietary supplements Biovital, Kinder Biovital and Supradyn. The company’s offer includes the flagship medicine Aspirin.Shareholders: Bayer Global Investments B.V. (Gemany) – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 625 441.3 698 812.3 1 020 391.9 1 092 040.0 1 256 981.0 1 265 063.8



Intangible assets 16 162.9 11 054.6 6 524.9 1 761.4 928.8

Total assets 310 151.9 357 265.7 471 760.5 607 748.2 508 911.1 551 598.7

Equity 163 418.3 179 777.8 23 095.2 40 065.1 166 754.1 183 018.8

Description of innovative activity: According to the 5A methodology, the Bayer Ltd. company process innovativeness level is highly rated. The company assessment in the 5A system is NCNNN.

Biofarm Sp. z o.o.

Assessment with 5A System: NCBNB www.biofarm.plPlace on the List of medical sector: 15 Established in: 1988Place on the 500’2010 List: 192 Company size: large

Address: 60–198 Poznań, ul. Wałbrzyska 13Voivodship: Greater Poland

Type of business: pharmaceuticalsDescription of business activity: The Biofarm Ltd. company is one of the largest Polish manufacturers of pharmaceuticals. It produces the OTC medicines (Ginkofar, Bioprazol Bio, Magnefar B6, Soyfem and Halset), a range of neurological, cardiology and internal medicines, which are available on prescription, as well as numerous dieta supplements. Biofarm produces about 20 million packages of medicines, which are sold in Poland and abroad.The company is also an investor in research and development. It has its own research and development department, which employs experts in the field of pharmacy, chemistry, biotechnology and chemical technology. Biofarm spent on research and development in 2010, more than 3.1 million PLN.Shareholders: Szwarczyński Waldemar – 30%, Denkowska Szwarczyńska Grażyna – 24%, Ostrowicz Andrzej – 24%, Ostrowicz Ewa – 10%, others – 12%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 3 582.7 3 747.5 2 154.7 1 967.4 3 113.6

Intangible assets 3 883.3 3 995.2 2 539.7 2 422.8 3 314.7

Total assets 145 196.3 135 166.3 151 788.1 143 889.1 164 284.7

Equity 100 694.9 96 986.9 118 059.5 94 730.4 98 620.7

Description of innovative activity: According to the 5A metodology, the Biofarm Ltd. company process innovativeness and expenditure on innovative activity levels are highly rated. The company is characterized by a very high assessment of the ability to obtain the financing of innovative projects from EU funds. The company assessment in the 5A system is NCBNB.Company status: innovative company, investor in research and development, patenting company, beneficiary of national opeatio-nal programmes of the European Union

05 06 07 08 09 10

625.

4

698.

8 1 02

0.4

1 09

2.0

1 25

7.0

1 26

5.1


05 06 07 08 09 10

139.

9

147.

9

191.

5 266.

9

284.

3




Bio-Ksel Sp. z o.o.

Assessment with 5A System: CBCNN www.bio-ksel.com.plPlace on the List of medical sector: 20 Established in: 2000Place on the 500’2010 List: 276 Company size: small

Address: 86–300 Grudziądz, ul. Kaliowa 3Voivodship: Kuyavian-Pomeranian

Type of business: medical equipmentDescription of business activity: The Bio-Ksel Ltd. company belongs to a group of the largest producers of apparatus for in vitro diagnostic on the Polish market. The company is developing based on its own designs and technology. The company’s objective is to provide a comprehensive supply (apparatus, reagents, consumables, service, methodical assistance in the analytical proce-dure) to carry out marking of coagulation. The company has its own design and technological office, where the development work on the next generation of apparatus is conducted. The sales offer is regularly extended by the newly emerging reagents and software in accordance with the development of measurement methods for in vitro diagnosis. The company’s activity is carried out in controlled conditions (the company has the quality management certificate i.e. ISO 9001: 2008 and ISO 13485: 2003).Shareholders: Stenzel Jan Marek – 34%, Grodkowski Bernard – 33%, Others – 33%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 4 319.0 4 442.2 4 918.3

Net financial income (profit/loss) 151.8 171.1 315.8


Intangible assets 223.3 118.9 18.7

Total assets 1 488.5 1 721.8 2 187.5

Equity 451.8 471.1 615.8

Description of innovative activity: According to the 5A methodology, the Bio-Ksel Ltd. company is charecterized by a high assessment of the market innovativeness level, a very high assessement of the process innovation level and a high assessement of the ability to obtain the financing of innovative activity. The company assessment with the 5A system is CBCNN.Company status: innovative company, investor in research and development

Biomaxima S.A.

Assessment with 5A System: CCBNC www.biomaxima.comPlace on the List of medical sector: 16 Established in: 2002Place on the 500’2010 List: 201 Company size: small

Address: 20–460 Lublin, ul. Mireckiego 29–31Voivodship: Lublin

Type of business: pharmaceuticalsDescription of business activity: The company BioMaxima JSC is a Polish company operating in the wider field of biotechnology on the laboratory diagnostics market. The company produces, among others, diagnostic reagents to test blood biochemical para-meters, rapid diagnostic tests for the detection of infectious diseases, tumor markers, heart attack markers, addictive substances with the readers, systems for the analysis of urine or blood glucose meters. The BioMaxima company also distributes products of renowned international diagnostic companies, among others Nova Biomedical, Mitsubishi Chemical and Dirui. The company is listed on the NewConnect market.Shareholders: Wojcieszuk Artur – 14.36%, Siwek Artur – 14.15%, Ipopema TFI S.A. – 10.41%, BM Inwestor Sp. z o.o. – 9.40%, Krzyżanowski Maciej – 7.48%, Kunda Mariusz – 5.49%, Others – 38.71%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 5 021.3 6 209.9 6 680.9 7 179.0

Net financial income (profit/loss) 418.2 478.0 610.4 539.0

Capitalized value of R&D expenses 61.7 4.9 284.2

Intangible assets 0.1 100.8 4.9 310.9

Total assets 3 305.4 3 979.1 5 739.1 10 501.8

Equity 1 939.8 2 609.9 3 195.1 6 732.2

Description of innovative activity: According to the 5A methodology, the BioMaxima JSC company is charecterized by a high assessment of the market and process innovativeness levels, a very high assessement of the financing of innovative activity and a high assessment of ability to obtain financing of innovative projects from the EU funds. The company assessment in the 5A system is CCBNC.Company status: innovative company, investor in research and development, company listed on NewConnect market, beneficiary of national operational programmes of the EU

05 06 07 08 09 10

4.3 4.4 4.

9


05 06 07 08 09 10

5.0 6.

2 6.7 7.2




Biomed Lublin Wytwórnia Surowic i Szczepionek S.A.

Assessment with 5A System: NCBNC www.biomed.lublin.plPlace on the List of medical sector: 24 Established in: 1984Place on the 500’2010 List: 342 Company size: large

Address: 20–029 Lublin, ul. Uniwersytecka 10Voivodship: Lublin

Type of business: pharmaceuticalsDescription of business activity: Biomed Lublin Wytwórnia Surowic i Szczepionek JSC is a Polish pharmaceutical company. The company is a manufacturer of numerous medicinal preparations, medical products, and laboratory reagents, that meet all the necessary certified quality requirements. Biomed is improving its products, so as to meet the quality and market requirements and to comply with the highest standards of modern pharmacy. The company implements new technologies, cooperates with Polish scientific centres and conducts research with them in order to improve the workforce and production processes – constantly improving the quality of products. Biomed is listed on the NewConnect market.Shareholders: Klif Sp. z o.o. – 77.67%, Ipopema TFI S.A. – 14.29%, Others – 8.04%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –283.0 4 625.0 1 583.0 2 540.6



Total assets 20 982.3 20 441.1 23 722.7 47 401.3 71 467.7

Equity 7 688.9 9 212.2 13 532.5 12 770.5 14 059.1

Description of innovative activity: According to the 5A methodology, the Biomed Lublin Wytwórnia Surowic i Szczepionek JSC company is characterized by a high assessment of process innovativeness, a very high assessment of innovative activity and a high assessment of ability to obtain the financing of innovative products from the EU funds. The company innovativeness asses-sment in the 5A system is NCBNC.Company status: innovative company, investor in research and development, patenting company, beneficiary of national operatio-nal programmes of the European Union

Bioton S.A.

Assessment with 5A System: BCBNC www.bioton.plPlace on the List of medical sector: 7 Established in: 1989Place on the 500’2010 List: 79 Company size: large

Address: 02–516 Warszawa, ul. Starościńska 5Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The Bioton JSC is a biotechnological company operating on the global market. The company produces insulin, biotechnological and generic medicines. The company is an investor in research and development, during 2008–2010 years it spent 143 mln PLN on R&D. Bioton conducts together with the Institute of Biotechnology and Antibiotics the research works on biotechnological products and new forms of drugs and carries out research programs in the field of genetic engineering, biotechnology and pharmacology.Shareholders: Krauze Ryszard – 19.45%, Troqueera Enterprises Ltd. – 8.53%, Others – 72.02%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 34 627.0 93 772.0 28 132.0 –218 892.0 –567 545.0 117 180.0

Capitalized value of R&D expenses 4 155.0 645.0 645.0

Intangible assets 51 693.0 363 237.0 645 078.0 969 891.0 676 687.0 688 285.0

Total assets 358 123.0 988 669.0 1 500 255.0 2 064 772.0 1 575 015.0 1 581 662.0

Equity 255 418.0 787 608.0 871 106.0 1 106 545.0 973 848.0 1 093 704.0

Description of innovative activity: According to the 5A methodology, the Bioton JSC is characterized by a very high assessment of process and market innovativeness, a very high assessment of financing of innovative activity and a high assessment of ability to obtain the financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is BCBNC.Company status: innovative company, investor in research and development, company listed on the Warsaw Stock Exchange, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

21.0 24

.5 30.2

32.3

33.6


05 06 07 08 09 10

151.

6

215.

5

270.

9

293.

5

216.

8

378.

6




Carint Sp. z o.o.

Assessment with 5A System: CCNNN www.carint.com.plPlace on the List of medical sector: 44 Established in: 2001Place on the 500’2010 List: not listed Company size: small

Address: 30–055 Kraków, ul. Miechowska 5b, 6Voivodship: Lesser Poland

Type of business: hospital services and medical careDescription of business activity: Carint Ltd. is a company operating in the health sector. The company sets new standards in the field of diagnostic cardiology and cardiac surgery. It conducts a specialistic activity related to the protection of human health and life – from prevention through basic and advanced diagnostics to complex cardiac treatments. The company provides health care services in the field of cardiology, in particular highly specialized services in the field of interventional cardiology and angiology. The company also conducts training for cardiologists. The clinic performs diagnostic tests for patients of Tarnow and region.Shareholders: Dudek Dariusz – 75%, Legutko Jacek – 15%, Others – 10%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 1 111.0 2 485.0 3 666.3


Intangible assets

Total assets 3 352.0 6 733.0 10 970.6

Equity 2 174.0 4 159.0 6 427.0

Description of innovative activity: According to the 5A methodology, Carint Ltd. is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment in the 5A system is CCNNN.

Cefarm Białystok S.A.

Assessment with 5A System: NCNNN www.cefarm.bialystok.plPlace on the List of medical sector: 88 Established in: 1951Place on the 500’2010 List: not listed Company size: large

Address: 15–691 Białystok, ul. Kleeberga 34Voivodship: Podlasie

Type of business: pharmaceuticalsDescription of business activity: The Cefarm Białystok JSC company is one of the biggest and most active commercial group ln the north-eastern region of Poland. The range of activity is a wholesale and retail sale of medicines and cosmetics. The company has 47 chemist’s shops of its own, 6 chemist’s shops in subsidiary company and its own wholesale. The company has one third of the Podlasie pharmaceutical region. In 2010, the company opened in Poland at the expense of 30 million PLN one of the most modern logistics distribution centres. There were installed in warehouses the lines for atomatic completion of orders and for automatic internal transport. With an integrated information system, large-scale application of techniques based on automatic identification barcodes and handheld radio terminals, the new logistic centre enhances the warehouse processes.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 4 494.2 5 562.8 5 651.7 5 981.2 –9 767.3 7 428.5



Total assets 56 848.1 57 411.6 66 134.7 86 081.4 89 191.0 73 959.4

Equity 30 048.2 32 313.5 34 685.5 37 144.6 27 377.3 39 947.9

Description of innovative activity: According to the 5A methodology, the Cefarm Białystok JSC Company is characterized by a high innovativeness process level. The company innovativeness assessment in the 5A system is NCNNN.

05 06 07 08 09 10

3.6 5.

2

8.5 11

.3 13.8


05 06 07 08 09 10

215.

4

238.

4

258.

6

273.

3

288.

1

222.

8




Cefarm Wrocław Centrum Zaopatrzenia Farmaceutycznego S.A.

Assessment with 5A System: CCNNN www.cefarm.wroc.plPlace on the List of medical sector: 62 Established in: 1949Place on the 500’2010 List: not listed Company size: medium

Address: 50–422 Wrocław, ul. Rakowiecka 65, 67Voivodship: Lower Silesian

Type of business: pharmaceuticalsDescription of business activity: The Cefarm Wrocław Pharmaceutical Supply Centre JSC company is a pharmaceutical whole-sale operating in the south-eastern region of Poland. The primary objective of the company is the distribution of high quality pro-ducts at affordable prices. The company guarantees a prompt execution of an order, which is the foundation upon which the trust of pharmacy owners and managers are build. Since October 2002, the company operates in a new logistics and distribution faci-lity located in Wroclaw, having a warehouse and expedition and office spaces. In warehouses with a total area of approximately 4600 m2, equipped with shelves that are longer than 10 km, the cutting-edge solutions have been used for the storage and distri-bution of pharmaceuticals, meeting the requirements of the Good Distribution Practice.Shareholders: Farmacol JSC – 93.59%, State Treasury – 6.41%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 7 483.0 7 338.0 6 383.0 5 443.0 3 942.0 444.0



Total assets 80 367.0 101 025.0 124 768.0 135 700.0 131 496.0 123 619.0

Equity 61 779.0 69 117.0 77 597.0 83 039.0 88 123.0 88 567.0

Description of innovative activity: According to the 5A methodology, the market and process innovatveness levels of the Cefarm Wrocław Pharmaceutical Supply Centre JSC company are highly rated. The company innovativeness assessment in the 5A system is CCNNN.

Celon Pharma Sp. z o.o.

Assessment with 5A System: CCNNA www.celonpharma.comPlace on the List of medical sector: 28 Established in: 2002Place on the 500’2010 List: 455 Company size: medium

Address: 05–092 Łomianki, Kiełpin, ul. Ogrodowa 2aVoivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Celon Pharma Ltd. is an integrated pharmaceutical company conducting advanced scientific research and produces modern medicines. A major advantage of Celon Pharma is a strong research and development base, which allows to create a whole new class of effective medicines. The R&D department of Celon Pharma employs more than 40 scientists, of which ¼ holds a PhD title in molecular biology, pharmacy or chemistry.The company invests in the development of innovative pharmaceuticals for potential use in the treatment of cancer, neurological diseases, diabetes and other metabolic diseases. The funding for research into new drugs were obtained from the sale of generic medicinal products, as well as from the EU funds received under the Innovative Economy programme.Shareholders: Wieczorek Maciej – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 5 917.4 12 362.7 28 102.7 33 205.0 53 420.5

Equity 4 386.9 6 923.1 19 748.0 24 022.5 25 186.6

Description of innovative activity: According to the 5A methodology, the market and process innovativenes level assessment of the Celon Pharma Ltd. company is highly rated and the ability assessment for obtaining financing of innovative projects from the EU fund is very highly rated. The company innovativeness assessment in the 5A system is CCNNA.Company status: innovative company, beneficiary of national innovating operational programmes of the EU

05 06 07 08 09 10

284.

5

288.

5

341.

7

401.

7

444.

1

494.

2


05 06 07 08 09 10

9.0 14

.6

28.2 34

.2 39.3




Centrala Farmaceutyczna Cefarm S.A.

Assessment with 5A System: CCNNN www.cefarm.com.plPlace on the List of medical sector: 48 Established in: 1947Place on the 500’2010 List: not listed Company size: large

Address: 01–248 Warszawa, ul. Jana Kazimierza 16Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The main activity type of the Centrala Farmaceutyczna Cefarm JSC is a distribution on the pharmaceutical market. The commercial offer includes more than 13 thousand assortment items of different product categories. The company offers services in the field of introduction and distribution of new medicines on the Polish market. It has a wide offer of logistic services connecting with transport and rental of specialistic warehose spaces.The company leads consignment ware-houses, customs warehouses, warehouse of the importer and label medicines. The company constantly improves the quality of the process, thanks to the introduction of modern management methods, training staff and adapting international standards of the Good Manufacturing Practice (GMP) and the Good Distribution Practice (GDP). The company has the ISO 9001 certificate and the GMP certificate for the import and manufacture.Shareholders: State Treasury – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 542 696.1 561 790.1 682 868.1 710 021.1 914 091.3 1 014 661.7

Net financial income (profit/loss) 2 513.2 –192.1 –8.6 6 525.6 8 386.3 8 520.9



Total assets 169 217.3 185 503.3 204 222.4 241 045.6 291 807.5 305 377.7

Equity 68 836.5 67 115.6 67 174.4 72 764.0 74 344.5 76 349.1

Description of innovative activity: According to the 5A methodology, the market and process innovativenes level assessment of the Centrala Farmaceutyczna Cefarm JSC company is highly rated. The company innovativeness assessment in the 5A system is CCNNN.

Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie

Assessment with 5A System: CNNNN www.cskmswia.plPlace on the List of medical sector: 75 Established in: 1998Place on the 500’2010 List: not listed Company size: large

Address: 02–507 Warszawa, ul. Wołoska 137Voivodship: Mazovian

Type of business: hospital services and medical careDescription of business activity: The Central Clinical Hospital of the Ministry of Internal Affairs and Administration in Warsaw is one of the biggest hospital in Poland. The unit is a multi-profile hospital, which means that it provides comprehensive care thro-ughout the treatment process from diagnosis to hospitalization. It holds polyclinic in Warszawa, Ciechanów, Płock, Radom, Siedlce and Rehabilitation Centres in Konstancin and Wesoła. In 2010, the hospital has given more than 513 000 ambulatory specialist advices, more than 348 000 advices on basic health care and hospitalized over 56 000 patiens. Nowadays, the Central Clinical Hospital of the Ministry of Internal Affairs and Administration is a modern diagnostic and treatment patients friendly centre, having one of the most modern Postoperative Intensive Care Unit in the country.Shareholders: State Treasury – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 112 153.0 –34 817.0 –15 620.1 –8 634.2 894.9



Total assets 271 511.9 320 148.9 354 387.8 342 183.3 343 029.2

Equity 220 247.5 229 308.7 241 928.6 239 123.4 250 420.3

Description of innovative activity: According to the 5A methodology, the Central Clinical Hospital of the Ministry of Internal Affairs and Administration in Warsaw is characterized by a high market innovativeness assessment level. The company innovati-veness assessment in the 5A system is CNNNN

05 06 07 08 09 10

542.

7

561.

8

682.

9

710.

0

914.

1

1 01

4.7


05 06 07 08 09 10

221.

6

224.

2

269.

9

299.

2

321.

4




Centrum Słuchu i Mowy Sp. z o.o.

Assessment with 5A System: NCNNC www.csim.plPlace on the List of medical sector: 80 Established in: 2000Place on the 500’2010 List: not listed Company size: small

Address: 00–217 Warszawa, ul. Konwiktorska 3Voivodship: Mazovian

Type of business: hospital services and medical careDescription of business activity: Hearing and Speech Centre Ltd. is a private health care facility providing highly specialized services: otorhinolaryngology, audiology, phoniatrics, tinnitus, speech therapy, psychology, physiotherapy, balance disorders, hearing and speech rehabilitation, and the fit and sell hearing aids. The comprehensive care of patients with problems of hearing and speech facility the centre carries out in seven NZOZ centres of the Hearing and Speech Center MEDINCUS in Poland.Shareholders: Xingzhou Venture Capital Trettiovacorp AB – 15.42%, Others – 84.58%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 2 005.6 3 044.6 2 904.4 1 559.6


Intangible assets

Total assets 6 647.6 10 010.6 24 841.8 55 714.0

Equity 6 501.6 9 546.2 12 470.6 14 030.2

Description of innovative activity: According to the 5A methodology, the Hearing and Speech Centre Ltd. is characterized by a high assessment level of the process innovativeness and a high level of the ability for the financing of the innovative projects from the EU funds. The company innovativeness assessment in the 5A system is NCNNC.Company status: beneficiary of the national operational programmes of the European Union

Chema Elektromet Spółdzielnia Pracy

Assessment with 5A System: NCNNC www.chema.rzeszow.plPlace on the List of medical sector: 83 Established in: 1951Place on the 500’2010 List: not listed Company size: medium

Address: 35–105 Rzeszów, ul. Przemysłowa 9Voivodship: Subcarpathian

Type of business: pharmaceuticalsDescription of business activity: The Chema Elektromet Cooperative is a private pharmaceutical company operating on the market. The company has two production plants, one of them produces medicinal products and the second one produces medical equipment. The company offers more than 80 different products, primarily for dentists and dermatologists. Manufacture of dental devices are mostly used in dentistry, endodontics, oral and maxillofacial surgery, prosthodontics, and preparations used in the prevention and treatment of dental caries and periodontal disease. Dermatological production mainly includes antibiotic ointment with various active substances applicable in most skin diseases.Shareholders: Cooperative members – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 20.0


Total assets 12 098.7 12 425.0 13 818.2 15 041.0 15 347.9

Equity 8 903.0 9 375.0 10 353.7 11 841.0 11 845.7

Description of innovative activity: According to the 5A methodology, the Chema Elektromet Cooperative is characterized by a high assessment level of the process innovativeness and a high level of the ability for financing of the innovative projects from the EU funds. The company innovativeness assessment in the 5A system is NCNNC.Company status: investor in research and development, patenting company, beneficiary of the national operational innovative programmes from the EU funds

05 06 07 08 09 10

3.6 5.

0

8.8 10

.3

10.2


05 06 07 08 09 10

16.9

16.1 17

.7

17.2

16.6




Chemapol S.C.

Assessment with 5A System: CABCN www.chemapol.plPlace on the List of medical sector: 14 Established in: 2004Place on the 500’2010 List: 181 Company size: micro

Address: 43–450 Ustroń, ul. Urocza 53Voivodship: Silesian

Type of business: medical equipmentDescription of business activity: Company Chemapol Partnership is a manufacturer of hardware and equipment for the pharma-ceutical and food industries. The company produces high-quality powder mixers, including mixers for laboratories, automatic washers for washing and drying of containers, tanks and bins. In addition, the company manufactures semi-automatic washing and pharmaceutical baths used for hand washing of containers, bins, tanks and process equipment components.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 602.0 743.0 633.0




Total assets 680.0 860.0 701.0

Equity 46.0 37.0 35.0

Description of innovative activity: According to the 5A methodology, the Chemapol Partnership company is characterized by a high assessment of market innovativeness level, the highest assessment of process innovativeness level, a very high assessment of financing of innovative activity and a high ability of obtaining patents. The company innovativeness assessment in the 5A sys-tem is CABCN.Company status: innovative company, investor in research and development, patenting company

Chm Sp. z o.o.

Assessment with 5A System: CBNNB www.chm.plPlace on the List of medical sector: 21 Established in: 1997Place on the 500’2010 List: 292 Company size: large

Address: 16–061 Juchnowiec Kościelny, ul. Lewickie 3bVoivodship: Podlasie

Type of business: medical equipmentDescription of business activity: The ChM Ltd. is a well known and respected manufacturer of specialty implants and instruments for orthopedics and traumatology. It has its own production departments, marketing department, research and development depart-ment and also distribution network in this country and abroad. The company has its own design and technological facilities, where innovative solutions are developed. The company offers more than 30.000 different products, including locking intramedullary nail system CHARFIX and CHARFIX2, ChFN, spinal stabilization system BIALSTAB and CHARSPINE, locking plate system ChLP, CHARSTAB external fixator and dynamic stabilizer DSB / DSK. Production and sale of medical implants is possible thanks to ongo-ing cooperation with the medical and scientific research institutions. In addition, the company has its own machines equipped with modern computer-controlled machines (CNC).Shareholders: Charkiewicz Mikołaj – 44.98%, Charkiewicz Teresa – 44.97%, Others – 10.05%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 140.0 970.8 1 951.1 2 614.6 4 202.7



Total assets 14 311.6 21 497.7 25 373.8 39 338.3 44 694.6

Equity 9 103.8 10 020.8 11 971.8 14 586.4 18 789.1

Description of innovative activity: According to the 5A methodology, the ChM Ltd. company is characterized by a high asses-sment of market innvovativeness level, a very high assessment of process innovativeness and a very high assessment of ability for obtaining the financing of the innovative projects from the EU funds. The company innovativeness assessment in the 5A system is CBNNB.Company status: innovative company, beneficiary of the national operational programmes of the EU

05 06 07 08 09 10

0.6 0.

7

0.6


05 06 07 08 09 10

11.5 16

.7 21.2

20.9

29.7




Curtis Health Caps Sp. z o.o.

Assessment with 5A System: CNNNC www.curtish.com.plPlace on the List of medical sector: 63 Established in: 1989Place on the 500’2010 List: not listed Company size: medium

Address: 60–544 Poznań, ul. Żeromskiego 9Voivodship: Greater Poland

Type of business: pharmaceuticalsDescription of business activity: Curtis Health Caps Ltd. is a dynamically developing pharmaceutical company, that focuses its activities on the provision of pharmaceutical production and food supplements and cosmetics to other operators.The company has developed service base for the production of soft capsules and the development of technologies for new products in this form. Curtis Caps Health offers research and development services and production at all stages of the capsules, i.e. from the purchase of raw materials to packaging. The company is a beneficiary of the national operational programmes of the European Union. Fun-ding obtained in the framework of the Innovative Economy Programme made it possible to start building a new production plant in Wysogotowo, with all the facility services for the development of innovative manufacturing technology and test methods for medicinal products, dietary supplements and cosmetics in the form of soft capsules.

Finan

cial d

ata

(thou

sand

PLN

)

2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 8.3 28.7 –441.8 –1 668.9

–1 845.4


Intangible assets 29.5 30.6 12.9 9.6 3 943.9

Total assets 4 237.7 4 930.3 7 829.4 11 183.2 33 477.7

Equity 3 743.2 3 771.8 3 330.1 1 661.2 13 900.6

Description of innovative activity: According to the 5A methodology, the Curtis Health Caps Ltd. company is characterized by a high assessment of market innvovativeness level and by a high assessment of ability for the financing of innovating projects from the EU funds. The company innovativeness assessment in the 5A system is CNNNC.Company status: beneficiary of the national operational programmes of the EU

Dental Nanotechnology Sp. z o.o.

Assessment with 5A System: CCCNC www.dentalnt.comPlace on the List of medical sector: 19 Established in: 1992Place on the 500’2010 List: 268 Company size: small

Address: 40–534 Katowice, ul. Czajek 5, 2Voivodship: Silesian

Type of business: hospital services and medical careDescription of business activity: Nanotechnology Dental Ltd. is a company focused on the implementation of various program-mes in the area of dentistry. As part of its business, the company is developing a network of licenced DCL offices and began a program of building of its own clinics. The first clinic is the clinic opened in Zabrze. The company also develops its own work on preparations for dentistry: Nanocare + Nanocare Gold. The company is also working on the production of modern equipment supporting the work of dentists i.e. Nanotec Endo and Nanotec. Nanotec Endo is a unique system of irrigation canals. The owner of the world patent is the main shareholder of the company dr Roman Borczyk. Nanozon is a modern device for the treatment of ozone and ozone water mouthwash. The company also conducts training for dentists.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 916.7 1 362.5 1 473.5

Net financial income (profit/loss) –180.7 2.5 57.1



Total assets 971.4 1 491.6 2 069.6

Equity 626.3 628.8 907.8

Description of innovative activity: According to the 5A methodology, the Dental Nanotechnology Ltd. is characterized by a high assessment of market innovativeness level, a high assessment of process innovativeness level, a high assessment of financing the innovative activity and a high assessment of ability for the financing innovating projects from the EU funds. The company innova-tiveness assessment in the 5A system is CCCNC.Company status: innovative company, patenting company, beneficiary of national operatinal porgrammes of the EU

05 06 07 08 09 10

7.3

6.7

6.7 8.

0 8.8


05 06 07 08 09 10

0.92

1.36 1.47




Fabryka Aparatury Elektromedycznej Famed Łódź S.A.

Assessment with 5A System: NNBNN www.famed.plPlace on the List of medical sector: 55 Established in: 1975Place on the 500’2010 List: not listed Company size: medium

Address: 91–211 Łódź, ul. Szparagowa 2Voivodship: Lodz

Type of business: medical equipmentDescription of business activity: Famed Łódź JSC is one of the leading in Poland and well- known in the world Polish manufac-turer of high quality medical equipment. The company specializes mainly in manufacturing of operational and surgical lamps. The offer also includes diagnostic lamp, UV germicidal lamps, flow bactericidal devices, X-ray and the standard array. The company bears the cost of research and development works and is a beneficiary of national operational programmes of the European Union.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 144.9 353.9 –64.5 –853.8 –931.6 –936.1



Total assets 6 272.5 6 815.4 6 564.0 6 324.2 5 687.6 3 658.7

Equity 4 724.8 5 078.6 5 014.1 3 573.5 2 641.9 1 084.1

Description of innovative activity: According to the 5A methodology, Famed Łódź JSC is characterized by a high value asses-sment of financing of the innovatice activity. The company innovativeness assessment in the 5A system is NNBNN.Company status: innovative company, investor in research and development, patenting company

Farmaceutyczna Spółdzielnia Pracy Galena

Assessment with 5A System: CNBNC www.galena.plPlace on the List of medical sector: 26 Established in: 1962Place on the 500’2010 List: 356 Company size: medium

Address: 50–984 Wrocław, ul. Krucza 62Voivodship: Lower Silesian

Type of business: pharmaceuticalsDescription of business activity: Pharmaceutical Cooperative Galena is a company of over 65 years of tradition and experience dealing with the pharmaceutical production, production services and confectioning of medicines. The company also offers services in the field of a synthesis of the pharmaceutical substances. Since its establishment in 1946, the company has constantly expan-ded and widened its commercial offer, thereby rasing the quality of its products.Shareholders: Members of the cooperative company – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 2 308.5 2 335.9 838.6 553.6 –5 150.1 –1 055.9

Capitalized value of R&D expenses 95.6 740.8 982.1 1 077.2 510.8

Intangible assets 271.8 821.6 1 037.4 1 389.2 751.9

Total assets 39 152.8 41 769.6 41 293.5 42 649.8 42 129.5 41 202.9

Equity 33 956.5 35 620.9 35 629.9 35 534.2 30 029.9 28 982.0

Description of innovative activity: According to the 5A methodology, the Pharmecutical Cooperative Galena is characterized by a high assessment of market innovativeness level, a very high assessment of the financing of innovating activity and a high asses-sment ability of the financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is CNBNC.Company status: innovative company, investor in research and development, beneficiary of national operational programmes of the EU

05 06 07 08 09 10

8.2

8.3

8.5

6.9

6.7

6.8


05 06 07 08 09 10

29.4 31.9

29.4 35

.4

27.8 34

.2




Farmacol S.A.

Assessment with 5A System: CCNNN www.farmacol.com.plPlace on the List of medical sector: 64 Established in: 1990Place on the 500’2010 List: not listed Company size: medium

Address: 40–541 Katowice, ul. Rzepakowa 2Voivodship: Silesian

Type of business: pharmaceuticalsDescription of business activity: The Farmacol JSC company is the leading pharmaceutical distributor in Poland. Since 1999 the company’s shares have been listed on the Warsaw Stock Exchange. Activity of the Capital Group Farmacol covers the region of the whole country, supplying medicines and other pharmaceutical products for several thousands pharmacies and hundreds hospi-tals.Shareholders: Olszewski Andrzej – 26.88%, Olszewska Zyta – 23.54%, ING General Pension Society JSC – 8.55%, Aviva General Pension Society Aviva BZ WBK JSC – 6.72%, Others – 34.31%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 2 708 071.0 3 021 419.0 3 305 685.0 3 823 103.0 4 619 744.0 4 953 885.0



Intangible assets 57 136.0 55 593.0 2 278.0 8 090.0 8 324.0 8 670.0

Total assets 969 871.0 1 041 196.0 1 123 671.0 1 419 142.0 1 541 569.0 1 573 144.0

Equity 382 334.0 442 879.0 455 529.0 501 554.0 549 658.0 599 797.0

Description of innovative activity: According to the 5A methodology, Farmacol JSC is characterized by a high assessment of market and process innovativeness levels.The company innovativeness assessment in the 5A system is CCNNN.Company status: company listed on the Warsaw Exchange Stock

Frey Sp.J.

Assessment with 5A System: CCNNC www.frey.plPlace on the List of medical sector: 35 Established in: 2005Place on the 500’2010 List: not listed Company size: small

Address: 05–502 Piaseczno, ul. Wołodyjowskiego 38Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: The company Frey General Partnership is a manufacturer of the optical instruments perimeters. The company was established in 2005 and currently employs 15 employees. The company rises the innovativeness level i.a. through the assistance programmes of the European Union. The company executed in the years 2008–2009 the project „Streng-thening of company innovation by introducing a new design” for the value PLN 1.21 million (the EU funding in the amount of 35.6%).Shareholders: Frey Jacek Krzysztof – 50%, Frey Wojciech Zbigniew – 50%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 4 914.2 4 621.1 6 666.1

Equity 3 567.0 3 573.2 5 800.8

Description of innovative activity: According to the 5A methodology, Frey General Partnership company is characterized by a high assessment of market and process innvoativeness level and a high ability assessment for financing of the innovating pro-jects from the EU funds. The company innovativeness assessment in the 5A system is CCNNC.Company status: beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

2 70

8.1

3 02

1.4

3 30

6.7

3 82

3.1

4 61

9.7

4 95

3.9


05 06 07 08 09 10

6.0

5.5 6.

9




GlaxoSmithKline Consumer Healthcare Sp. z o.o.

Assessment with 5A System: NCNNN www.gsk.com.plPlace on the List of medical sector: 96 Established in: 1992Place on the 500’2010 List: not listed Company size: medium

Address: 00–609 Warszawa, ul. Armii Ludowej 26Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: GlaxoSmithKline Consumer Healthcare Ltd. belongs to the world consortium GlaxoSmithKline Plc. The main kind of activity is the wholesale distribution of pharmaceuticals, including measures for the care of the mouth and skin.Shareholders: Setfirst Ltd. (Great Britain) – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets 241.0 1 331.0 1 127.0 997.0 1 331.0

Total assets 169 095.0 231 341.0 261 869.0 387 985.0 414 127.0 462 373.0

Equity 102 817.0 129 806.0 183 293.0 241 789.0 288 122.0 310 384.0

Description of innovative activity: According to the 5A methodology, the GlaxoSmithKline Consumer Healthcare Ltd. company is characterized by a high value of process innovativeness level. The company innovaticeness assessment in the 5A system is NCNNN.

GlaxoSmithKline Pharmaceuticals S.A.

Assessment with 5A System: CCNNN www.gsk.com.plPlace on the List of medical sector: 43 Established in: 1958Place on the 500’2010 List: not listed Company size: large

Address: 60–322 Poznań, ul. Grunwaldzka 189Voivodship: Greater Poland

Type of business: pharmaceuticalsDescription of business activity: The GlaxoSmithKline Pharmaceuticals JSC company manufactures pharmaceuticals, dental products and dietary supplements. The company is best known for a wide range of vaccines and modern medicines, as well as engaging in increasing access to effective treatment and health education of the Polish patients. The company offers over 470 products. GlaxoSmithKline JSC is an exporter – over 40% of production goes abroad. GlaxoSmithKline Pharmaceuticals JSC belongs to a world pharmaceutical giant, a global investor in research and development, who spent on R&D over 4.37 mld EUR in 2010.Shareholders: Glaxo Group Ltd. – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 1 489 119.0 1 650 615.0 2 367 979.0 2 829 937.0 3 473 584.0



Intangible assets 2 182.0 940.0 1 566.0 852.0 1 288.0

Total assets 1 258 454.0 1 374 035.0 1 615 882.0 1 898 497.0 2 096 432.0

Equity 1 168 478.0 1 303 068.0 1 531 817.0 1 793 163.0 1 221 312.0

Description of innovative activity: According to the 5A methodology, the GlaxoSmithKline Pharmaceuticals JSC company is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment in the 5A system is CCNNN.

05 06 07 08 09 10

297.

6 529.

5

574.

6

680.

2

823.

3

799.

1


05 06 07 08 09 10

1 48

9.1

1 65

0.6

2 36

8.0

2 82

9.9

3 47

3.6




Herbanordpol Gdańsk Sp. z o.o.

Assessment with 5A System: CCNNN www.herbanordpol.plPlace on the List of medical sector: 50 Established in: 1996Place on the 500’2010 List: not listed Company size: small

Address: 82–230 Nowy Staw, ul. Obrońców Westerplatte 28Voivodship: Pomeranian

Type of business: pharmaceuticalsDescription of business activity: The company Herbanordpol Gdańsk Ltd. specializes in the acquisition and processing of medi-cinal plants. The company headquarter is situated in Nowy Staw. The company has its branch offices in Złotów i Karlin. The company manufactures water and alcoholic extracts of herbal raw materials, essential oils and oils of pumpkin seeds. It provides services of drying and cleaning of seeds and fruits, as well as pulverizing. The company makes laboratory tests and sells herbal raw materials.Shareholders: Andrzejewski Jerzy – 50%, Gajewski Jan Franciszek – 50%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 1 325.0 912.0 991.9

Net financial income (profit/loss) –121.6 –141.5 580.2


Intangible assets

Total assets 1 376.9 1 159.6 1 227.6

Equity 275.4 133.9 714.0

Description of innovative activity: According to the 5A methodology, the company Herbanordpol Gdańsk Ltd. is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment in the 5A system is CCNNN.

Herbapol Lublin S.A.

Assessment with 5A System: CBBNN www.herbapol.com.plPlace on the List of medical sector: 12 Established in: 1949Place on the 500’2010 List: 139 Company size: large

Address: 20–471 Lublin, ul. Diamentowa 25Voivodship: Lublin

Type of business: pharmaceuticalsDescription of business activity: The company Herbapol Lublin JSC is a leader on the herbal products market, the leader on the food syrup market and occupies a high position on the tea market. The company offers both food products, as well as pharmaceu-ticals, assortment of teas, syrups, food and beverages, homogeneous herbs, medicinal herbal mixtures, drops, pharmaceutical syrups and herbal capsules. All products are produced from natural components of vegetable origin. The company’s products are appreciated by customers, and are valued by doctors and pharmacists.Shareholders: Starak Jerzy – 64.13%, Windstorm Trading & Investments Limited – 35.87%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 740.5


Total assets 114 970.7 103 313.7 115 692.7 108 712.1 114 012.3 116 433.8

Equity 37 263.9 23 209.2 69 497.9 57 728.4 51 253.7 70 770.1

Description of innovative activity: According to the 5A methodology, the company Herbapol Lublin JSC is characterized by a high assessment of market innovativeness level, a very high assessment of process innovativeness level and a very high assessment of investment in innovative activity. The company innovativeness level in the 5A system is CBBNN.Company status: innovative company, investor in research and development

05 06 07 08 09 10

1.32

0.91 0.99


05 06 07 08 09 10

172.

6

190.

3

199.

2

193.

9

209.

7

225.

8




Hurtap S.A.

Assessment with 5A System: NCNNC www.hurtap.com.plPlace on the List of medical sector: 69 Established in: 1999Place on the 500’2010 List: not listed Company size: large

Address: 99–100 Łęczyca, ul. Górnicza 2Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: Hurtap JSC is a company dealing with a wholesale distribution of medical products and mate-rials for pharmacies. The company’s headquarter is located in Łęczyca in Łódź region. Nowadays, the company has developed distribution network with the branch offices in Głogów, Tychy, Warszawa and Gdańsk. The company headquarter and main distri-bution centre are located in a modern building specially built for this type of activity. An integral part of the warehouse is fully automated warehouses with an area of about 6.5 thousand m2. The company works with about 2.500 pharmacies and has more than 5% of the shares at the wholesale in Poland. Hurtap is a company with Polish capital and its shareholders are 240 pharmaci-sts, who actively support the policy of the company.Shareholders: Napióra Wiktor – 80%, Others – 20%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 207 742.0 235 270.6 262 145.0 325 799.7 292 310.2 278 297.8

Equity 24 809.6 27 425.0 30 757.9 33 758.0 39 956.0 45 791.0

Description of innovative activity: According to the 5A methodology, the company Hurtap JSC is characterized by a high asses-sment of process innovativeness level and a high assessment of ability for the financing obtaining from the EU. The company innovativeness assessment in the 5A system is NCNNC.

Instytut Biotechnologii Surowic i Szczepionek Biomed S.A.

Assessment with 5A System: NCBNN www.biomed.plPlace on the List of medical sector: 33 Established in: 1945Place on the 500’2010 List: not listed Company size: large

Address: 30–224 Kraków, ul. Sosnowa 8Voivodship: Lesser Poland

Type of business: pharmaceuticalsDescription of business activity: The Biotechnology Institute of Sera and Vaccines Biomed JSC is a Polish biotechnological company combining sixty years of experience in the pharmaceutical industry with the latest knowledge on medicinal products, medical devices and dietary supplements. Through the use of modern technology and cooperation with renowned research units, the products are of high quality and safety of use. The company is an investor in research and development. As part of the R&D, the company focused on the development and implementation of the production of the new preparations.The company continues to improve the already existing original products (probiotics, vaccines, allergens), implementing new technologies, research methods and improves work and laboratory equipment.Shareholders: Biomar JSC – 92.39%, Others – 7.61%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 6 214.0 7 355.5 8 053.0 812.3 18 971.7 17 515.7



Total assets 30 418.0 40 236.4 45 472.7 47 345.2 79 677.1 94 883.7

Equity 27 803.7 35 159.2 43 212.2 44 024.5 62 996.2 80 511.9

Description of innovative activity: According to the 5A methodology, the Biotechnology Institute of Sera and Vaccines Biomed JSC is characterized by a high assessment of process innovativeness level and a high assessment of financing level of innovative activity. The company innovativeness assessment in the 5A system is NCBNN.Company status: innovative company, investor in research and development

05 06 07 08 09 10

6.98

4

778.

9

831.

5

959.

4

969.

7

737.

6


05 06 07 08 09 10

29.4

31.0 36

.7

36.5 47

.3

43.2




Jarmed Sp. z o.o.

Assessment with 5A System: NCNNN Place on the List of medical sector: 90 Established in: 2003Place on the 500’2010 List: not listed Company size: micro

Address: 35–615 Rzeszów, ul. Leszka Czarnego 1aVoivodship: Subcarpathian

Type of business: medical equipmentDescription of business activity: The company Jarmed Ltd. is the multi-specialistic clinic and ambulatory care centre.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 89.7 71.2 64.4

Equity –50.2 –9.9 –2.4

Description of innovative activity: According to the 5A methodology, the company Jarmed Ltd. is characterized by a high asses-sment of process inovativeness level. The company innovativeness assessment in the 5A system is NCNNN.

JZO Sp. z o.o.

Assessment with 5A System: NBNNN www.jzo.com.plPlace on the List of medical sector: 65 Established in: 1945Place on the 500’2010 List: not listed Company size: large

Address: 58–500 Jelenia Góra, ul. Waryńskiego 12Voivodship: Lower Silesian

Type of business: medical equipmentDescription of business activity: JZO Ltd. is a company offering the latest generation of eyeglass lenses, that provide excellent vision correction and protection. The company’s products are the highest quality medical devices, that comply with international standards for eyepiece optics. They fully meet the needs of patients in the comfort of view and use of glasses. The company also offers products for the care of glasses (including tissues and fluids for cleaning spectacle lenses), and machinery and equipment for opticians and ophthalmic surgeries.Shareholders: Invoptic S.A.S. 98.25%, Others – 1.74%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets 242.8 219.5 388.4 1 066.0 1 354.2

Total assets 22 782.8 25 000.2 24 924.2 34 797.7 33 879.5 38 742.1

Equity 8 604.3 13 883.0 14 715.0 23 314.5 24 501.2 30 040.2

Description of innovative activity: According to the 5A methodology, the company JZO Ltd. is characterized with a very high assessment of process innovativeness level. The company innovativeness assessment in the 5A system is NBNNN.

05 06 07 08 09 10

0.09

0.09

0.04


05 06 07 08 09 10

51.7

51.1

56.0

54.7

54.0 56

.0




Krakowskie Zakłady Zielarskie Herbapol w Krakowie S.A.

Assessment with 5A System: NCNNC www.herbapol.krakow.plPlace on the List of medical sector: 84 Established in: 1949Place on the 500’2010 List: not listed Company size: medium

Address: 31–464 Kraków, ul. Chałupnika 14Voivodship: Lesser Poland

Type of business: pharmaceuticalsDescription of business activity: Herbal Plant Company Cracow in Krakow JSC Herbapol offers food supplements in the form of capsules and tablets, teasfruit and herbal teas, functional herbal and fruit syrups, tinctures and herbal remedies and cosmetics. The company also produces preparations and slimming supplements: slimming drops, cleansing drops, tea (Figuretka, Figuretka--Max with L-Carnitine, Deck, Deck-Max from Garcinia Cambogia and capsules Applecaps, Pu-erhcaps and Liniacaps). The offer also includes formulations against mosquitoes (ANTYKOMAR-spray), and brand new products: syrups and urinary tract cleansing gel for tired leg muscles.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 314.8 936.6 3 217.9 755.0 1 016.6 562.8



Total assets 13 669.9 13 794.3 16 439.5 16 658.7 17 380.3 17 382.5

Equity 10 991.8 11 686.6 14 692.8 15 070.0 15 708.7 15 787.8

Description of innovative activity: According to the 5A methodology, Herbal Plant Company Cracow in Krakow JSC. Herbapol is characterized by a high assessment of process inovativeness level and a high assessment of ability for the financing innovative projects from the EU funds. The company innovatinevess assessment in the 5A system is NCNNC.Company status: pantenting company, beneficiary of national operational projects of the EU

Krka Polska Sp. z o.o.

Assessment with 5A System: NCNNN www.krkapolska.plPlace on the List of medical sector: 82 Established in: 1993Place on the 500’2010 List: not listed Company size: large

Address: 02–235 Warszawa, ul. Równoległa 5Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The company Krka Polska Ltd. is a manufacturer, distributor and exporter of high quality generic medicines. It is one of the leading, reconstructive pharmaceutical company on the Polish market for almost 40 years. The compa-ny offers Polish patients high quality products with proven safety profile studies. The company is a part of an international Slove-nian pharmaceutical group Krka, whose the basic direction of activity is the production and sale of prescription medicines and those available without a prescription, as well as veterinary products. The group also concentrates on development of its own, high quality generic medicines.Shareholders: Krka D.D., Novo Mesto – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets 247.8 360.2 3 015.2

Total assets 171 894.6 205 261.4 229 893.5 241 885.1 317 174.3 340 098.6

Equity 89 293.6 99 330.1 129 595.9 167 762.9 168 735.7 199 772.7

Description of innovative activity: According to the 5A methodology, the level of process innovativeness of the company Krka Polska Ltd. is highly rated. The company innovativeness assessment according to the 5A system is NCNNN.

05 06 07 08 09 10

16.8

16.9

18.9 19

.7

19.9

19.1


05 06 07 08 09 10

304.

9

372.

9

452.

9

543.

7

639.

3

624.

7




Lek S.A.

Assessment with 5A System: NCNNN www.lek.com.plPlace on the List of medical sector: 93 Established in: 1945Place on the 500’2010 List: not listed Company size: large

Address: 95–010 Stryków, ul. Podlipie 16Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: The company Lek JSC is a production company of pharmaceutical sector and is a part of the Sandoz Group, which is the leader on the generic (retrospective) medicines market. The company manufactures antibiotics, car-diac, neurological medcines and painkillers.Shareholders: Novartis International AG – Novartis Pharma AG (Switzerland) – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 956 131.0 1 219 563.2 1 349 912.5 1 439 331.2 1 541 369.3 1 598 413.2

Net financial income (profit/loss) –1 051.5 8 297.5 18 183.9 21 044.3 20 095.4 22 616.7



Total assets 427 984.6 628 263.6 677 066.8 829 388.0 704 371.5 908 238.1

Equity 46 440.8 54 738.2 72 922.1 176 347.7 196 443.1 414 060.1

Description of innovative activity: According to the 5A methodology, the level of process innovativeness of the company Lek JSC is highly rated. The company innovativeness assessment according to the 5A system is NCNNN.

LfC Sp. z o.o.

Assessment with 5A System: CAAAA www.lfc.com.plPlace on the List of medical sector: 1 Established in: 1989Place on the 500’2010 List: 2 Company size: small

Address: 65–364 Zielona Góra, ul. Kożuchowska 41Voivodship: Lubusz

Type of business: medical equipmentDescription of business activity: The company LfC Ltd. is a manufacturer of medical devices used in orthopedic surgery and neurosurgery. The company conducts research, development and deployment of implants for treating musculo-neuro-muscular system, especially the man’s spine, implanted biomaterials for use in orthopedic and neurosurgery and strength of implanted medical devices. The result of research and development works is to create the Spine System DERO, which is the original high level world system. The company has its own scientific stuff, whose mission is carrying out innovative research and develpment activity, designing, constructing and testing prototypes, cooperation with relevant experts from the leading research and develop-ment centres in this country and abroad.Shareholders: Ciupik Lechosław – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 550.0 584.0 10 869.0 465.0 558.0 695.0


Intangible assets 32.0 2 037.0 1 618.0 3 396.0 4 512.0

Total assets 849.0 891.0 12 836.0 10 129.0 12 528.0 16 381.0

Equity 1 167.0 1 202.0 9 287.0 7 189.0 7 853.0 7 991.0

Description of innovative activity: According to the 5A methodology, the company LfC Ltd. is characterized by a high assessment of market innovativeness level, the highest assessment of process innovativeness level, the highest assessment of financing of innovative activity, the highest ability for obtaining patents and the highest assessment of ability for financing projects from the EU funds. The company innovativeness assessment in the 5A system is CAAAA.Company status: innovative company, investor in research and development, patenting company, beneficiary of national operatio-nal programmes of the European Union

05 06 07 08 09 10

956.

1

1 21

9.6

1 34

9.9

1 43

9.3

1 54

1.4

1 59

8.4


05 06 07 08 09 10

6.5

22.2

3.6

3.4 6.

6

6.4




mabion S.A.

Assessment with 5A System: CNNNN www.mabion.euPlace on the List of medical sector: 72 Established in: 2007Place on the 500’2010 List: not listed Company size: small

Address: 99–300 Kutno, ul. Józefów 9Voivodship: Lodz

Type of business: scientific research in the field of biotechnologyDescription of business activity: Mabion JSC is a Polish biotechnology company, established to launch on the market the latest generation of biotech medicines based on humanized monoclonal antibodies. Mabion was established in 2007 by four national pharmaceutical companies i.e. Celon Pharma, Polfarmex, IBSS Biomed and Genexo. Mabion has the power of production of any biotechnological medicines from the design phase through the choice of platform and manufacturing technologies to produce the finished medicines. In their laboratories, the company conducts research and development works of biotech medicines used in the treatment of cancer and metabolic diseases. The company Mabion is listed on the NewConnect market. Mabion acquired from the issuance of 22.8 million PLN, which were destined to expand the scale of production of medicines to the size enabling to conduct clinical trials.Shareholders: Genexo Ltd. – 19.03%, Wieczorek Maciej – 16.76%, Wośko Mieczysław – 16.37%, IBSS Biomed JSC – 6.52%, Aleksandrowicz Robert – 0, 29%, Others – 41.03%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 88.5 3 084.9



Intangible assets

Total assets 134.0 348.2 23 438.7

Equity –46.0 –74.8 21 719.2

Description of innovative activity: According to the 5A methodology, the level of market innovativeness of the company Mabion JSC is highly rated. The company innovativeness assessment in the 5A system is CNNNN.Company status: company listed on NewConnect

medana Pharma S.A.

Assessment with 5A System: CBBNN www.medana.plPlace on the List of medical sector: 11 Established in: 1956Place on the 500’2010 List: 134 Company size: medium

Address: 98–200 Sieradz, ul. Władysława Łokietka 10Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: The company Medana Pharma JSC is a leader in the field of production of pediatric medicines and vitamin supplements in modern forms. The company’s portfolio also includes medicines used in dermatology and musculoske-letal diseases, as well as foods (dietary supplements), cosmetics and medical devices. The company offers a wide range of modern medicine – liquid form (syrups, suspensions, drops, gels, solutions), dried (tablets, including coated tablets), and soft and hard capsules. This also applies to contract manufacturing, which is a very important part of the company business. The company is an investor in research and development.Shareholders: Zakłady Farmaceutyczne Polpharma JSC – 98.30%, Others – 1.70%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 434.2 450.3 1 998.3 1 707.8 1 219.0


Total assets 91 612.2 113 279.1 157 897.9 160 965.3 192 008.0

Equity 78 606.8 96 734.0 140 062.8 147 621.2 164 341.0

Description of innovative activity: According to the 5A methodology, the company Medana Pharma JSC is characterized by a high assessment of market innovativeness level, a very high assessment of process innovativeness level and a very high asses-sment of financing of innovative activity. The company innovativeness assessment in the 5A system is CBBNN.Company status: innovative company, investor in research and development

05 06 07 08 09 10

0.09

3.08


05 06 07 08 09 10

77.4 98

.1 125.

5

132.

0 164.

9




Medicalgorithmics S.A.

Assessment with 5A System: CCBNB www.medicalgorithmics.plPlace on the List of medical sector: 8 Established in: 2005Place on the 500’2010 List: 94 Company size: small

Address: 00–515 Warszawa, ul. Żurawia 22Voivodship: Mazovian

Type of business: scientific research in the field of biotechnologyDescription of business activity: Medicalgorithmics Company JSC is a manufacturer of technologically of advanced in the world for the diagnosis of arrhythmias – PocketECG system. This system allows for diagnosis of heart arrhythmia during the period of several weeks and thanks to innovative algorithms of ECG interpretation, generates a real-time survey results with an accuracy of Holter test and sends the results at the same time to a specialist in the monitoring centre. Besides the PocketECG and services associated with it, the company also sells cardiac monitoring system in animals – CardVET.Shareholders: New Europe Ventures LLC – 27.29%, BIB Seed Capital JSC – 21.57%, Dziubiński Marek – 20.22%, Others – 30.92%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 458.7 290.3 4 107.3

Net financial income (profit/loss) –2 085.2 –928.5 1 748.4


Intangible assets 37.0 1 033.3 834.1

Total assets 1 646.8 1 374.2 2 910.6

Equity 1 436.7 919.4 2 667.8

Description of innovative activity: According to the 5A methodology, the company Medicalgorithmics JSC is characterized by a high assessment of market and process innovativeness level, a very high assessment on financing of innovative activity and a very high assessment of ability of financing of innovative projects from the EU funds.Company status: innovative company, investor in research and development, beneficiary of national operational projects from the EU

Melisa Olga Cherkasova Sp.K.

Assessment with 5A System: CBNNN www.melisa.poznan.plPlace on the List of medical sector: 36 Established in: 2005Place on the 500’2010 List: not listed Company size: micro

Address: 60–178 Poznań, ul. Oskierki 14Voivodship: Greater Poland

Type of business: hospital services and medical careDescription of business activity: The company Melisa Olga Cherkasova Limited Partnership provides services in the field of natural medicine. Services are run by: Olga Cherkasova and Serghei Melihov. The company offers acupuncture, massage, manual therapy, bioresonance, quantum therapy, Vitafonem therapy, ear candling, homeopathy, herbalism and irydologia (determining the health status of the iris of the eye).

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 72.8 124.8 120.6

Equity 53.5 110.0 107.7

Description of innovative activity: According to the 5A methodology, the company Melisa Olga Cherkasova Limited Partnership is characterized by a high assessment of market innovativeness level and a very high assessment of process innovativeness level. The company innovativeness assessment in the 5A system is CBNNN.

05 06 07 08 09 10

0.46

0.29

4.11


05 06 07 08 09 10

0.10 0.

13 0.15




mobilex Sp. z o.o.

Assessment with 5A System: NNCNN www.mobilex.plPlace on the List of medical sector: 70 Established in: 2000Place on the 500’2010 List: not listed Company size: small

Address: 90–540 Łódź, ul. Radwańska 23, 1Voivodship: Lodz

Type of business: medical equipmentDescription of business activity: The company Mobilex Ltd. is a manufacturer of rehabilitation equipment, including wheelchairs for active rehabilitation, seats for comprehensive rehabilitation, or individual verticalling items. The Company has also in its offer electric wheelchairs and scooters, lifts, car seats and support products, such as balloons, supports, canes and crutches.The company offers the equipment and devices enabling to overcome architectural barriers of environment. An important part of the services provided by the company is also Mobilex service of rehabilitation equipment.Shareholders: Włodarczyk Wojciech Bartłomiej – 20%, Fendorf Aneta Izabela – 10%, Others – 70%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 645.2 1 076.0 762.8 122.4 –114.9



Total assets 2 441.9 3 126.5 3 847.1 4 351.1 2 942.7

Equity 1 216.2 1 972.1 2 209.9 1 952.3 1 815.0

Description of innovative activity: According to the 5A methodology, financing the innovative activity by Mobilex Ltd. is highly rated. The company innovativeness assessment in the 5A system is NNCNN.Company status: innovatice company, investor in research and development

MPW Med Instruments Spółdzielnia Pracy

Assessment with 5A System: NCNNN www.mpw.plPlace on the List of medical sector: 85 Established in: 1970Place on the 500’2010 List: not listed Company size: medium

Address: 04–347 Warszawa, ul. Boremlowska 46Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: The company MPW Med Instruments Cooperative is a manufacturer of medical and laboratory centrifuges. It manufactures 17 types of modern medical and laboratory centrifuges, including universal and specialist ones: hematocrit, cytological, microtiter, chilled, chilled and heated, for the preparation of blood, the column tests. In addition, MPW Med Instruments has technical equipment enabling the production of electromechanical devices with electronics. Every year the com-pany announces the launch of 2–3 new models of centrifuges and the upgraded existing versions. The MPW Med Instruments products are exported to more than 80 countries and the export value is as high as 70% of net sales revenues.Shareholders: Members of cooperative – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 508.2 744.9 328.8 861.9 631.1



Total assets 7 292.5 8 315.2 7 638.2 8 255.8 8 222.8

Equity 3 384.4 3 789.5 3 746.0 4 464.1 4 578.7

Description of innovative activity: According to the 5A methodology, the company MPW Med Instruments Cooperative process innovativeness is highly rated. The company innovativeness assessment in the 5A system is NCNNN.Company status: investor in research and development

05 06 07 08 09 10

8.1 9.

4 10.8

9.2

8.3


05 06 07 08 09 10

11.0

10.4

11.0 12

.1

11.6




Neuca S.A.

Assessment with 5A System: CCNNN www.neuca.plPlace on the List of medical sector: 51 Established in: 1990Place on the 500’2010 List: not listed Company size: large

Address: 87–100 Toruń, ul. Szosa Bydgoska 58Voivodship: Kuyavian-Pomeranian

Type of business: pharmaceuticalsDescription of business activity: The company Neuca JSC is the largest wholesale distributor of pharmaceuticals in Poland. The company is a leader in wholesale sales of medicines to pharmacies, arriving each day up to 10 thousand. pharmacy outlets. The company’s strategy is to focus on developing the main business, while developing synergistic businesses directly associated with it. These include the management of their own brands of pharmaceutical products, development of information systems, the pro-vision of advertising specialist services on the healthcare market. The group is building a network of partner pharmacies, currently has more than 2.5 thousand under the brands the Health World and the Pharmacy of Good Prices, provides marketing services, IT for companies in the healthcare and manufactures its own medicines.Shareholders: Herba Wiesława – 23.07%, Herba Kazimierz Michał – 23.07%, FPT Foundation – 10.56%, Sucharski Piotr – 0.11%, Others – 43.19%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets 6 684.0 6 292.0 5 544.0

Total assets 371 264.0 543 566.0 1 014 806.0 1 287 173.0 1 491 006.0 1 741 701.0

Equity 69 155.0 78 457.0 166 536.0 161 949.0 192 086.0 202 491.0

Description of innovative activity: According to 5A methodology, the company Neuca JSC Market and process innovativeness level is highly rated. The company innovativeness assessment in the 5A system is CCNNN.

Neuroreha Sp. z o.o.

Assessment with 5A System: CCNNN www.fizjoterapiaopole.plPlace on the List of medical sector: 41 Established in: 2007Place on the 500’2010 List: not listed Company size: micro

Address: 45–273 Opole, ul. Tysiąclecia 7cVoivodship: Opole

Type of business: hospital services and medical careDescription of business activity: The company Neuroreha Ltd. provides neurological rehabilitation of children and adults by PNF, Vojta and NDT Bobath methods. It offers specialized neurological and functional therapy for children and adults with disorders such as stroke, trauma, cranial-cerebral, spinal cord injury, cerebral palsy (CP), scoliosis, posture, meningomyelocele, torticollis, disor-ders of central coordination nerve (ZOKN), postural asymmetries and dysplasia. The company provides consulting specialists, assesses the child’s motoric development, neurolopede, care teaching of a sick person, proper care teaching of a newborn and an infant, evaluation and rehabilitation of posture, feet and scoliosis.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 51.5 82.7 102.0

Equity 50.5 81.5 96.8

Description of innovative activity: According to the 5A methodology, the company Neuroreha Ltd. is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment in the 5A system is CCNNN.

05 06 07 08 09 10

1 41

4,8

1 70

0,9

2 53

8,5

3 59

5,0

4 25

6,1

4 62

2,7


05 06 07 08 09 10

0.06

0.11

0.21




Niepubliczny Zakład Opieki Zdrowotnej Medicor Sp. z o.o.

Assessment with 5A System: NCNNN Place on the List of medical sector: 79 Established in: 2001Place on the 500’2010 List: not listed Company size: small

Address: 50–231 Wrocław, ul. Trzebnicka 88Voivodship: Lower Silesian

Type of business: hospital services and medical care

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 1 065.8 1 403.8 1 663.5

Equity 995.1 1 330.7 1 590.6

Description of innovative activity: According to the 5A methodology, the Independent Health Care Centre Medicor Ltd. is cha-racterized by a high assessment of process innovativeness level. The company innovtiveness assessment in the 5A system is NCNNN.

Niepubliczny Zakład Opieki Zdrowotnej Praktyka Zespołu Lekarza Rodzinnego Zdrovita Michniewicz-Nowak, Rólka, Wiśniewska-Prałat, Śnieg Sp.P.

Assessment with 5A System: NBNNN Place on the List of medical sector: 67 Established in: 2004Place on the 500’2010 List: not listed Company size: small

Address: 66–600 Krosno Odrzańskie, ul. Srebrna Góra 1aVoivodship: Lubusz

Type of business: hospital services and medical careDescription of business activity: Health Centre Independent Healthcare Centre (NZOZ) Family Doctor Practice Group Zdrovita Michniewicz-Nowak, Rólka, Wiśniewska-Prałat, Śnieg Limited Liability Parntership carries on business in the town of Krosno Odrzańskie. The company specializes in family medicine.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 771.8 1 094.0 932.8


Intangible assets

Total assets 725.6 894.2 722.2

Equity 494.1 686.5 675.9

Description of innovative activity: According to the 5A methodology, Independent Healthcare Centre (NZOZ) Family Doctor Practice Group Zdrovita Michniewicz Nowak Rólka Wiśniewska Prałat Śnieg Limited Liability Partnership is charecterized by a high assessment of process innovativeness level. The company innovativeness assessment is NBNNN.

05 06 07 08 09 10

1.2 1.

5

1.5


05 06 07 08 09 10

1.6

2.1

2.1




Niepubliczny Zakład Opieki Zdrowotnej Przychodnia Lekarska Zdrowie A. Graczyk-Duda E. Raczyńska A. Walorski Sp. P.L.


Address: 49–200 Grodków, ul. Szpitalna 13Voivodship: Opole

Type of business: hospital services and medical careFin

ancia

l dat

a (th

ousa

nd P

LN) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 127.6 137.4 133.6

Equity 117.8 2.5 30.0

Description of innovative activity: According to the 5A methodology, Independent Healthcare Centre (NZOZ) Medical Health Centre A.Graczyk-Duda E.Raczyńska A.Walorski Limited Liability Partnership is charecterized by a very high assessment of process innovativeness level. The company innovativeness assessment is NBNNN.

Niepubliczny Zakład Opieki Zdrowotnej Zdrowie Sp. P.L. Beata Duda-Chełstowska i Partnerzy

Assessment with 5A System: NCNNN Place on the List of medical sector: 86 Established in: 2002Place on the 500’2010 List: not listed Company size: small

Address: 14–100 Ostróda, ul. Kościuszki 2Voivodship: Warmian-Mazurian

Type of business: hospital services and medical careShareholders: Duda-Chełstowska Beata Jolanta – 16%, Mojska Teresa Jolanta – 16%, Antończyk Michał Jacek – 16%, Dudzińska Ewa Maria – 16%, Palczewska-Muchlado Bogumiła – 16%, Sztejter Mirosława – 16%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 328.9 208.7 202.2

Equity 5.1 5.1 5.1

Description of innovative activity: According to the 5A methodology, Independent Healthcare Centre (NZOZ) Medical Health Centre Doctors’ Limited Liability Partnership Beata Duda Chełstowska and Partners is charecterized by a high assessment of pro-cess innovativeness level. The company innovativeness assessment is NCNNN.

05 06 07 08 09 10

1.3 1.

5

1.5


05 06 07 08 09 10

1.3 1.

7

2.2

2.1




Novo Nordisk Pharma Sp. z o.o.

Assessment with 5A System: CCNNN www.novonordisk.plPlace on the List of medical sector: 52 Established in: 1991Place on the 500’2010 List: not listed Company size: medium

Address: 02–146 Warszawa, ul. 17 Stycznia 45bVoivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The company Novo Nordisk Pharma Ltd. is a part of the global pahramceutical group Novo Nordisk, that is one of the leaders in diabetes treatment. The company also occupies a leading position in the treatment of haemo-philia, growth hormone therapy and hormone replacement therapy. Novo Nordisk offers the largest selection of insulin, such as drugs used to treat diabetes. The company manufactures and supplies the market with pharmaceutical products and services, that have a significant impact on the lives of patients and the development of medicine. Novo Nordisk headquarters is located in Den-mark. In Poland, a subsidiary of Novo Nordisk has been present since 1991 and belongs to the region of Eastern Europe, which brings together 17 countries. In Poland, the company employs 150 people.Shareholders: Novo Nordisk Region Europe A.S. – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 18 045.8 13 010.8 –4 540.7 247.6 5 807.5



Total assets 114 747.5 149 627.0 140 540.1 156 667.3 186 140.5

Equity 70 412.4 83 423.2 78 882.5 79 130.1 83 428.5

Description of innovative activity: According to the 5A methodology, the company Novo Nordisk Pharma Ltd. market and process innovativeness level is highly rated. The company innovativeness level in the 5A system is CCNNN.

Nycomed Pharma Sp. z o.o.

Assessment with 5A System: NNNNC www.nycomed.plPlace on the List of medical sector: 100 Established in: 1997Place on the 500’2010 List: not listed Company size: large

Address: 02–305 Warszawa, ul. Al. Jerozolimskie 146aVoivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Nycomed Pharma Ltd. is dealing with production, distribution and wholsale of medicinal pro-ducts and dietary supplements. The company belongs to the Swiss Nycomed Group, that is present worldwide and merged with the Japanese pharmaceutical consortium Takeda Pharmaceutical Company Ltd. The company has the production plant located in Łyszkowice, that manufactures the medicines delivered on the Polish market and abroad, among others, to such countries as Germany, Spain, Italy, Holland, Canada and Arab countries. The production plant carries the contract production for the industry and, in a large extent, meets the reqjuirements of the Nycomed Group.Shareholders: Nycomed Norway Holdings AS – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 173 967.0 179 643.0 196 712.0 248 883.0 295 799.0 272 666.0

Equity 133 537.0 148 758.0 175 307.0 200 793.0 217 257.0 216 089.0

Description of innovative activity: According to the 5A methodology, The company Nycomed Pharma Ltd. is chadracterized by a high assessment of ability for obtaining the financing from the EU funds. The company innovativeness assessment in the 5A system is NNNNC.

05 06 07 08 09 10

353.

9

379.

0

399.

9

447.

3

483.

8


05 06 07 08 09 10

198.

2

225.

0

282.

8

330.

8

383.

4

373.

5




olimp Laboratories Sp. z o.o.

Assessment with 5A System: CBNNA www.olimp-labs.comPlace on the List of medical sector: 13 Established in: 1996Place on the 500’2010 List: 170 Company size: medium

Address: 39–200 Dębica, ul. Nagawczyna 109cVoivodship: Subcarpathian

Type of business: pharmaceuticalsDescription of business activity: The company Olimp Laboratories Ltd. is a manufacturer of pharmaceuticals, vitamin prepara-tions and dietary supplements. The products offered by Olimp Laboratories are targeted to both, the people who care about the overall health condition, as well as to the people, who want to enrich their dietary with vitamins, macro and micronutrients, in particular in the framework of its deficiency in the body. Within two decades, the company has become a pan-European company, achieving a high position in the German, Austrian, Swiss, French and Scandinavian markets. The company has its own research base and modern production facilities. The company also has a modern research and development laboratory.Shareholders: Jedliński Stanisław Zygmunt – 33.33%, Jedliński Rafał – 33.33%, Jedliński Marcin – 33.33%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 29 946.0 36 738.9 45 059.1 54 904.3 67 642.3 86 498.3

Equity 14 671.3 16 388.7 21 019.1 25 297.8 31 258.6 42 515.8

Description of innovative activity: According to the 5A methodology, the company Olimp Laboratories Ltd. market innovativeness level is highly rated, process innovativeness level is very highly rated and the ability of financing from the EU funds is the highest one. The company innovativeness level in the 5A system is CBNNA.Company status: innovative company, patenting company, beneficiary of national operational programmes of the EU

Organizacja Polskich Dystrybutorów Farmaceutycznych S.A.

Assessment with 5A System: CCNNN www.opdf.com.plPlace on the List of medical sector: 46 Established in: 1999Place on the 500’2010 List: not listed Company size: medium

Address: 01–942 Warszawa, ul. Kabaretowa 21Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The company Organisation of the Polish Pharmaceutical Distributors JSC is one of the most dynamically developing pharmaceutical wholesalers in Poland. The company consists of six independent regional wholesalers who are also shareholders of the company. The group consists of: Hurtap JSC – distributor of medcal products and materials for phar-macies, Pharmaceutical Wholesaler Intra Ltd., Lubfarm JSC – recognized as a company with experience in the distribution of pharmaceutical products, Medicare Ltd. – pharmaceutical wholesaler operating in the southern Poland, Pharmaceutical Wholesaler Novo JSC and the Pharmaceutical Wholesaler Preska Ltd.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 553.8 713.8 330.1 200.5 328.0 369.9



Total assets 44 922.2 56 375.4 61 345.8 82 099.4 103 794.0 108 767.7

Equity 11 085.8 11 799.6 9 403.5 9 624.0 10 985.3 12 801.9

Description of innovative activity: According to the 5A methodology, the company Organisation of the Polish Pharmaceutical Distributors JSC market and process innovativeness level is highly rated. The company innovativeness level in the 5A system is CCNNN.

05 06 07 08 09 10

38.0 48

.4 65.3 76.3 99

.6 125.

2


05 06 07 08 09 10

214.

8

275.

9

335.

8

386.

3

465.

7

536.

7




Ośrodek Badawczo-Produkcyjny Politechniki Łódzkiej Ichem Sp. z o.o.

Assessment with 5A System: CBNNB www.ichem.com.plPlace on the List of medical sector: 22 Established in: 1988Place on the 500’2010 List: 308 Company size: medium

Address: 93–231 Łódź, ul. Dostawcza 12Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: The Centre for Research and Production Łódź Technical University Ichem Ltd. is a manufacturer of dietary supplements, foodstuff and functional foods. The company’s offer includes a wide range of cosmetic products. The company also offers services to develop a formulation from the laboratory scale to the production scale, the search for suppliers of raw materials and packaging materials for the developed formulation, modification of existing products compostions, production of test series, the creation of documentation for the products, making laboratory testing and storage of archival samples.Shareholders: Kiluva JSC – 24.87%, Zamodiet JSC – 24.87%, Jankowski Jacek Kazimierz – 12.56%, Others – 37.7%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –1 363.5 251.1 2 030.5 1 424.5 4 008.3 5 202.4



Total assets 13 323.5 20 559.5 31 834.6 32 912.8 54 873.7 66 494.6

Equity 4 861.9 9 745.3 11 772.1 12 793.2 16 516.7 20 913.7

Description of innovative activity: According to the 5A methodology, the Centre for Research and Production Łódź Technical University Ichem Ltd. market innovativeness level is highly rated and process innovativeness level and the ability of financing from the EU funds are very highly rated. The company innovativeness level in the 5A system is CBNNB.

Pelion S.A.

Assessment with 5A System: CCNNN www.pelion.euPlace on the List of medical sector: 53 Established in: 1989Place on the 500’2010 List: not listed Company size: large

Address: 91–342 Łódź, ul. Zbąszyńska 3Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: The company Pelion JSC, formerly the Polish Pharmaceutical Group JSC has operated in the medical sector for 22 years. The company is one of the largest capital groups of companies operating in the healthcare market in Poland. The company is also present in Lithuania and the United Kingdom. Services provided by the company cover all segments of the pharmaceutical distribution from the wholesale market, retail, hospital services and are targeted to patients, pharmacies, hospitals and manufacturers. Pelion JSC, as a holding company, fulfills ownership supervision over all areas of the company acti-vity, carried out respectively by PGF Hurt Ltd. (wholesale), Pharmapoint Ltd. (pre-wholesale), PGF Urtica Ltd. (supplies of hospi-tals), CEPD NV (retail sales) and Pharmalink Ltd. (services for producers).Shareholders: Szwajcowski Jacek – 10.18%, Legg Mason Zarządzanie Aktywami JSC – 9.96%, ING OFE – 9.58%, Aviva OFE – 8.56%, Molenda Zbigniew – 6, 26%, Others – 55.46%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 1 445 378.0 1 490 410.0 2 011 720.0 2 149 268.0 2 191 370.0 2 339 196.0

Equity 213 335.0 246 734.0 286 429.0 341 330.0 402 045.0 454 835.0

Description of innovative activity: According to the 5A methodology, the company Polish Pharmaceutical Group JSC market and process innovativeness level is highly rated. The company innovativeness level in the 5A system is CCNNN.Company status: company listed on the Warsaw Stock Exchange

05 06 07 08 09 10

57.9

57.6

127.

9

128.

5 200.

7

217.

8


05 06 07 08 09 10

3 89

0.7

4 00

7.6

4 41

0.5

5 09

5.0

5 42

7.4

5 79

5.4




Pfizer Trading Polska Sp. z o.o.

Assessment with 5A System: CCNNN www.pfizer.comPlace on the List of medical sector: 61 Established in: 2005Place on the 500’2010 List: not listed Company size: small

Address: 02–676 Warszawa, ul. Postępu 17bVoivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The main activity of the Pfizer Trading Polska Ltd. is the wholesale of pharmaceutical and medi-cal products. The company is a part of the American biopharmaceutical consortium Pfizer Inc. operating globally, one of the biggest investor in research and development in the world. Pfizer Poland occupies the leading position in the list of the largest pharmaceu-tical companies in Poland. The company maintains a strong market position by offering innovative medicines in several therapeutic areas, including: cardiology, neurology, psychiatry, diabetes, rheumatology, ophthalmology, endocrinology, sexology, urology, onco-logy and infectious diseases. The Pfizer offer for medicines also includes veterinary preparations. The company is also active in the field of clinical trials.Shareholders: Pfizer Holdings International Luxembourg SARL – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –10 937.5 7 780.8 15 256.4 12 391.0 6 328.6 6 222.5



Total assets 229 597.2 257 819.3 252 740.1 268 504.6 301 551.0 415 738.5

Equity 2 112.5 9 893.3 25 149.7 37 540.7 43 869.3 49 629.9

Description of innovative activity: According to the 5A methodology, the company Pfizer Trading Polska Ltd. market and process innovativeness level is highly rated. The company innovativeness level in the 5A system is CCNNN.

PharmaGea Sp. z o.o.

Assessment with 5A System: CNNNN www.pharmagea.plPlace on the List of medical sector: 74 Established in: 2005Place on the 500’2010 List: not listed Company size: small

Address: 40–403 Katowice, ul. Oswobodzenia 1Voivodship: Silesian

Type of business: pharmaceuticalsDescription of business activity: The company PharmaGea Ltd. was established in 2005 and is a sole distributor of Aboca com-pany – the italian manufacturer of natural vegetable, improving health and comfort of life. Aboca is the undisputed leader on the Italian market in production and sale of vegetabale preparations, improving health and comfort of life. The PharmaGea company is systematically expanded Aboca offer, entering the Polish market the highest quality medical devices, dietary supplements and cosmetics, biological, whose highest value is the 100% natural composition.Shareholders: Aboca S.P.A. Societa Agricola – 95.01%, Others – 4.99%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 966.3 1 402.6 1 480.5

Equity –2 478.9 –2 681.0 437.8

Description of innovative activity: According to the 5A methodology, the company PharmaGea Ltd. is characterized by a high level of market innovativeness level. The company innovativeness assessment is CNNNN.

05 06 07 08 09 10

219.

3

455.

0

441.

0

466.

8

473.

9

556.

5


05 06 07 08 09 10

3.0

4.1 4.

6




Phytopharm Dobrzyca Sp. z o.o.

Assessment with 5A System: NCNNN www.phytopharm.com.plPlace on the List of medical sector: 98 Established in: 1987Place on the 500’2010 List: not listed Company size: large

Address: 63–330 Dobrzyca, ul. Parkowa 5Voivodship: Greater Poland

Type of business: pharmaceuticalsDescription of business activity: The company Phytopharm Dobrzyca Ltd. is a manufacturer of herbal preparations and dietary supplements used in the early stages of diabetes.Shareholders: Martin Bauer GmbH & Co. KG – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 1 581.9 953.9 971.7

Equity 564.8 605.7 613.8

Description of innovative activity: According to the 5A methodology, the company Phytopharm Dobrzyca Ltd. is characterized by a high level of process innovativeness level. The company innovativeness assessment is NCNNN.

Polfarmex S.A.

Assessment with 5A System: CCBNN www.polfarmex.com.plPlace on the List of medical sector: 17 Established in: 1991Place on the 500’2010 List: 203 Company size: large

Address: 99–300 Kutno, ul. Józefów 9Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: Polfarmex JSC is a rapidly growing pharmaceutical company in Poland. The company is a manu-facturer of prescription medicines and those without a prescription, dietary supplements, dietary foods and cosmetics. The com-pany operates not only in the domestic market but also abroad. The company has its own Research and Development Department, located in Kutno, where specialized workers are employed in the pharmaceutical, chemical and biotechnology. The Research and Development Department is engaged in the development of technology, registration documentation and implementation of a pro-duction scale of medicinal products, dietary supplements and cosmetics (including the external orders). In addition, R&D activities include organizing, conducting, managing and monitoring clinical trials and also monitoring of pharmacotherapy safety. The Rese-arch and Development Department is developing modern forms of medicines, examines patent purity and medical assessment.Shareholders: Vosko Ltd. – 99.65%, Others – 0.35%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 832.1 2 319.3 2 340.4 1 800.7


Total assets 120 477.1 150 610.6 181 641.2 216 092.6 252 905.2

Equity 78 926.9 79 407.1 97 548.9 116 366.3 134 750.4

Description of innovative activity: According to the 5A methodology, the company Polfarmex JSC is characterized by a high assessment of market and process innovativeness level and a very high assessment of investment in the innovative activity. The company innovativeness assessment in the 5A system is CCBNN.Company status: innovative company, investor in research and development, patenting company

05 06 07 08 09 10

4.8

3.0

2.1


05 06 07 08 09 10

106.

5

95.9 11

1.6 15

5.7

171.

7




Poznańskie Zakłady Zielarskie Herbapol S.A.

Assessment with 5A System: NCCNN www.herbapol.poznan.plPlace on the List of medical sector: 57 Established in: 1994Place on the 500’2010 List: not listed Company size: large

Address: 61–896 Poznań, ul. Towarowa 47, 51Voivodship: Greater Poland

Type of business: pharmaceuticalsDescription of business activity: The Herbal Plants Poznan JSC Herbapol is one of the oldest and most respected herbal compa-nies in Poland. Its position in the market and recognition of patient, the company owes to the implemented quality policy, imple-menting innovative solutions, conducting research, and finally, the people who create it – committed and passionate professionals. The Herbapol Poznań has worked that way for over 140 years. The company offers a nearly 40 plant-based medicines, in various forms and in a wide range of application. In addition, the company produces herbal supplements, cosmetics and food flavourings for the industry in a wide range of odour-taste.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 269.1 1.6 24.6 28.5


Total assets 108 811.0 111 079.0 115 773.6 122 943.8 125 691.5 124 954.7

Equity 94 921.5 100 778.0 106 793.1 113 254.4 114 146.7 115 437.3

Description of innovative activity: According to the 5A methodology, the company Herbal Plants Poznan JSC Herbapol is charac-terized by a high assessment of process innovativeness level and a very high assessment of investment in the innovative activity. The company innovativeness assessment in the 5A system is NCCNN.Company status: innovative company, investor in research and development

Pro Plus Sp. z o.o.

Assessment with 5A System: CNNNN www.pro-plus.plPlace on the List of medical sector: 73 Established in: 2004Place on the 500’2010 List: not listed Company size: micro

Address: 02–762 Warszawa, ul. Capri 2, 46Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: Pro Plus Ltd. is a manufacturer of cardiac telemonitoring system at a distance, which includes the measurement of ECG, heart rate, blood oxygen saturation, blood pressure and weight, measurements transmition to monitoring centre, voice communication with the physician directly from the ECG camera and notification of doctors of a new ECG testing by SMS . The system consists of teleECG cameras performing measurements and digital data transmission and CardioScp software to receive and archive of the received test results.Shareholders: Radwańscy Iwona i Jan – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 164.5 –173.3 –36.4


Intangible assets

Total assets 488.7 292.7 255.7

Equity 335.6 130.0 93.6

Description of innovative activity: According to the 5A methodology, the company Pro Plus Ltd. is characterized by a high assessment of market innovativeness level. The company innovativeness assessment in the 5A system is CNNNN.

05 06 07 08 09 10

82.8

82.0

81.5

84.2 85

.5

83.8


05 06 07 08 09 10

0.7

0.3

0.7




Prosper S.A.

Assessment with 5A System: NNNNC www.prosper.plPlace on the List of medical sector: 97 Established in: 1990Place on the 500’2010 List: not listed Company size: large

Address: 02–255 Warszawa, ul. Krakowiaków 65Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The company Prosper JSC is one of pharmaceutical distribution leader on the Polish market. The company’s product range is based on the latest technological achievements and innovative logistics solutions. The offer includes more than 17 thousand pharmaceutical products and medical supplies. The company has 13 distribution centers throughout the country, each of which has its own warehouse and transport fleet. The company works on a permanent basis from more than 500 manufacturers of medicines from the country and abroad, and runs regular services nearly 4.000 pharmacies across the Polish market. The company organizes the largest nationwide fair addressed to the owners of pharmacies and pharmacists of Medica-mentum Forum. Since 2005, the format of the fair enables the pharmaceutic family to read the comprehensive offer of manufactu-rers, new products on the market and conclude contracts with the most favourable price conditions.Shareholders: Oktogon Investment ApS (Copenhagen, Denmark) – 30.66%, Wesołowski Tadeusz – 21.60%, Wesołowska Ewa – 0.55%, Jędrzejak Piotr – 0.04%, Others – 47.15%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 8 394.0 5 157.0 1 790.0 706.0 2 785.0 –2 591.0



Total assets 499 929.0 525 321.0 543 408.0 562 659.0 625 508.0 645 764.0

Equity 119 574.0 121 298.0 119 313.0 120 019.0 122 804.0 120 212.0

Description of innovative activity: According to the 5A methodology, the company Prosper JSC is characterized by a high asses-sment of investment ability from the EU funds. The company innovativeness assessment in the SA system is NNNNC.Company status: company listed on the Warsaw Exchange Stock

Przedsiębiorstwo Farmaceutyczne Jelfa S.A.

Assessment with 5A System: NBCCC www.jelfa.com.plPlace on the List of medical sector: 18 Established in: 1945Place on the 500’2010 List: 242 Company size: large

Address: 58–500 Jelenia Góra, ul. Wincentego Pola 21Voivodship: Lower Silesian

Type of business: pharmaceuticalsDescription of business activity: The pharmaceutical company Jelfa JSC is now a part of the Lithuanian pharmaceutical group Sanitas. Jelfa was established in 1945 and from the very beginning, it focuses on the production of pharmaceuticals. Merging of Jelfa and Sanitas companies resulted in the transformation of the production-oriented company into the modern market-oriented pharmaceutical company focused on the patient health.Shareholders: AB Sanitas (Vilnius, Lithuania), Sanitas Polska Sp. z o.o. (Lithuania) – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –24 642.2 56 574.6 6 032.1 36 654.0 64 312.3



Total assets 416 880.7 430 237.4 469 928.2 424 193.8 417 505.1

Equity –242 860.2 61 634.5 59 822.9 89 928.9 153 007.8

Description of innovative activity: According to the 5A methodology, the Pharmaceutical Company Jelfa JSC is characterized by a very high assessment of market innovativeness, a high assessment of investment in innovative activity and ability of obtaining patents, as well as a high assessment of ability for financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is NBCCC.Company status: inovative company, investor in research and development, patenting company, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

1 66

9.4

1 77

1.2

1 86

5.7

1 79

3.6

1 98

8.7

1 88

6.2


05 06 07 08 09 10

206.

8 299.

7

332.

3

338.

1

351.

6




Przedsiębiorstwo Farmaceutyczne Lek-Am Sp. z o.o.

Assessment with 5A System: CCBNA www.lekam.plPlace on the List of medical sector: 6 Established in: 2000Place on the 500’2010 List: 53 Company size: large

Address: 05–170 Zakroczym, ul. Ostrzykowizna 14aVoivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The Pharmaceutical Company Lek-Am Ltd. is the Polish company operating on the pharmaceu-tical market. The production of preparations of the company is located in Zakroczym near Warszawa. The production facilities are modern pharmaceutical manufacturing plant and laboratory equipped with the highest quality equipment. The production lines and the laboratory operate according to the European standards. The production methods of preparations meet all requirements of the Good Manufacturing Practice (GMP) and the products for a clinic research are manufactured according to guidelines of the Good Laboratory Practice (GLP) and GMP. In the registration of new medicines, the company is working closely with leading clinical centres in medical schools and academic institutions in Poland and abroad. Research is conducted in accordance with the requ-irements of the procedures used in the European Union.Shareholders: Grzymała Józef – 49.46%, Wyrzykowski Andrzej – 49.46%, Others – 1.08%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 988.0 7 162.0 3 685.0 1 950.0 6 954.3 7 915.2

Capitalized value of R&D expenses 5 829.0 4 276.0 4 292.7


Total assets 31 124.0 45 729.0 90 814.0 117 505.9 140 746.0 156 949.2

Equity 9 401.0 16 467.0 20 153.0 22 103.1 29 057.5 45 120.3

Description of innovative activity: According to the 5A methodology, the Pharmaceutical Company Lek-Am Ltd. is characterized by a very high assessment of market and process innovativeness, a very high assessment of investment in innovative activity, as well as the highest assessment of ability for financing of innovative projects from the EU funds.Company status: inovative company, investor in research and development, beneficiary of national operational programmes of the European Union

Przedsiębiorstwo Yavo Sp. z o.o.

Assessment with 5A System: NCCNC www.yavo.com.plPlace on the List of medical sector: 34 Established in: 2000Place on the 500’2010 List: brak Company size: medium

Address: 97–400 Bełchatów, ul. Bawełniana 17Voivodship: Lodz

Type of business: medical equipmentDescription of business activity: The company Yavo Ltd. is the Polish manufacturer of medical eqipment. The company was founded in 2000 and since then it has produced devices for infusion and transfusion. Since 2004 the production of surgical suture has started. Addition to the sales of medical equipment, the company also offers services for packaging and sterilization of medical products with ethylene oxide. The quality of both products and services is guaranteed by the quality management system for medical devices ISO 13485 and the CE certificates.Shareholders: Kantorski Andrzej Ireneusz – 63.55%, Patura Anna Maria – 18.22%, Maćkowiak Izabela Dorota – 18.22%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 57.0 –3 341.8 –1 475.5 325.8 501.5



Total assets 15 794.0 16 069.3 15 835.1 17 006.8 17 838.9

Equity 4 370.0 1 028.1 –447.4 490.9 992.4

Description of innovative activity: According to the 5A methodology, the company Yavo Ltd. is characterized by a very high assessment of process innovativeness, a high assessment of investment in innovative activity and the highest assessment of ability for financing of innovative projects from the EU funds.Company status: innovative company, investor in research and development, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

45.4 85

.8 108.

8 149.

7

157.

8

176.

8


05 06 07 08 09 10

9.7

8.6 10

.3

10.5

9.5




Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm Kielce S.A.

Assessment with 5A System: CCNNN www.cefarm.kielce.plPlace on the List of medical sector: 59 Established in: 1951Place on the 500’2010 List: not listed Company size: large

Address: 25–956 Kielce, ul. Jagiellońska 70Voivodship: Swietokrzyskie

Type of business: pharmaceuticalsDescription of business activity: History of the Pharmaceutical Supply Company Cefarm Kielce JSC dates back to 1953, then created Kielce Pharmacy Company, which in 1975 adopted the name Cefarm Kielce. The company is now the distributor of phar-maceutical products, prescription and OTC medicines and dietary supplements.Shareholders: Farmacol JSC – 86.10%, Others – 13.90%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 79 476.0 84 426.0 103 280.0 109 254.0 106 678.0 101 756.0

Equity 39 407.0 42 997.0 51 672.0 53 910.0 56 949.0 58 452.0

Description of innovative activity: According to the 5A methodology, the Pharmaceutical Supply Company Cefarm Kielce JSC is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment is CCNNN.

Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm Szczecin S.A.

Assessment with 5A System: NCNNN www.cefarm-szczecin.plPlace on the List of medical sector: 77 Established in: 1953Place on the 500’2010 List: not listed Company size: medium

Address: 70–812 Szczecin, ul. Pomorska 132Voivodship: Western Pomeranian

Type of business: pharmaceuticalsDescription of business activity: The main scope of activity of the Pharmaceutical Supply Enterprises Cefarm Szczecin JSC is a wholesale and retail sales of pharmaceutical, medical hygienie and cosmetic products. The company offer includes about 15 thousand items. The subject of sale are ready made medicines, homeopathic remedies, herbs and herbal preparations, sanitary materials and dressings, cosmetics, prescription substances and materials, disinfectants, medical equipment, auxiliary computer support articles and medicines not registered in Poland carried out under the direct import.The biggest market for Cefarm-Szczecin is a regional market area covering the voivodeships West Pomeranian and Lubusz. The wide range of the Cefarm Szczecin includes private pharmacies, patient healthcare units, clinics, Health Care Centres (ZOZ) and numerous wholesalers, health care facilities and numerous s retail audience. In addition, the company has 34 own outlets (phar-macies and pharmacy points).Shareholders: Farmacol JSC – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 72 052.0 82 451.0 97 230.0 110 550.0 119 691.0 115 811.0

Equity 24 938.0 29 648.0 42 856.0 48 363.0 54 146.0 61 913.0

Description of innovative activity: According to the 5A methodology, the pharmaceutical Supply Enterprises Cefarm Szczecin JSC is charcterized by a high assessment of process innovativeness level. The company innovativeness assessment is NCNNN.

05 06 07 08 09 10

304.

4

321.

4

347.

4

373.

8

423.

3

529.

3


05 06 07 08 09 10

296.

0

324.

6

353.

0

400.

0

465.

6

472.

7




Przychodnia Lekarska Medeo Henryka Mikuła Telenga Tomasz Matecki Barbara Elżbieta SchmidtJacek Szymaniak Sp.J.


Address: 61–397 Poznań, ul. Rzeczypospolitej 6Voivodship: Greater Poland

Type of business: hospital services and medical careDescription of business activity: The Clinical Surgery Unit Medeo Henryka Mikuła Telenga, Tomasz Matecki, Barbara Elżbieta Schmidt, Jacek Szymaniak General Partnership is a clincal surgery as well as a multi-specialty ambulatory care centre. The unit includes dermatological clinic (dermatology and venereology – specialized laboratory treatment), GP clinic, family medicine (treat-ment within primary health care), rheumatology clinic (rheumatology – specialized laboratory treatment), urology clinic (urology – specialized laboratory treatment) and ultrasound workshop with department of radiology and diagnostic ultrasound imaging.Shareholders: Mikuła Telenga Henryka Józefa – 25%, Matecki Tomasz Stefan – 25%, Schmidt Barbara Elżbieta – 25%, Szymaniak Jacek – 25%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets

Total assets 635.6 669.4 538.2

Equity 253.9 321.3 203.6

Description of innovative activity: According to the 5A methodology, the Clinic Surgery Medeo Henryka Mikuła Telenga Tomasz Matecki Barbara Elżbieta Schmidt Jacek Szymaniak Genral Parntership assessment of process innovativeness level is very highly rated. The company innovativeness assessment in the 5A system is NBNNN.

PZ Cormay S.A.

Assessment with 5A System: BBCNA www.pzcormay.plPlace on the List of medical sector: 5 Established in: 2006Place on the 500’2010 List: 35 Company size: medium

Address: 05–092 Łomianki, ul. Wiosenna 22Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: PZ Cormay JSC is a recognized manufacturer of high quality diagnostic reagents and distributor of world-class medical equipment. It produces in vitro tests for clinical chemistry, electrophoresis, hematology, coagulation and blood grouping. In addition, the company offers on the market automatic biochemical and hematology analyzers. The offer includes automated system for the analysis of parasitological and vacuum blood collection system. The company PZ Cormay Poland cur-rently has 5% market share in the field of clinical chemistry and 5% in terms of hematology, providing nearly two thousand labora-tories. The company has now in Poland 5% market share in the field of clinical chemistry and 5% in field of hematology, providing nearly two thousand laboratories. Diagnostic reagents and equipment are delivered to the laboratory door with a specialist trans-port. The company is Poland’s largest producer and exporter of diagnostic reagents.Shareholders: Tuora Tomasz – 23.64%, Ipopema TFI S.A. – 22.60%, Others – 53.76%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 1 728.0 1 420.0 2 956.0 6 130.0



Total assets 19 829.0 27 828.0 50 754.0 85 065.0

Equity 12 933.0 18 953.0 42 806.0 66 448.0

Description of innovative activity: According to the 5A methodology, the company PZ Cormay JSC is characterized by a very high assessment of market and process innovativeness, a high assessment of investment in innovative activity and the highest assessment of ability for financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is BBCNA.Company status: innovative company,investor in research and development, company listed on the Warsaw Stock of Exchange, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

4.1 4.

9

4.9


05 06 07 08 09 10

29.9

31.1 38

.5

61.9




PZ HTL S.A.

Assessment with 5A System: NCBNN www.htl.com.plPlace on the List of medical sector: 32 Established in: 1989Place on the 500’2010 List: 497 Company size: medium

Address: 03–230 Warszawa, ul. Daniszewska 4Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: PZ HTL JSC is a leading manufacturer of the laboratory eqipment. The company has over 30 years of experience in the design and manufacture of manual dispensing systems and laboratory equipment. The company offers single-channel automatic pipettes at variable and constant volume, multi-channel pipette, automatic pipette tips, pipettors, serological pipettes and dispensers syringe. The company has a certified quality management system according to ISO 9001:2008 for the manufacture design and sale of laboratory products. The company is an exporter, sells its products to 80 countries worldwide.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 16 987.3 17 493.9 22 424.3 45 519.0 50 206.5

Equity 14 442.9 14 394.8 18 409.5 25 121.5 31 090.7

Description of innovative activity: According to the 5A metodology, the company PZ HTL JSC Is characterized by a high asses-sment of process innovativeness level and a very high assessment of investment in innovative activity. The company innovative-ness assessment in the 5A system is NCBNN.Company status: innovative company, investor in research and development, patenting company

Read-Gene S.A.

Assessment with 5A System: NNBNC www.read-gene.comPlace on the List of medical sector: 39 Established in: 2008Place on the 500’2010 List: not listed Company size: small

Address: 71–253 Szczecin, ul. Akacjowa 2Voivodship: Western Pomeranian

Type of business: scientific research in the field of biotechnologyDescription of business activity: The company Read-Gene JSC is a biotechnological company. The main business segments of the company are chemoprevention (the use of natural or synthetic substances to inhibit, delay or reverse the cancer process), clinical trials (consisting of checking whether a potential medicines, preparation or medical technology is effective, safe and meets its primary objectives) and genetic testing. Read-Gene is an investor in research and development. In 2010, the company has released for this activity over 5.1 million PLN.Shareholders: Gen-Pat-Med Ltd. – 67.05%, Lubiński Jan – 7.15%, Adamed Sp. z o.o. – 5.93%, Others – 19.87%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –204.9 47.0 325.7 –399.2



Total assets 41.4 5 511.6 5 843.6 11 037.8

Equity –212.1 369.0 5 203.4 4 804.2

Description of innovative activity: According to the 5A methodology, the company Read-Gene JSC is characterized by a very high assessment of investment in innovative activity and a high assessment of ability for obtaining of financing innovative projects from the EU funds. The company innovativeness assessment in the 5A system is NNBNC.Company status: innovative company, investor in research and development, company listed on the NewConnect, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

25.5

25.5

25.9 30

.0

31.5


05 06 07 08 09 10

0.05

0.98

0.36




Roche Diagnostics Polska Sp. z o.o.

Assessment with 5A System: CCNNN www.rochediagnostics.plPlace on the List of medical sector: 49 Established in: 2000Place on the 500’2010 List: not listed Company size: medium

Address: 01–531 Warszawa, ul. Wybrzeże Gdyńskie 6bVoivodship: Mazovian

Type of business: medical equipmentDescription of business activity: The company Roche Diagnostics Ltd. is dealing in Poland with sales and distribution of medical products used in in vitro diagnostic, histopathological diagnosis of cancer and diabetes therapy. The company’s products help both patients and physicians to identify better the disease and also to monitor effectively the progress of the treatment. The ultimate goal of the company is to improve the quality of life of thousands of patients.Shareholders: Roche Finance Ltd. – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010




Intangible assets 530.4 1 274.1 703.6 407.2 236.6

Total assets 133 825.7 153 380.6 172 966.2 196 122.3 245 831.7 245 653.7

Equity 35 678.2 46 965.6 56 682.0 67 113.0 81 471.5 95 854.7

Description of innovative activity: According to the 5A methodology, Roche Diagnostics Polska Ltd. is characterized by a high assessment of market and process innovativeness level. The company innovtiveness level in the 5A system is CCNNN.

Salus International Sp. z o.o.

Assessment with 5A System: CCNNN www.salusint.com.plPlace on the List of medical sector: 47 Established in: 1991Place on the 500’2010 List: not listed Company size: medium

Address: 40–273 Katowice, ul. Pułaskiego 9Voivodship: Silesian

Type of business: pharmaceuticalsDescription of business activity: The company Salus International Ltd. is a distributor of pharmaceutical products and medical equipment. The company provides comprehensive services of the general and hospital pharmacies, wholesalers and dentists, while ensuring the welfare and health of patients. In 2000, the company began expanding into dental market. Currently, it supplies comprehensively dentists, dental wholesalers and shops with specialist medical supply throughout the country. Salus International supports over 5 000 dentists in the territory of Poland. It is also the creator of dental Salus Quatro online store.Shareholders: Żurek Aleksander Jan – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 78 969.4 89 059.8 101 785.2 123 405.7 136 905.5 147 299.8

Equity 9 689.7 10 868.2 14 644.4 13 990.1 16 209.5 20 196.6

Description of innovative activity: According to the 5A methodology, the company Salus International Ltd. is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment is CCNNN.

05 06 07 08 09 10

273.

8

321.

5

334.

7

366.

2

423.

1

467.

1


05 06 07 08 09 10

262.

6

329.

9

357.

2

385.

8

455.

9

522.

5




Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

Assessment with 5A System: NNNNC www.su.krakow.plPlace on the List of medical sector: 95 Established in: 1999Place on the 500’2010 List: not listed Company size: large

Address: 31–501 Kraków, ul. Kopernika 36Voivodship: Lesser Poland

Type of business: hospital services and medical careDescription of business activity: The Independent Public Health Care University Hospital in Krakow is the leading multi-specialist medical centre in the country. The main objective of the hospital is to ensure the comprehensive health care – from prevention through treatment to rehabilitation. At the University Hospital there are provided services such as ambulatory and stationary, highly specialized services in the field of health care, in the specialties represented by the clinical departments, establishments and hospital clinics. The hospital has 26 specialist clinical departments and 1300 stationary beds, 7 diagnostic and therapeutic facili-ties, nearly 60 profile clinics. During the year in the hospital is about 75 thousand patients from across Poland and the number of consultations provided in clinical outpatient exceeds 380 thousand.Shareholders: Local Municipal Council – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –26 275.4 –16 042.3 –28 610.6 11 293.2 –2 222.7


Intangible assets 1 163.4 688.4 243.2 410.4 125.6

Total assets 232 919.1 274 605.2 274 182.3 267 287.4 289 395.8

Equity 78 348.4 88 198.4 66 657.8 86 200.4 86 500.1

Description of innovative activity: According to the 5A methodology, the company Independent Public Health Care University Hospital in Krakow is characterized by a high assessment of ability for obtaining financing of the innovative projects from the EU funds. The company innovativeness assessment in the 5A system is NNNNC.Company status: beneficiary of national operational programmes of the European Union

Sanofi Aventis Sp. z o.o.

Assessment with 5A System: CCNNN www.sanofi-aventis.com.plPlace on the List of medical sector: 60 Established in: 1993Place on the 500’2010 List: not listed Company size: large

Address: 00–203 Warszawa, ul. Bonifraterska 17Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Sanofi Aventis Ltd. is a part of the global supplier of Sanofi-Aventis health services engaged in the exploration, production and distribution of medicines, that are intended to improve the health of patients around the world. In 2010 Sanofi-Aventis has spent on R&D over 4.39 mld EUR. Polish subsidiary of the world giant is one of the largest pharmaceutical company in the country. The Sanofi group in Poland includes, among others Nepentes JSC company, recognized in the industry, the Polish manufacturer of medicines and dermo-cosmetics and Genzyme, the manufacturer of medicines for rare diseases. Sano-fi Group in Poland employs more than 1.300 people, including about 200 in the manufacturing plant in Rzeszów.Shareholders: Sanofi Aventis JSC i Aventis Pharma JSC (Francja) – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 429 877.6 1 118 984.1 1 236 736.7 1 338 790.0 1 442 647.0 1 798 050.7




Total assets 273 450.6 570 559.9 582 522.9 594 890.9 679 527.7 1 072 631.0

Equity 206 478.7 287 298.6 321 778.4 392 944.3 449 032.8 444 127.2

Description of innovative activity: According to the 5A methodology, the company Sanofi Aventis Ltd. is characterized by a high assessment of market and process innovativeness level. The company innovativeness assessment in the 5A system is CCNNN.

05 06 07 08 09 10

266.

0

332.

3

387.

7

422.

6

416.

4


05 06 07 08 09 10

429.

9 1 11

9.0

1 23

6.7

1 33

8.8

1 44

2.6

1 79

8.1




Selvita S.A.

Assessment with 5A System: ACAAA www.selvita.comPlace on the List of medical sector: 2 Established in: 2007Place on the 500’2010 List: 3 Company size: medium

Address: 30–348 Kraków, ul. Bobrzyńskiego 14Voivodship: Lesser Poland

Type of business: scientific research in the field of biotechnologyDescription of business activity: Selvita JSC is the Polish research and development company, that provides comprehensive solutions in the field of biotechnology and bioinformatics to other R&D units. The company carries out its own projects to develop original chemical molecules of the therapeutic action, provides research and development services to the biotechnology and phar-maceutical industry, develops innovative and cost effective informatic solutions to accelerate research and reduce the risk of failure. The company participates in research projects both commercial and co-financed from public funds (Selvita is the beneficiary of the 7th Framework Programme of the European Union and national operational programmes). The company owns the company BioCen-trum Krakow performing services for preclinical studies, protein chemistry, crystallography and enzyme production.Shareholders: Przewięźlikowski Paweł – 47.77%, Sieczkowski Bogusław – 8.67%, Privatech Holdings Ltd. – 7.83%, Others – 35.73%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –2 778.0 –2 826.0 –1 611.0



Total assets 2 739.3 4 063.1 10 589.4

Equity 2 392.5 1 700.5 2 605.7

Description of innovative activity: According to the 5A methodology, the company Selvita JSC is characterized by the highest assessment of market innovativeness level, a high assessment of process innovativeness level, the highest assessment of invest-ment in innovative activity and ability for obtaining patents and the highest assessment of ability for obtaining the financing of innovative projects from the EU funds. The company innovaiveness assessment in the 5A system is ACAAA.Company status: innovative cmpany, investor in research and development, patenting company, beneficiary of the 7th Framework Programme of the European Union, beneficiary of national operational programmes of the European Union

Spółdzielnia Mechaników SMS

Assessment with 5A System: CCCNN www.sms.com.plPlace on the List of medical sector: 27 Established in: 1963Place on the 500’2010 List: 384 Company size: medium

Address: 02–673 Warszawa, ul. Konstruktorska 8Voivodship: Mazovian

Type of business: medical equipmentDescription of business activity: The Mechanics Cooperative SMS is mainly a manufacturer of steam sterilizers. The scope of activities also includes comprehensive solutions and supplies of disinfection and sterilization equipment with the additional equip-ment, such as technology furniture, water purification systems, steam generators, welding machines for sterilization packaging, and supplies used for sterilization. Equipment offered by SMS meets all requirements of the Polish and European applicable provi-sions.Shareholders: Cooperative members – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 103.9 245.5 75.0 47.2 254.5



Total assets 9 604.3 10 476.5 10 370.8 9 712.4 10 173.2

Equity 2 686.3 2 876.8 2 844.7 2 885.6 3 181.8

Description of innovative activity: According to the 5A methodology, the Mechanics Cooperative SMS is characterized by a high assessment of market and process innovativeness level and a high assessment of investment in innovative activity. The company innovative assessment in the 5A system is CCCNN.Company status: innovative company, investor in research and development

05 06 07 08 09 10

0.58

3.31

8.85


05 06 07 08 09 10

8.6 10

.8

9.2 10

.0 10.8




Steripack medical Poland Sp. z o.o.

Assessment with 5A System: CBNNC www.steripack.plPlace on the List of medical sector: 31 Established in: 2005Place on the 500’2010 List: 470 Company size: medium

Address: 55–220 Jelcz Laskowice, Łęg, ul. JapońskaVoivodship: Lower Silesian

Type of business: medical equipmentDescription of business activity: Steripack Medical Poland Ltd. is a distributor and is a part of the world manufacturer of sterilized packaging for the medical industry. The company is an investor in research and development.Shareholders: Steripack International Ltd. – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –3 711.4 1 137.6 1 217.9



Total assets 13 113.0 14 036.0 14 092.1

Equity –414.2 1 814.5 3 032.5

Description of innovative activity: According to the 5A methodology, the company Steripack Medical Poland Ltd. is characterized by a high assessment of market innovativeness level, a very high assessement of process innovativeness level and a high asses-sment of ability of obtaining the financing from the EU funds. The company innovtiveness assessment in the 5A system is CBNNC.Company status: innovative company

Stolter Sp. z o.o.

Assessment with 5A System: CBNNC www.stolter.plPlace on the List of medical sector: 30 Established in: 1992Place on the 500’2010 List: 469 Company size: medium

Address: 86–212 Stolno, ul. Grubno 63Voivodship: Kuyavian-Pomeranian

Type of business: medical equipmentDescription of business activity: Stolter Ltd. is a manufacturer of furniture and medical equipment. The company designs and manufactures hospital beds with additional equipment, cabinets and bedside tables, children and neonatal beds, specialized trucks to transport patients, gynecological chairs, tables and chairs for research, treatment and surgical tables and hospital furniture. The company’s offer is addressed to the public and private health care providers, clinics, long-term care homes, as well as specialized surgeries. Stolter is a part of the Stiegelmeyer Group – the leading European manufacturer of medical furniture.Shareholders: Joh Stiegelmeyer Co GmbH – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 503.5 –740.9 –953.7 510.7 4 247.8 7 461.0


Intangible assets 1 184.9 1 004.4 922.8 826.8 714.9

Total assets 13 862.4 18 325.0 17 516.8 24 442.8 26 303.4 48 706.9

Equity 5 265.4 5 485.6 8 034.9 8 698.4 15 371.1 26 019.9

Description of innovative activity: According to the 5A methodology, the company Stolter Ltd. is characterized by a high asses-sment of market innovativeness level, a very high assessment of process innovativeness level and a high assessment of ability for obtaining the financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is CBNNC.Company status: innovative company, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

4.9

12.7 13

.9


05 06 07 08 09 10

33.4

35.7

35.5 42

.2 59.1 64.6




Swissmed Centrum Zdrowia S.A.

Assessment with 5A System: CNBNC www.swissmed.com.plPlace on the List of medical sector: 23 Established in: 1996Place on the 500’2010 List: 320 Company size: medium

Address: 80–215 Gdańsk, ul. Wileńska 44Voivodship: Pomeranian

Type of business: hospital services and medical careDescription of business activity: The company Swissmed Health Centre JSC provides a full range of medical services from family medicine to hospital treatment. The company develops a network of clinics and hospitals in Gdańsk, Gdynia, Pruszcz Gdań-ski and Warszawa. It provides services of magnetic resonance, computer tomography, echocardiography, ultrasound or X-ray flu-oroscopy. Swissmed offer to corporate customers include a wide range of medical packages from the occupational health packa-ges including comprehensive outpatient care. For individuals in the subscription, the company offers a wide range of medical services from consultation with medical specialists to laboratory and diagnostic tests, internist medical care and pediatricians.Shareholders: Hangartner Bruno – 40.87%, Theo Frey East – 7.97%, TF Holding AG – 6.55%, Prokom Investments S.A. – 5.23%, Others – 39.38%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –4 324.0 –11 768.0 –4 236.0 –2 392.0 –1 068.0 –463.0

Capitalized value of R&D expenses 1 950.0

Intangible assets 2 138.0 92.0 245.0 193.0 488.0 400.0

Total assets 57 401.0 62 435.0 54 681.0 53 539.0 53 800.0 80 323.0

Equity 9 364.0 29 283.0 25 047.0 19 667.0 23 931.0 42 779.0

Description of innovative activity: According to the 5A methodology, the company Swissmed Health Centre JSC is characterized by a high assessment of market innovativeness level, a very high assessment of investment in innovative activity and a high assessment of ability for obtaining the financing of the projects from the EU funds. The company innovativeness assessment in the 5A system is CNBNC.Company status: innovative company, investor in research and delvelopment, company listed on the Warsaw Stock Exchange, beneficiary of national operaional programmes of the European Union

Tarchomińskie Zakłady Farmaceutyczne Polfa S.A.

Assessment with 5A System: NNBNN www.polfa-tarchomin.com.plPlace on the List of medical sector: 54 Established in: 1945Place on the 500’2010 List: not listed Company size: large

Address: 03–176 Warszawa, ul. A. Fleminga 2Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Polfa Tarchomin JSC is one of the largest generic companies operating in Poland. The company is a leader in the field of anti-infectious medicines. It has an important market position In the insulin group, psychotropic drugs and dermatological preparations. The company offers more than 100 medicinal products used for effective treatment of the people. All products are available in different forms and doses providing optimal medical therapy and minimal side effects in the patient. Polfa Tarchomin specializes in prescription medicines. Medicines without a prescription supplement the offered medicines.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 7 586.8 3 291.6 –32 524.2 –12 760.0 5 297.0 –17 414.8

Capitalized value of R&D expenses 8 337.1 5 266.1 3 633.1 931.3 834.5

Intangible assets 8 347.8 5 269.9 3 638.7 1 035.1 937.9

Total assets 379 917.0 380 423.6 363 040.9 324 025.5 343 815.3 334 045.8

Equity 268 348.4 268 000.6 235 476.4 218 911.2 223 733.3 203 356.3

Description of innovative activity: According to the 5A methodology, the company Polfa Tarchomin JSC Is characterized by a very high assessement of investment in innovative activity. The company innovativeness assessment in the 5A system is NNBNN.Company status: innovative company, investor in research and development, patenting company

05 06 07 08 09 10

12.1 17

.1 24.0 31

.9

45.3

48.1


05 06 07 08 09 10

304.

3

288.

7

240.

5

219.

2

227.

9

214.

9




Technopharma Sp. z o.o.

Assessment with 5A System: NCNNN www.vita-medical.plPlace on the List of medical sector: 91 Established in: 2000Place on the 500’2010 List: not listed Company size: small

Address: 02–390 Warszawa, ul. Grójecka 132Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Technopharma Ltd. is a clinic, the dental clinic and centre of multi-specialized ambulatory care.Shareholders: Bagniewski Marek – 50%, Rotenberg Aron – 50%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 7.3 606.7

Net financial income (profit/loss) 172.6


Intangible assets

Total assets 1 226.3

Equity –563.1

Description of innovative activity: According to the 5A methodology, the company Technopharma Ltd. is characterized by a high assessment of process innovativeness level. The company innovativeness assessment is NCNNN.Company status: patenting company

Telemedycyna Polska S.A.

Assessment with 5A System: BCNNN www.telemedycynapolska.plPlace on the List of medical sector: 42 Established in: 2008Place on the 500’2010 List: not listed Company size: small

Address: 40–142 Katowice, ul. Modelarska 12Voivodship: Silesian

Type of business: hospital services and medical careDescription of business activity: Telemedicine Poland JSC operates on the telemedical services market throughout Poland. The company specializes in the cardiac care via phone or internet from anywhere around the clock.The company has achieved market leadership on the telecardiology in Poland. The first service provided by Telemedicine Poland JSC is Kardiotele service for individu-al patients. The company began providing Kardiotele services for companies and public centres. The service is to provide employ-ees and customers with first aid in an emergency. Telemedicine Poland JSC is equipped with Kardiotele Life Pack, which includes the camera to perform ECGs on the phone. Currently, the company is going to deploy new Kardiotele services for health centres and doctors.Shareholders: TLP Inwest Ltd. – 36.20%, Plaza Ireneusz – 24.13%, Orzeł Janusz – 10.34%, BBI Seed Fund Ltd. Fundusz Kapitałowy – 10%, PZU Asset Management JSC – 5.17%, Others – 14.16%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –325.7 72.9 103.5



Total assets 605.4 843.9 2 610.8

Equity 154.5 502.4 1 908.5

Description of innovative activity: According to the 5A methodology, the company Telemedicine Poland JSC is characterized by a very high assessment of market innovativeness level and a high assessment of process innovativeness level. The company innovativeness assessment in the 5A system is BCNNN.Company status: company listed on NewConnect

05 06 07 08 09 10

0.6


05 06 07 08 09 10

0.57

1.41

2.19




Temapharm Sp. z o.o.

Assessment with 5A System: NNNNB www.temapharm.comPlace on the List of medical sector: 71 Established in: 2005Place on the 500’2010 List: not listed Company size: small

Address: 02–091 Warszawa, ul. Żwirki i Wigury 81Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: The company Temapharm Ltd. is the Polish pharmaceutical company established in 2005. It produces gynecologicals, neurological, dermatological and gastrointestinal medicines, both prescription and OTC ones. The com-pany has a modern research and development laboratory, in which a team of experienced experts develops novel medicines with documentation required for their registration. The company has a full line for the design of solid forms of medicines forms such as tablets, coated tablets, capsules, pellets, granules and powders.Shareholders: Alkmaar Export B.V. – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –5 019.7 –10 991.5 –338.1 –5 013.5

Capitalized value of R&D expenses 2 267.2 5 112.2


Total assets 25 647.2 21 985.6 27 258.1 29 948.4

Equity 15 768.1 4 776.6 4 438.5 –575.0

Description of innovative activity: According to the 5A methodology, the company Temapharm Ltd. is characterized by a very high assessment of ability for obtaining the financing form the EU funds. The company innovativeness assessment in the 5A system is NNNNB.Company status: innovative company, investor in research and development

Tomograf Sp. z o.o.

Assessment with 5A System: NCNNN www.tomograf.torun.plPlace on the List of medical sector: 87 Established in: 2004Place on the 500’2010 List: not listed Company size: small

Address: 87–100 Toruń, ul. Stefana Batorego 17, 19Voivodship: Kuyavian-Pomeranian

Type of business: hospital services and medical careDescription of business activity: The company Tomograf Ltd. is a company that provides medical services in the field of diagno-stic imaging methods, magnetic resonance imaging and multidetector computed tomography. The company provides diagnostic testing in an open magnetic resonance imaging, which allows study of patients with the presence of metal parts in the body, as well as suffering from claustrophobia. In a closed system the company performs highly specialized magnetic resonance imaging.Shareholders: Narloch Danuta Elżbieta – 25%, Ochociński Jarosław – 25%, Nowak Lech Krzysztof – 25%, Czyszkowski Przemysław – 25%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 827.7 1 888.1 1 155.6


Intangible assets

Total assets 4 454.2 4 742.7 9 785.8

Equity 1 190.9 2 041.0 2 209.0

Description of innovative activity: According to the 5A metodology, the company Tomograf Ltd. is characterized by a high assessment of process innovativeness level. The company innovativeness assessment in the 5A system is NCNNN.

05 06 07 08 09 10

1.1 5.

1 11.6

41.6

27.8


05 06 07 08 09 10

3.7

6.2

5.5




Towarzystwo Przemysłowo Handlowe Secfarm Sp. z o.o.

Assessment with 5A System: NNBNN www.secfarm.com.plPlace on the List of medical sector: 56 Established in: 1993Place on the 500’2010 List: not listed Company size: small

Address: 04–502 Warszawa, ul. Korkowa 120Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Industrial and Commercial Company SecFarm Ltd. was established in March 1993. The compa-ny has licenses for the manufacture of medicinal products in the form of sterile solid and semi-solid. At the beginning the compa-ny produced contraceptive pessaries and suppositories pain, now the offer is expanded by ointment against hemorrhoids, ointment against psoriasis and seborrheic inflammation. The company is a founding member of the Polish Chamber of Pharmaceutical Industries and Medical Equipment Polfarmed. It also belongs to the Chamber of Commerce Pharma Poland.Shareholders: Rostafińska Barbara – 34%, Jench Elżbieta – 20%, Grzywińska-Kletsch Krystyna – 18%, Kletsch Wolfgang – 18%, Strogulski Marcin – 10%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 3 455.6 4 845.0 4 739.0 1 354.6 625.6

Net financial income (profit/loss) 1 815.7 1 288.6 –2 435.7 –263.3



Total assets 5 065.6 4 894.6 1 822.8 1 613.7

Equity 4 446.3 4 381.1 1 607.8 1 344.5

Description of innovative activity: According to the 5A methodology, the industrial and Commercial Company Secfarm Ltd. is characterized by a very high assessment of investment in innovative activity. The company innovative assessment in the 5A system is NNBNN.Company status: investor in research and development

Tricomed S.A.

Assessment with 5A System: BCACN www.tricomed.comPlace on the List of medical sector: 9 Established in: 1995Place on the 500’2010 List: 111 Company size: small

Address: 93–493 Łódź, ul. Świętojańska 5/9Voivodship: Lodz

Type of business: medical equipmentDescription of business activity: Tricomed Company JSC is a manufacturer of orthopedic equipment, dressing material, bioma-terials used in surgery, neurosurgery and urology. The company manufactures prosthetic skull, eye socket bone, vascular prosthe-ses, ligaments and tendons. The manufacturer produces urological inserts and compression materials for the treatment of after-burn scars. The company’s products are considered as one of the most innovative on the market, including product CODUBIX CT – skull prosthesis was awarded by the Institute of Economic Sciences as the most innovative product in Poland in 2010.Shareholders: Toruńskie Zakłady Materiałów Opatrunkowych TZMO S.A. – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 42.5 237.0 46.0 765.0 934.0 –581.0



Total assets 3 342.0 3 600.0 3 611.0 4 615.0 5 771.0 5 739.0

Equity 2 175.0 3 015.0 2 983.0 3 728.0 4 663.0 3 147.0

Description of innovative activity: According to the 5A methodology, the company Tricomed JSC is characterized by a very high assessment of market innovativeness level, a high assessment of process innovativeness level, the highest assessment of invest-ment in innovative activity and a high assessment of ability for obtaining patents. The company innovativeness assessment in the 5A system is BCACN.Company status: innovative company, investor in research and development, patenting company

05 06 07 08 09 10

3.5

4.8

4.7

1.4

0.6


05 06 07 08 09 10

3.6 3.8

3.6

5.1 5.

6

5.7




US Pharmacia Sp. z o.o.

Assessment with 5A System: NCCNN www.usp.plPlace on the List of medical sector: 40 Established in: 1995Place on the 500’2010 List: not listed Company size: medium

Address: 50–507 Wrocław, ul. Ziębicka 40Voivodship: Lower Silesian

Type of business: pharmaceuticalsDescription of business activity: US Pharmacia Ltd. is the Polish company, which has set the trends in the market of medicines available over the counter (OTC) for more than 20 years. The company was established in the United States as US Pharmacia and now it is a group of some companies operating in the field of health care. The company is the leader of medicines available over the counter (OTC) in Poland. The company has its own laboratories and R&D department. In Wroclaw there is the manufacturing facility, which provides an average of more than 140 million individual packages per year. The main office is located in Warszawa. The company’s offer includes such medicines as Ibuprom, Apap, Gripex, Stoperan, Vigor, Verdin and Xenna. The company’s port-folio has over 100 products.Shareholders: Medvic S.A.R.L. (Luxembourg) – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 2 869.3 317.4

Intangible assets 49 766.4 2 392.7 11 350.6 8 709.8

Total assets 204 827.0 199 589.0 201 114.0 339 535.2 386 588.6 265 709.4

Equity 101 012.5 104 541.0 112 176.2 230 054.1 290 880.6 69 954.3

Description of innovative activity: According to the 5A methodology, the company US Pharmacia is characterized by a high assessment of process innovativeness level and a high assessment of investment in innovative activity. The company innovative-ness assessment in the 5A system is NCCNN.Company status: investor in research and development

Voxel S.A.

Assessment with 5A System: CCNNC www.voxel.plPlace on the List of medical sector: 45 Established in: 2005Place on the 500’2010 List: not listed Company size: small

Address: 30–663 Kraków, ul. Wielicka 265Voivodship: Lesser Poland

Type of business: hospital services and medical careDescription of business activity: Voxel Company JSC is one of the market leaders in Poland diagnostic imaging by offering a comprehensive range of services and products associated with the use of the latest technological advances in medicine. The company provides services in the field of diagnostic imaging and teleradiology outsourcing and provides IT systems for hospitals and diagnostic centers and deals with the implementation of projects fitting the diagnostic laboratory. The company brings together a unique team of medical imaging professionals with extensive clinical experience and recognized scientific achievements. By working closely with major suppliers of medical equipment, Voxel MCD labratories have modern equipment and provide specialized services at the highest level.Shareholders: Voxel International S.a r.l. – 53.16%, Ipopema TFI JSC – 17.07%, Others – 29.77%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 373.5 2 601.9 49.7


Intangible assets 1 146.1 1 221.8

Total assets 47 484.9 57 231.4 148 429.1

Equity 24 711.4 27 288.8 68 127.9

Description of innovative activity: According to the 5A methodology, the company Voxel JSC is characterized by a high asses-sment of market and process innovativeness level and a high assessment of ability of obtaining the financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is CCNNC.Company status: beneficiary of national programmes of the EU

05 06 07 08 09 10

353.

3

360.

7 519.

8 715.

0

481.

7

488.

2


05 06 07 08 09 10

14.6

31.3 36

.6




Warszawskie Zakłady Farmaceutyczne Polfa S.A.

Assessment with 5A System: CBBNN www.polfawar.com.plPlace on the List of medical sector: 10 Established in: 1824Place on the 500’2010 List: 133 Company size: large

Address: 01–207 Warszawa, ul. Karolkowa 22, 24Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: Polfa Warszawa JSC is one of the largest pharmaceutical company, that offer more than 140 types of medicines. The company’s products are deliverd both to the domestic market and are exported to dozens of countries around the world. The company is a part of the ZF Polpharma JSC.Shareholders: ZF Polpharma JSC – 85,14%, Others – 14,86%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010



Capitalized value of R&D expenses 2 965.2 3 088.8 2 443.2 1 305.3


Total assets 413 734.0 425 622.0 427 882.0 451 616.8 451 724.9 473 020.2

Equity 358 020.0 365 529.0 371 604.0 378 291.5 385 198.1 397 762.5

Description of innovative activity: According to the 5A methodology, Warsaw Pharmaceutical Works Polfa JSC is characterized by a high assessement of market innovativeness level, a very high assessement of process innovativeness level and a very high assessment of investment in innovativeness activity. The company innovativeness assessment is CBBNN.Company status: innovative company, investor in research and development

Wiki met Sp. z o.o.

Assessment with 5A System: NCNNN www.wikimet.comPlace on the List of medical sector: 81 Established in: 1992Place on the 500’2010 List: not listed Company size: medium

Address: 63–600 Kępno, ul. Krążkowy 167Voivodship: Greater Poland

Type of business: medical equipmentDescription of business activity: Wiki Met Ltd. is a manufacturer of beds used in the medical care.Shareholders: Joh Stiegelmeyer Co GmbH – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 828.6 1 998.5 1 003.2 6 992.4 3 491.4



Total assets 7 660.7 10 855.7 13 601.8 19 265.2 21 269.2

Equity 1 549.8 3 548.3 4 551.4 11 543.8 6 698.6

Description of innovative activity: According to the 5A methodology, the company Wiki Met Ltd. is characterized by a high assessment of process innovativeness level. The company innovativeness assessment in the 5A system is NCNNN.

05 06 07 08 09 10

282.

8

292.

6

290.

0

336.

2

321.

6

364.

4


05 06 07 08 09 10

29.6 37

.9 45.4

49.0

48.1




Wojewódzki Szpital Specjalistyczny we Wrocławiu

Assessment with 5A System: ABACB www.wssk.wroc.plPlace on the List of medical sector: 4 Established in: 1984Place on the 500’2010 List: 21 Company size: large

Address: 51–124 Wrocław, ul. H. Kamieńskiego 73aVoivodship: Lower Silesian

Type of business: hospital services and medical careDescription of business activity: The Provincial Specialist Hospital in Wrocław is a modern fitted base. It has a highly qualified staff, that uses modern surgical techniques and treatment and care standards. The hospital treats in the closed and open care system more than 100.000 patients a year. All children brought into the world in this hospital are subjected to a full screaning examination: in addition to routine metabolism, also hearing and vision tests. Thanks to modern medical equipment, the doctors of the Department of Ophthalmology perform neonatal laser sight-saving treatments in cases of retinopathy of prematurity and the Department of Hearing Prosthesis enables early testing and supply of newborn child in a hearing aid. The hospital has the status of research and development facility and is a beneficiary of the national and operational programmes of the Europeann Union (the WROVASC programme is financed from the EU funds under the Operational Programme Innovative Economy 2007–2013).Shareholders: Local community council – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 70 294.0 83 623.0 109 512.0 126 974.0 156 449.0 195 236.0

Equity 59 989.0 69 884.0 83 328.0 100 563.0 124 714.0 141 129.0

Description of innovative activity: According to the 5A methodology, the company Provincial Specialist Hospital in Wrocław is characterized by the highest assessment of market innovativeness level, a high level of assessment of process innovativeness level, the highest assessment of investment in innovative activity, a high assessment of ability of obtaining the financing of inno-vative projects form the EU funds. The company innovativeness assessment in the system is ABACB.Company status: innovative company, investor in research and development, beneficiary of national and operatinal programmes of the European Union

Wrocławski Medyczny Park Naukowo-Technologiczny Sp. z o.o.

Assessment with 5A System: NNNNC www.parkmedyczny.plPlace on the List of medical sector: 99 Established in: 2005Place on the 500’2010 List: not listed Company size: small

Address: 53–135 Wrocław, ul. Kutnowska 1, 3Voivodship: Lower Silesian

Type of business: scientific research in the field of biotechnologyDescription of business activity: Wrocław Scientific and Technological Medical Park Ltd. is a business sourroundings institution, that is the point of contact between scientific and business circles and local community. It is also the initiator and coordinator of the new project „National e-Health Cluster”. This project brings together themes of modern ICT technologie in health care, both in management and in the field of telemedicine support systems of care.Shareholders: Institute of Management and Self-Management Ltd. – 32.72%, Others – 67.28%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 963.4 979.5 1 921.0 1 741.4

Net financial income (profit/loss) –188.1 753.0


Intangible assets 221.7 107.1

Total assets 6 936.6 7 398.8

Equity 1 779.9 2 808.4

Description of innovative activity: According to the 5A methodology, the company Wrocław Scientific and Technological Medical Park Ltd. is characterized by a high assessment of ability of obtaining the financing of innovative projects form the EU funds. The company innovativeness assessment in the 5A system is NNNNC.Company status: innovative company, beneficiary of national operational programmes of the European Union

05 06 07 08 09 10

67.1 78

.5 94.5 12

6.8

142.

0

160.

9


05 06 07 08 09 10

0.96

0.98

1.92

1.74




Wrocławskie Zakłady Zielarskie Herbapol S.A.

Assessment with 5A System: NCNNN www.herbapol.plPlace on the List of medical sector: 78 Established in: 1993Place on the 500’2010 List: not listed Company size: large

Address: 50–951 Wrocław, ul. Św. Mikołaja 65, 68Voivodship: Lower Silesian

Type of business: pharmaceuticalsDescription of business activity: The Wrocław Herbal Works Herbapol JSC specializes in production of the pharmaceutical pro-ducts on the basis of herbal raw materials. The company is the largest manufacturer of herbal medicines in Poland. From more than 50 years, the company has introduced to the market the modern herbal preparations combining the achievements of natural medicine and latest technologies used in production of medicines.

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010





Total assets 131 824.3 144 470.1 150 579.7 157 677.0 157 242.2 161 751.2

Equity 114 174.0 126 453.9 124 941.4 131 610.9 131 616.3 133 916.8

Description of innovative activity: According to the 5A methodology, the Wrocław Herbal Works Herbapol JSC is characterized of a high assessment of process innovativeness level. The company innovativeness level in the 5A system is NCNNN.Company status: investor in research and development

Zakład Badawczo-Wdrożeniowy Ośrodka Salmonella Immunolab Sp. z o.o.

Assessment with 5A System: NNNNC immunolab.com.plPlace on the List of medical sector: 92 Established in: 1999Place on the 500’2010 List: not listed Company size: medium

Address: 81–451 Gdynia, ul. Zwycięstwa 96Voivodship: Pomeranian

Type of business: pharmaceuticalsDescription of business activity: The principal activities of the Research and Implementation Department Immunolab Salmonella Centre Ltd. is the production and sale of diagnostic formulations in the form of sera for diagnosis of serotype Salmonella bacteria. The company offers high-quality organic products for health and veterinary services in Poland, as well as for research institutes individual orders. The company is an investor in research and development and a beneficiary of national operational programmes of the European Union.Shareholders: Głośnicki Krzysztof, Lieder Dorota – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010

Net sales revenues 345.6 366.3

Net financial income (profit/loss) 13.1 22.6


Intangible assets 13.8 12.3

Total assets 149.1 171.5

Equity 35.7 58.3

Description of innovative activity: According to the 5A methodology, the Research and Implementation Department Immunolab Salmonella Centre Ltd. is characterized by a high assessment of ability of obtaining the financing of innovative projects from the EU funds. The company innovativeness assessment in the 5A system is NNNNC.Company status: innovative company, investor in research and development, beneficiary of national and operational programmes of the European Union

05 06 07 08 09 10

87.8 91

.9

92.5

88.8

99.1

99.0


05 06 07 08 09 10

0.35 0.37




Zakłady Farmaceutyczne Pliva Kraków S.A.

Assessment with 5A System: NCNNN www.pliva.plPlace on the List of medical sector: 76 Established in: 1931Place on the 500’2010 List: not listed Company size: large

Address: 31–546 Kraków, ul. Mogilska 80Voivodship: Lesser Poland

Type of business: pharmaceuticalsDescription of business activity: The company Teva Polska Ltd. is one of the leaders on the reproductive medicines market in Poland. Among the nearly 500 products, there are include analgesics, anti-inflammatory, anti-infectives medicines for use in dise-ases of the cardiovascular system, central nervous system disorders, transplantation, oncology and dermatology. The Teva Group in Poland, employing over 1500 staff, consists of two modern production facilities with 80-year tradition in Kraków and Kutno. The Polish factories are manufacturing prescription mediciness and OTC (over the counter) medicines such as Aviomarin or Flegamina and dietary supplements such as Hepatil or Vibovit. The company is a part of Teva Pharmaceutical Industries Ltd, a company listed on the NASDAQ, the global leader in the pharmaceutical industry.Shareholders: TEVA Pharmaceutical Industries Ltd. – TEVA Pharmaceutical Europe B.V. (Utrecht, The Netherlands) (Izrael) – 99.9%, inni – 0.1%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 3 508.0 23 397.0 –71 580.0 –26 918.0 73 004.3



Total assets 542 428.0 553 780.0 505 804.0 479 263.0 533 943.7

Equity 469 548.0 444 233.0 372 653.0 345 735.0 418 633.1

Description of innovative activity: According to the 5A methodology, the Pharmaceutical Works Pliva Kraków JSC is characteri-zed by a high assessment of process innovativeness level. The company innovativeness assessment in the 5A system is NCNNN.Company status: patenting company

Zakłady Farmaceutyczne Polfa Łódź S.A.

Assessment with 5A System: NCNNA www.polfa-Łódź.com.plPlace on the List of medical sector: 37 Established in: 1945Place on the 500’2010 List: not listed Company size: medium

Address: 91–002 Łódź, ul. Drewnowska 43, 55Voivodship: Lodz

Type of business: pharmaceuticalsDescription of business activity: The Pharmaceuital Works Polfa Łódź JSC specializes in creation of the highest quality medicinal products. The company is one of the largest medicine manufacturers, dietary supplements and cosmetics in Poland. Every year the 5 million product packaging is delivered to the market. The Polfa Łódź offer includes more than 50 different preparations. The company is a leading manufacturer of calcium preparations based on the best absorbed form of calcium. The Polfa offer includes biocidal products, disinfectant lotions and powders for surgical and hygienic hand washing and medical instruments washing.Shareholders: Employees – 100%

Finan

cial d

ata

(thou

sand

PLN

) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) –2 266.0 –4 509.0 –2 709.2 95.8 121.0


Intangible assets 151.5 153.6 125.0 23 490.4 22 018.4

Total assets 25 829.7 20 551.1 33 882.0 60 817.0 70 513.8

Equity 19 668.6 15 133.3 –3 624.0 12 850.7 20 791.6

Description of innovative activity: According to the 5A methodology, the Pharmaceutical Works Polfa Łódź JSC is characterized by a high assessment of process innovativeness level and the highest assessment of ability of obtaining the financing of innovati-ve projects from the EU funds. The company innovtiveness assessment in the 5A system is NCNNA.Company status: patenting company, beneficiary of national and operational programmes of the European Union

05 06 07 08 09 10

411.

0

441.

3

478.

9

570.

3

586.

8


05 06 07 08 09 10

17.5 21

.3

23.6

41.3

43.3




05 06 07 08 09 10

6.76.98.

5

8.3

8.2

6.8


ExPLANATIoN To DESCrIPTIoN oF INNoVATIVE ComPANIES IN THE mEDICAL SECTor

Description card of an innovative companyABC Sp. z o.o.

Assessment with 5A System: NNCNC www.abc.plPlace on the List of medical sector: 23 Established: 1990Place on the 500’2010 List: not listed Company size: small

Address: 00–111 Warszawa, 123 Alfabetowa Str.Voivodship: Mazovian

Type of business: pharmaceuticalsDescription of business activity: ABC Ltd. company is a production company, specializing in production and distribution of pharmaceuticals.Shareholders: Abecadło JSC – 100%

Fina

ncia

l dat

a (th

ousa

nd P

LN) 2005 2006 2007 2008 2009 2010


Net financial income (profit/loss) 144.9 353.9 –64.5 –853.8 –931.6 –936.1



Total assets 6 272.5 6 815.4 6 564.0 6 324.2 5 687.6 3 658.7

Equity 4 724.8 5 078.6 5 014.1 3 573.5 2 641.9 1 084.1

Description of innovative activity: According to the 5A methodology, the ABC JSC company is characterized by a high asses-sment of investment in innovative activity and a high assessment of ability for obtaining the financing of innovative projects from the EU funds.The company innovativeness assessment in the 5A system is NNCNC.Company status: innovation company, investor in research and development, beneficiary of national programme of the EU

ExplanationBasic information about the company1.

Company name�� ,Website�� ,Year of establishment�� ,Company size�� – assessment of the company size according to the employment criterion i.e. if the latest available employment in the period 2005–2010 was in the range of <1;49> – small company, <50;249> – medium com-pany, above 250 – large company,Company address�� (code, town, street, number, voivodship),Type of business�� – separate sector according to five digits of the NACE based Polish Classification of Activities (PKD 2007), assorted by expert method, definition of sectors in table on page 75,Description of company activity �� – short description of basic activity of the company,Shareholders �� – information of the majority shareholders or the company shareholders,

Place of company in the rankings2. Assessment in the 5A System �� – the company innovativeness assessment in the 5A system, description of metho-dology assessment is included in the Glossary to the Report,Place on the List of the medical sector �� – place in ranking of the 100 most innovative companies of the medical sector 2010,Place on the 500’2010 List �� – specifies the place on the List of the most innovative companies in Poland in 2010, developed by the MSN Scientific Network and INE PAN.

Financial data3. Table „Financial data” – contains a set of financial characteristics of a company in the 2005–2010 period. The level of filling the table depends on data availability.

12

4

5

3



The table presented in sequence:Net sales revenues,��

Net financial income (profit/loss),��

Capitalized value of R�� &D expenses,Intangible assets,��

Total assets,��

Equity.��

Diagram „Sales revenues” – diagram presents the company net sales revenues in the 2005–2010 period (data in mln PLN),

Innovative activity of the company4. Description of innovative acivity of the company �� – shows the description of the 5A assessment indicated under the company name in the field “Assessment in the 5A System”.

Company status5. Innovative company �� – company covered by the innovativeness research of the MSN Scientific Network and INE PAN, holding an assessment in the 5A system in the period of the latest 3 years,Investor in research and development�� – company showing investment in research and development in the 2007–2010 period,Patenting company �� – company showing patents granted by the Polish Patent Office in 2004–2010 period, or European or American patents in 2008–2010 period,Company listed on Warsaw Stock Exchange �� – company listed on Warsaw Stock Exchange at the end of 2010,Company listed on NewConnect�� – company listed in alternative NewConnect trade system at the end of 2010,Beneficiary of the 7. Framework Programme of the European Union�� – company holding a contract in the 7. Framework Programme of the European Union in the 2007–2010 period,Beneficiary of the national operational programmes of the European Union�� – contracting company in national operational programmes (OP) in the 2007–2010 period (OP Innovative Economy, OP Human Resaurces, OP Infrastructure and Environment, OP Development of Eastern Poland, Regional Operational Programmes).



The research program on innovativeness of the Polish economy was launched in 2005. Its indirect goal was and is to stimulate innovative processes in the Polish economy and to show national achievements in the field of innovation, as well

as to identify companies most focused on development. Within its framework a num-ber of projects can be specified which merit special attention.

Report on Innovativeness of the Polish Economy

Between 2005 and 2012 Institute of Economics of the Polish Academy of Sciences published seven reports on innovativeness in Poland. They con-tain a total of 205 original articles and 2012 pages. Their authors are experts representing the leading research centres in the field of innovation in Poland. Prof. Tadeusz Baczko is the scientific editor of all publications.

An integral part of each Report is The List of the 500 Most Innovative Companies in Poland. The winners of the ranking, have been already rewar-ded with this title of the most innovative company in Poland seven times. For the first time the awards ceremony took place on the gala on 13th December 2005 in the Main Hall of the Warsaw Stock Exchange. Since then, the formula of awarding ceremony has expanded to include regional meetings. They took place in Gdańsk, Łódź, Katowice, Poznań, Sopot and Wrocław. In total, more than 2 thousand people participated therein. Since 2009 the awards ceremonies have been held in the Mirror Room of the Staszic Palace in Warszawa, seat of the Polish Academy of Sciences.

The Ministry of Science and Higher Education of the Republic of Poland assessed that the innovation galas were an important achievement in the promotion of science. A honorary patronage over the galas was taken, by the representatives of the European Commission, in 2006 by Prof. Danuta Hübner, Commissioner for Regional Policy, and in 2007 by Dr. Janez Potočnik, Commissioner for Science and Research. On the natio-nal level Report is published under the aegis of The Ministry of Economy of the Republic of Poland and the President of the Polish Academy of Sciences.

The report has evolved. It applies not only to the subject area, but also to extent of research. In the next issues of the Report following appendices were added: The List of the Most Innovative Products and Services (2006), rankings of the most innovative microenterprises and small and medium enterprises (2006), lists of the enterprises on regional level (2006). In the publications that are spin-offs from the main report new list were added: The List of Companies Patenting in Poland (2010) and The List of the Lar-gest Investors in Research and Development (2010). Since 2011 every year five hundred most innovative enterprises in Poland are sent certifica-tes that are including 5A System innovation assessment.

Between 2005–2007 BRE Bank S.A was the main partner of the pro-ject, while media coverage was by daily “Gazeta Prawna”. Respectively in 2005 and 2006 a series of articles on innovation were published there. Moreover three special supplements to the paper on the ranking were issued.

INNOvATIvES RESEARCH PROGRAMAT INE PAN



Regional Reports on Innovativeness

The idea of such reports came during organization of regional award cere-monies. It was implemented in 2008, when 16 regional (on voivodship level) reports were developed. Each of report contain regional analyses, microeco-nomic analyses, lists of the most innovative companies in a voivodship in the same order as in the report on national level (large, small and medium and micro firms, innovative products and services). Three additional materials were added: lists of the research and developing centres, scientific institutes and maps of spatial distribution of innovative firms. The Regional Reports were officially presented at the conference organized by the Polish Informa-tion and Foreign Investment Agency at its head office at Bagatela Str. in Warszawa. The next edition of reports has been prepared in 2010.

Report on the Largest Investors in Research and Development in Poland

The first ranking of largest investors in research and development was published in 2010. The winners were awarded diplomas at the special conference. A year later the ranking was completed with the analytical part as Report on the Largest Investors in Research and Development in Poland in 2010. The ranking was prepared also in 2012.

List of Companies Patenting in Poland

List of the obtained patents by Polish firms for the first time was shown in Report on Innovativeness of the Polish Economy in 2005. In 2010 has changed its formula and now is a separate project. Thrice, in the years 2010-2012 holders of the biggest num-ber of the patents received awards from the management of the MSN Scientific Network, INE PAN and the Polish Patent Office. Additional publications were issued, some containing analytical study. In 2010 the gender factor was included and firms whose patenting teams were mixed were distinguished. The results are available at www.firmy-patentujace.pl

Sector Reports

The first report devoted to a sector of the Polish economy was Report on Innovativeness of the Aviation Sector in Poland in 2010. This bilingual book partly financed by Ministry of Economy was presented at the confe-rence on 13th October 2011 in Warszawa based Institute of Aviation. The conference was accompanied by the first exhibition Innovativeness of Aviation. The publication got international, and helped promoting Polish economy at fairs in Berlin, Tokyo, and Hague. The full text and more information is available at: http://www.innovation-in-aviation.pl/en/.

In the same Polish-English mixed formula a year later a report on innovativeness of health sector showed up. The presentation took place at the conference “Innova-tions for Health Sector” in the Nałęcz Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences on 23rd October 2012.

Innovation Strategy for Poland

On the basis of the previous surveys results in 2009 Institute launched series of seminars and confences to define the Innovation Strategy for Poland, They served to integration of social environment, public institutions and innovative companies that should lead to defining a basic assumption of the innovation development in Poland. It should also bring specific legal, institutional and informational solutions. The strategy is prepared in accordance with the most important Polish and inter-national strategic documents, with particular reference to the OECD Innovation Strategy.



Future-oriented Research (Foresight)

As a result of conducting research on innovativeness of Polish enterprises in 2005-2006, Institute of Economics of the Polish Academy of Sciences entered three research consortiums conducting EU-funded foresight pro-jects in 2006-2008. Respectively: The National Program Foresight Poland 2020, consortium FOREMAT conducting research on future of material technologies and the consortium ROTMED with project Monitoring Sys-tem and Scenarios of the Medical Technologies Development in Poland. The last of above mentioned projects resulted in expenditure of research topics related with health sector and cooperation and cooperation with research institutions on that field. The present book is the indirect outcome of that.

Remaining research results

invitation to cooperation by the Polish Ministry of Foreign Affairs to ��

the organization of the conference devoted to Polish aviation sector in Seattle, WA (2012)consultation of the project �� Strategy of Innovation and Efficiency of Economy of the Ministry of Economy of the Republic of Poland (2011)cooperation with the Ministry of Economy in organization of Roundtable ��

on OECD Innovation Strategy – Towards New Perception of Innovation (2010) the English language book The Future of Science and Technology and Innovation Indicators and the Challenges Implied (2009)consultancy with Market Street Associations from San Francisco, CA ��

on creating of the semantic platform easing technology transfer (2009–2010)Poland and Russia on the road to innovative development�� , edited by prof. Joanna Kotowicz-Jawor. The book is a result of cooperation between Polish and Russian Academy of Sciences, within the Standing Committee of Economists of PAS and RAS (2008)Shareholding in spin-off company �� Park Innowacyjny Celestynów Uni-press. The main goal is to build the modern research and implemen-tation centre in Celestynów (2008)Distinction of the research program on innovation conducted by the Institute. The ��

program served as a model example of the cooperation between science, business and media. As a case study, it has been introduced during the training Promotion in Science and has been described in detail in the brochure Promotion in Science and in the bilingual folder Kaleidoscope of Science (2006–2007)Joint research with Germany’s European University Viadrina and Deutsches Insti-��

tut für Wirtschaftsforschung (DIW) on importance of localization factors and effi-ciency and innovation of the companies in Poland and East Germany (2006–2007)Carrying out research works for the international network European Techno-Eco-��

nomic Policy Support Network – ETEPS AISBL (2005–2006)Cooperation with the network of the European Commission ERAWATCH (2005–��

2006)Participation in the IRIM project – Industrial Research Investment Monitoring, ��

within the 6th Framework Program of the European Union (2005–2006)Conferences with the participation of world-renowned research methodologists: ��

the founder of fractal geometry prof. Benoit Mandelbrot (2005) and the Chairman of NESTI (National Experts on Science & Technology Indicators) in OECD dr. Fred Gault (2006).



mSN SCIENTIFIC NETWorK Assessment of the Impact of research and Development (r&D) Activity and Innovation on the Social and Economic Development

INE PAN (Institute of Economics of the Polish Academy of Sciences) is the coordinator of the MSN Scientific Network “Assessment of the Impact of the Research And Development (R&D) Activity and Innovation on the Social and Economic Development”. Starting of the scientific network in July 2003 was to help to reduce a gap of Poland in relation to the most

developed countries in R&D and innovation. The aim was to find areas, where coope-rative action could help to accelerate the process of reducing that distance.

The network includes centres of different profile of the scientific activity – which allows the creation of infrastructure, including tools to facilitate technology transfer into business practice and the development of faculty, to be engaged in the process of building the knowledge-based economy in Poland. Currently there are four members of the network.

MSN Scientific Network comprises:Institute of High Pressure Physics of the Polish Academy of Sciences�� ,Institute of Biochemistry and Biophysics of the Polish Academy of Sciences�� ,Institute of Economics of the Polish Academy of Sciences�� ,Faculty of Management of the Warsaw University of Technology�� .In addition to research on innovativeness carried out jointly with the Institute of

Economics of the Polish Academy of Sciences, the network activity also focused on helping its members in submitting proposals in the 7th European Union Framework Program, in the Operational Programme Innovative Economy and also help in apply-ing for funds from national grants.

MSN facilitates transfer of technology developed in member-institutes into econo-mic practice, mainly through assistance in establishing contacts between the those centres and companies. The network reveals a high international activity – in the years 2004–2007 contacted 35 institutions outside the Poland.

The Network organizedmethodological seminars,��

seminars presenting the research results of other centres,��

conferences attended by eminent world authorities in the field of methodology ��

(Benoit Mandelbrot, Fred Gault).The MSN Scientific Network disseminates research results through publications i.e.��

Report of Innovativeness of the Polish Economy,�O

MSN Bulletin,�O

MSN Working Papers,�O

Research Bulletin.�O

In cooperation with the European Advisors Institute in Kalisz, the MSN Scientific Network conducted a series of training courses leading to obtain the title of Consul-tant, Innovation Expert and Innovation Auditor.

MSN creates expert networks comprising scientists (including Warsaw School of Eco- nomics, Warsaw University of Technology, Faculty of Economic Sciences and Faculty of Management of the Warsaw University, Institute of Fundamental Technological Rese-arch of the Polish Academy of Sciences, Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, Institute of High Pressure Physics of the Polish Academy of Sciences, National Bank of Poland, Central Statistics Office, as well as representatives of companies representing the most important sectors of the national economy.

Prepared by Michał Baranowski


raeport on innovativeness of health sector in poland in 2012

Documents

n s t i t u t e o f

s c i e n t i c e d

e n e s s o f t h e

n n o v

n d i n

t hs e c t o r i n p

y o f s c i e n c e

r e p o r